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Abstract 
Parkinson’s disease (PD) is a common neurodegenerative condition, with multiple 
associated non-motor symptoms.  Of these, dementia is a frequent debilitating 
complication of the disorder, with significant morbidity and mortality.  Some forms of 
mild cognitive impairment in PD (PD-MCI) may represent a pre-dementia state and 
certain clinical, laboratory and neurophysiological parameters may increase the 
accuracy of prediction of cognitive decline.  If validated, these markers would offer the 
opportunity for disease modification and therapeutic intervention at a critical early 
stage of the illness, when the viable neuronal population is greater.  The key aim of this 
thesis was to characterise cognitive impairment in PD in a cohort of newly diagnosed 
cases, and evaluate how a panel of biomarkers correlated with cognitive phenotypes 
to predict risk of future cognitive decline.  
The main findings were that PD-MCI was common, and was associated with a distinct 
clinical phenotype.  Memory impairment was the most common single domain 
affected, although the majority of those with PD-MCI were classified as nonamnestic 
single domain subtype.  A significant correlation was found between pattern 
recognition memory, sensitive to temporal lobe impairments, and cerebrospinal 
amyloid-β 1-42 levels, thought to represent amyloid-β metabolism and deposition.  
Both amyloid-β 1-42 and 1-40 levels were significantly lower in those with impaired 
cognition.  In addition, short latency afferent inhibition, a neurophysiological in vivo 
non-invasive measurement of cholinergic function, was also reduced in participants 
with mild cognitive impairment.  These findings suggest that cholinergic dysfunction 
and amyloid deposition may contribute to the underlying pathophysiology of early PD-
MCI. 
The major conclusion from this thesis is that PD-MCI is heterogeneous and more 
frequent than previously reported in early disease.  This is associated with 
abnormalities of amyloid processing and cholinergic dysfunction, and may highlight 
those at risk of developing dementia.  Longitudinal assessment of these individuals will 
enable us to determine and better model those measures predictive of cognitive 
decline at an early disease stage.   
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Chapter 1 Parkinson’s disease in context 
Parkinson’s disease (PD) is the second commonest neurodegenerative disorder 
affecting patients in the UK after Alzheimer’s disease (AD).  Although historically 
classified as a motor system disorder, it is increasingly recognised that the majority of 
the morbidity and mortality associated with PD is related to non-motor aspects.  Thus, 
the focus of research in recent years has turned towards an improved understanding 
of the non-motor symptoms (NMS), of which cognitive impairment forms a significant 
burden.   
1.1 Epidemiology 
The annual incidence of PD has been estimated at 8 - 22/100,000 per year in both 
Europe and the USA (Twelves et al., 2003; Foltynie et al., 2004; von Campenhausen et 
al., 2005; Taylor et al., 2006; Alves et al., 2008; Winter et al., 2010), ranging from 9 per 
100,000 in Eastern Europe to 22 per 100,000 in Aberdeen, with a comparable local 
annual incidence rate in the Newcastle-Gateshead area of 15.9/100,000 (Duncan et al., 
2013b).  Reasons for differences between studies include differences in case 
ascertainment, the population denominator and case definition.  The greatest risk 
factor for development of PD is age, with prevalence figures estimated at 0.3% in those 
aged over 55, 1% in those over 65, 3.1% over 75 and 4.3% in the oldest age group of 
over 85 (de Rijk et al., 1995). The risk of PD is also increased in men, who are 
approximately 1.5 times more likely than women to develop the disease; however, this 
may only apply to Western populations and in older age groups (Taylor et al., 2007).  
Possible explanations for the excess in male cases include the protective effect of 
female hormones, gender-specific exposure to occupational or environmental risk 
factors or genetic influences (Alves et al., 2008), although the exact mechanisms 
remain unclear. 
PD is a chronic progressive neurodegenerative disorder for which at present there is 
no known cure.  Median age of disease onset is 60 years (Lees et al., 2009), with 
median time from symptom onset to death of just over 12 years (Hely et al., 2005; 
Hely et al., 2008).  The standardised mortality ratio is comparable to that of the 
general population in early disease (Marras et al., 2005), but rises to between 1.5 and 
3.1 as disease progresses (Hely et al., 1999; Herlofson et al., 2004; Hely et al., 2005; 
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Hely et al., 2008).  The commonest cause of death in patients with PD is pneumonia 
(Beyer et al., 2001; Hely et al., 2005). 
1.2 Aetiology of PD 
The precise cause of PD remains the subject of intense research, but is likely to be a 
combination of genetic and environmental factors.  Although the vast majority of cases 
are sporadic in nature, a monogenic aetiology is more likely in those aged under 45 
years old, while recent studies have identified at least eight significant loci (Nussbaum 
RL, 2003; Gasser et al., 2011) (Table 1-1).  After advancing age, family history of PD is 
the biggest risk factor for developing the disease, with early reports suggesting that 
patients with PD are four times more likely to have a first-degree relative affected than 
controls (Payami et al., 1994).  Mutations in the leucine-rich repeat kinase 2 gene 
(LRRK2) are the most frequent cause of inherited PD, with the commonest mutation 
producing a glycine to serine amino acid substitution at codon 2019 (G2019S), thought 
to be present in 1-2% of sporadic PD patients of European descent (Gilks et al., 2005). 
This figure is much higher in the southern Mediterranean population, in African Arabs 
and in Ashkenazi Jews.  The clinical presentation of LRRK2 is indistinguishable from 
that of idiopathic Parkinson’s disease, although dementia tends to be less prominent 
and the disease course is generally milder (Healy et al., 2008).  An age-related reduced 
penetrance is observed, with the risk of PD in those with G2019S mutations being 28% 
at 59 years, 51% at 69 years and 74% at 79 years (Healy et al., 2008).    
Genetic factors may still be important in so-called sporadic disease, but the impact of 
functional polymorphisms, for example, is less apparent than loss of function or toxic 
gain of function in monogenic forms, and thus less easy to establish.  The pathological 
hallmark of PD is the presence of Lewy bodies (LB) and Lewy neurites within the 
substantia nigra pars compacta (SNpc) with consequent degeneration of dopaminergic 
neurones (Braak et al., 2003).   LBs consist of insoluble α–synuclein, ubiquitin, 
neurofilament plus other proteins and aggregate in the neuronal cytoplasm or axons 
(when the protein aggregation is identified as Lewy neurites) in the central and 
autonomic nervous system (Braak et al., 2004).  Growing evidence argues for the role 
of altered intracellular protein handling in PD, with either an increase in abnormal 
protein production, impaired protein clearance, or both  (Olanow and McNaught, 
2011).  
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Table 1-1 Monogenetic causes of Parkinson's disease 
Locus Gene Mode of 
inheritance 
Pathology Comments References 
PARK1 α-
Synuclein 
(SNCA) 
Autosomal 
dominant 
Widespread 
Lewy bodies 
Rare; different 
point mutations 
correspond to 
different 
phenotypes, from 
early, severe, 
rapidly 
progressive plus 
dementia to mild 
late-onset PD 
(Polymeropoulos 
et al., 1997; Spira 
et al., 2001) 
PARK2 Parkin Autosomal 
recessive 
Substantia 
nigra 
degeneration
; occasional 
LB 
Commonest AR 
form of PD; early 
onset, slow 
progression 
(Kitada et al., 
1998; Farrer et al., 
2001)  
PARK4 α-
Synuclein 
(SNCA) 
Autosomal 
dominant 
Widespread 
α-syn 
accumulation 
Duplications- late 
onset typical PD; 
triplications- 
early onset, rapid 
progression, 
dementia 
(Singleton et al., 
2003; Fuchs et al., 
2007; Ikeuchi et 
al., 2008) 
PARK6 PINK1 Autosomal 
recessive 
Unknown (1 
case – LB 
pathology, 
nigral 
neuronal loss 
& gliosis) 
Early onset, slow 
progression 
(Valente et al., 
2001; Valente et 
al., 2004a; Valente 
et al., 2004b; 
Samaranch et al., 
2010) 
PARK7 DJ-1 Autosomal 
recessive 
Unknown Rare; early onset, 
slow progression 
(van Duijn et al., 
2001; Bonifati et 
al., 2003) 
PARK8 LRRK2 Autosomal 
dominant 
Variable; 
usually Lewy 
bodies 
Commonest AD 
form of PD; 
clinical features 
as for sporadic 
PD 
(Zimprich et al., 
2004; Di Fonzo et 
al., 2005) 
PARK9 ATP13A2 
(Kufor-
Rakeb 
disease) 
Autosomal 
recessive 
Iron 
deposition in 
basal ganglia 
Early onset 
parkinsonism, 
spasticity, 
dementia, 
supranuclear 
gaze palsy 
(Ramirez et al., 
2006; Schneider et 
al., 2010) 
PARK15 FBX07 Autosomal 
recessive 
Unknown Rare; early onset, 
LD-responsive, 
spasticity 
(Di Fonzo et al., 
2009) 
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Within cells, abnormal protein components are cleared via the autophagic-lysosomal 
system if insoluble (Ventruti and Cuervo, 2007), and largely through the ubiquitin-
proteasome system if soluble protein degradation is required (Pickart, 2001). Defects 
in the ubiquitin-proteasome system (such as those caused by Parkin mutations) or 
excessive abnormal protein production (for example, due to SNCA mutations) 
precipitate accumulation of abnormal proteins within the neurone, leading to 
proteolyic stress and ultimately cell death (Olanow and McNaught, 2011).  Some 
researchers hypothesise that in fact LBs may be a form of aggresome – an intracellular 
inclusion formed in response to proteolyic stress – and hence have a cytoprotective 
function (Olanow et al., 2004; Tanaka et al., 2004).  Recent post-mortem work 
challenges these views and suggests that neuronal cell dysfunction and cell death may 
actually precede the formation of LBs and Lewy neurites, when it was shown that 
substantia nigra (SN) cell dysfunction was greater in those with incidental Lewy bodies 
than those with PD or controls, with an intermediate number of LBs in the incidental 
LB group (Milber et al., 2012).  Further work is required to delineate the exact 
mechanisms underlying the function and formation of Lewy pathology and its relation 
to neurodegeneration in PD. 
The concept of epigenetics in neurodegeneration has received attention in recent 
years, and may go some way to bridging our understanding of the interplay between 
genetic and environmental factors (Urdinguio et al., 2009; Qureshi and Mehler, 2011).  
Epigenetics refers to heritable changes in gene expression that are not due to changes 
in the underlying DNA sequence (Urdinguio et al., 2009).  Examples of such epigenetic 
mechanisms include DNA methylation, histone modifications and non-coding RNA 
regulation, although few studies have specifically addressed this in PD. 
Environmental factors that may contribute to the pathophysiology of PD include 
smoking, caffeine, head trauma and exposure to solvents and other toxins.  The 
inverse relationship between smoking and risk of PD (Hernan et al., 2001; Allam et al., 
2004) and caffeine intake and risk of the disease (Ross et al., 2000) was initially 
thought to be related to pre-morbid low sensation seeking personality traits rather 
than neuroprotective effects of these substances per se (Evans et al., 2006).  However, 
evidence from animal model studies has demonstrated that some compounds in 
tobacco reduce the breakdown of dopamine via inhibition of monoamine oxidase 
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(MAO) A and B, and that nicotine may enhance dopaminergic release within the 
striatum by actions on nicotinic acetylcholine (ACh) receptors (Quik et al., 2012).  
Similarly, caffeine is an adenosine A2 receptor antagonist: These compounds normally 
reduce excessive motor activity through actions on the inhibitory gamma-aminobutyric 
acid (GABA) basal ganglia pathways (Jankovic, 2008).  Phase III trials are currently on 
going to determine whether an adenosine A2 receptor antagonist can delay the onset 
of motor symptoms of PD and reduce striatal neuronal loss.   
The concept of repeated severe head trauma as a cause of parkinsonism is not new; 
however, the association between head injury and idiopathic PD is disputed.  One 
reason why studies have found conflicting results as to whether head injury precedes 
the disease is that history of trauma is difficult to assess due to recall bias.  The most 
recent and largest study to date on the subject avoided the problem of recall bias by 
using hospital records of head injury in PD and control cases to determine the 
relationship between the two (Fang et al., 2012).  Although there was an increased risk 
of hospitalisation due to head injury in PD compared to control cases (odds ratio 1.42), 
the injuries generally occurred shortly before the index date (within a year), and the 
authors concluded that there was insufficient evidence to conclude that head trauma 
later in life increases the risk of PD.  Possible explanations as to why  this may have 
been biologically plausible include disruption to the blood-brain barrier with 
subsequent exposure to neurotoxins and the inflammatory response associated with 
brain injury (Morley and Duda, 2012). 
More controversial in the aetiology of PD is exposure to solvents and subsequent risk 
of the disease.  Trichloroethylene has been recognised as a potential risk factor for 
many years (Guehl et al., 1999), and a recent case-control study using twin pairs 
discordant for PD added to this body of evidence (Goldman et al., 2012b).  In this study, 
99 twin pairs were interviewed using a structured occupational questionnaire with 
respect to six specific solvents.  Twins with PD were six times more likely to have been 
exposed to trichloroethylene than their unaffected co-twin, and there was also a trend 
towards significance for exposure to perchloroethylene and carbon tetrachloride and 
PD risk.  Again this is biologically plausible and supported by rodent experiments 
demonstrating that these solvents trigger mitochondrial dysfunction and oxidative 
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stress, leading to degeneration of dopaminergic neurones in the SN (Sherer et al., 2007; 
Liu et al., 2010). 
Finally, there is evidence that some lifetime-related exposures may protect against the 
development of PD.  In a large longitudinal cohort study in Finland, individuals with 
adequate vitamin D status (vitamin D levels of at least 50 nmol/L) had a 65% lower risk 
than those with values less than 25 nmol/L after adjustment for several potential 
confounders including age, sex, physical activity and month of blood draw (Knekt et al., 
2010).  Vitamin D receptors and 1-α-hydroxylase are widespread throughout the 
human brain in neurons and glial cells, and are found in high density in the 
hypothalamus and large neurons of the SN (Eyles et al., 2005).  Vitamin D may exert a 
neuroprotective effect through antioxidant activities, immunomodulation, and 
neuronal calcium regulation or by improving nerve conduction (Newmark and 
Newmark, 2007; Evatt, 2010). 
In conclusion, the exact aetiology of Parkinson’s disease in the majority of individuals 
remains unknown, but environmental, occupational, genetic and epigenetic factors 
may contribute.  Determining the interplay of these factors is important in establishing 
the underlying disease mechanisms and in developing potential targets for treatment. 
1.3 Pathological correlates of PD 
The pathological diagnosis of PD is typified by the loss of neuromelanin containing 
dopaminergic neurones in the SNpc, with LBs and Lewy neurites seen in surviving 
neurones.  It is clear, however, that Lewy pathology is not limited to dopaminergic 
neurones, and also affects the cholinergic neurons of the nucleus basalis of Meynert 
(nbM), serotonergic neurones within the raphe nucleus and noradrenergic neurones in 
the locus coeruleus (Forno, 1996; Braak et al., 2003).   A major component of both LBs 
and Lewy neurites is an abnormally modified and aggregated form of α–synuclein, 
normally a presynaptic protein.  The precise mechanisms triggering fibrillization and 
aggregation of α-synuclein remains the subject of debate, as does the inter-cellular 
transfer of α-synuclein.  One hypothesis, proposed by Braak and colleagues, is that 
transfer of Lewy pathology is not random but spreads from the medulla oblongata and 
olfactory nucleus in a caudo-rostral direction to further susceptible structures within 
the brainstem, limbic system and finally neocortical regions (Braak et al., 2003).  This 
corresponds with the presumed preclinical and premotor stages of PD (Figure 1-1).  
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Braak stages 1 and 2, where pathology is confined to the medulla, pontine tegmentum 
and olfactory nucleus correlates with a premotor phase, with autonomic features and 
hyposmia.  Stages 3 and 4, when disease becomes symptomatic causing sleep and 
motor deficits, is associated with parallel neuropathology in the SN, other vulnerable 
areas of the midbrain and the basal forebrain.  Braak stages 5 and 6, with the 
occurrence of cortical Lewy pathology, are associated with cognitive and other 
neuropsychiatric deficits (Braak et al., 2004).  Against this hypothesis is work 
demonstrating widespread LB pathology in dementia with Lewy bodies (DLB) and 
Alzheimer’s disease (AD) without motor features consistent with PD, and also the 
absence of correlation between Braak staging and disease severity (Burke et al., 2008).  
In addition, a large clinicopathological study established that over half of subjects with 
Braak stage 5 or 6 disease actually had no clinical signs of an extrapyramidal syndrome 
or dementia (Parkkinen et al., 2008).  A further contentious issue is where Lewy 
pathology begins within the brain: one theory is that the process of PD actually begins 
in the gut through exposure to toxic or infectious agents and spreads trans-synaptically 
via the dorsal motor nucleus to the central nervous system (Braak et al., 2006; Hawkes 
et al., 2007; Olanow, 2012; Shannon et al., 2012a; Shannon et al., 2012b).  Lastly, the 
question of how α-synuclein pathology propagates remains unanswered, and indeed 
how allografts of foetal ventral mesencephalic tissue transplanted into the striatum of 
PD patients can develop LB pathology (Kordower et al., 2008; Li et al., 2008).  Theories 
include trans-synaptic spread through inflammation, oxidative stress or excitotoxic 
mechanisms (Li et al., 2008; Lees et al., 2009) or a prion-like process, where α-
synuclein misfolding initiates aggregation of the abnormal protein in adjacent cells by 
so-called “permissive templating” (Olanow and McNaught, 2011).   
1.4 Diagnosis of PD 
The diagnosis of PD remains based on clinical features, and depends critically on the 
demonstration of bradykinesia, defined as progressive fatiguing and decrement of 
repetitive alternating movements during finger or foot tapping (Abdo et al., 2010), plus 
at least one of rigidity, 4-6Hz rest tremor and postural instability.  Exclusion criteria 
include early severe autonomic involvement, neuroleptic treatment at onset of 
symptoms and early marked dementia, as these may point to alternative diagnoses 
(Hughes et al., 1992).  Three or more supporting features are required for a definite 
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diagnosis, comprising asymmetrical onset and progression, excellent response to 
levodopa and more recently, hyposmia and visual hallucinations (Lees et al., 2009) 
(Table 1-2).  The Queen Square Brain Bank (QSBB) criteria have been found to be highly 
accurate for the diagnosis of PD by movement disorder specialists, with a positive 
predictive value of  98.6%, negative predictive value of 90%, sensitivity 91.1% and 
specificity 98.4% in a longitudinal clinicopathological study (Hughes et al., 2002). 
The European Federation of Neurological Societies (EFNS) and Movement Disorder 
Society-European Section (MDS-ES) have recently published guidelines for the 
diagnosis of PD, and recommend the use of the QSBB criteria in the clinical diagnosis 
as Level B evidence (probably effective) (Berardelli et al., 2013).  In cases of diagnostic 
uncertainty, neuroimaging may be supportive (Berardelli et al., 2013).  Specifically, the 
use of single photon emission tomography (SPECT) with selective pre-synaptic 
radioligands targeting the dopamine transporter (DaTscan) can be a cost-effective 
method to differentiate degenerative parkinsonism and atypical tremor disorders or 
drug-induced parkinsonism (Level A evidence; effective).  A newer recommendation is 
the use of transcranial sonography (TCS), as hyperechogenicity of the substantia nigra 
is associated with a classification accuracy of nearly 90% (Berg et al., 2008; Gaenslen et 
al., 2008).  It is recommended that TCS can be used for the differentiation of PD from 
atypical and non-degenerative parkinsonian disorders, for the early diagnosis of PD 
and in the detection of subjects at risk for PD in conjunction with other screening tests.  
TCS is highly operator-dependent, however, and its use is still not widespread.  
Magnetic resonance imaging (MRI) at 1.5 Tesla can assist in discriminating PD and 
atypical parkinsonian disorders (Level B evidence), and lastly, olfactory testing can be 
used in confirming the diagnosis of PD (Level A evidence). 
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Table 1-2 Queen Square Brain Bank criteria for the diagnosis of Parkinson's disease 
Step 1 Diagnosis of parkinsonian syndrome 
Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in speed and 
amplitude or repetitive actions) and at least one of the following: 
• Muscular rigidity 
• 4- to 6-Hz rest tremor 
• Postural instability not caused by primary visual, vestibular, cerebellar or proprioceptive dysfunction 
Step 2 Exclusion criteria for Parkinson’s disease 
• History of repeated strokes with stepwise progression of parkinsonian features 
• History of repeated head injury 
• History of definite encephalitis 
• Oculogyric crises 
• Neuroleptic treatment at onset of symptoms 
• More than one affected relative 
• Sustained remission 
• Strictly unilateral features after 3 years 
• Supranuclear gaze palsy 
• Cerebellar signs 
• Early severe autonomic involvement 
• Early severe dementia with disturbances of memory, language and praxis 
• Babinski sign 
• Presence of a cerebral tumour or communicating hydrocephalus on CT scan 
• Negative response to large doses of L-dopa (if malabsorption excluded) 
• MPTP exposure 
Step 3 Supportive prospective positive criteria of Parkinson’s disease. Three or more 
required for the diagnosis of definite Parkinson’s disease: 
• Unilateral onset 
• Rest tremor present 
• Progressive disorder 
• Persistent asymmetry affecting the side onset most 
• Excellent response (70–100%) to L-dopa 
• Severe L-dopa-induced chorea 
• L-dopa response for 5 years or more 
• Clinical course of 10 years or more 
• Hyposmia 
• Visual hallucinations 
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1.5 Clinical features of PD 
1.5.1 Motor features 
The motor features of PD usually begin insidiously after the loss of up to 60% of 
dopaminergic SN neurones (Fearnley and Lees, 1991; Damier et al., 1999; Bohnen et al., 
2006a).  Postural instability develops later in the disease and its presence early on 
should prompt consideration of an alternative diagnosis.  Patients may complain of a 
loss of dexterity in tasks such as dressing or shaving, with or without associated 
micrographia, which may be noted more if the dominant hand is affected.  Indeed 
handedness is likely to be associated with side of onset of the disease: A recent meta-
analysis concluded that PD patients more often have symptoms affecting their 
dominant side (van der Hoorn et al., 2012).  Overall, 59.5% of right-handed patients 
had right-side dominant disease, with 59.2% of left-handed patients having 
predominantly left-sided symptoms (odds ratio 2.13; 95% confidence interval 1.71 - 
2.66).  Extrapyramidal rigidity may manifest as stiffness or non-specific muscular pains, 
with difficulty turning in bed or getting out of a low chair.  Tremor may be noticed by 
family and is typically present at rest initially.  Other motor features include 
hypomimia, hypophonia and dystonia. 
1.5.2 Non-motor symptoms 
The morbidity and mortality associated with non-motor symptoms (NMS) in PD is 
increasingly recognised.  NMS include gastrointestinal, urinary, cognitive, behavioural, 
sleep and cardiovascular symptoms.  Previously thought of in the context of 
established disease (Parkinson, 1817), it is now recognised that NMS such as 
constipation, rapid eye movement (REM) behaviour disorder (RBD), depression and 
hyposmia often precede the motor features by many years and may represent a 
“Parkinson’s At Risk Syndrome” (PARS), allowing  earlier diagnosis and a potential 
opportunity for more effective use of neuroprotective therapies (Stern and Siderowf, 
2010).  The PARS study developed by Stern and collaborators in the USA is currently in 
progress, with the aim of recruiting over 15,000 individuals, starting by screening for 
hyposmia (see ‘Premotor’ phase in Figure 1-1).  
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Figure 1-1 Parkinson's disease at risk syndrome.  Modified from Stern and Siderowf, 
2010    
 
Other studies have demonstrated that NMS are common even early in the disease 
process.  A large retrospective clinicopathological study of 433 subjects with 
pathologically-proven PD established that 21% of patients actually presented with 
NMS such as pain, urinary symptoms and neuropsychiatric features; these patients 
were also more likely to have had a delayed diagnosis than those presenting with 
motor symptoms (O'Sullivan et al., 2008).  A more recent study of 159 newly diagnosed 
PD participants and 99 age-matched controls in Newcastle demonstrated that even in 
those with a median disease duration of only 4.4 months, NMS were significantly more 
common in PD patients, with a mean number of 8.4 NMS experienced compared with 
2.8 in controls (Khoo et al., 2013).  The commonest symptoms experienced were 
sialorrhea, urinary urgency, hyposmia, anxiety, and constipation (Table 1-3).  
Increasing motor severity was associated with a greater number of NMS. 
NMS are a significant cause of disease burden in early PD and are associated with 
reduced functional status and sense of wellbeing.  NMS with the greatest negative 
impact on health related quality of life, as measured by the Parkinson’s Disease Quality 
of Life Questionnaire (PDQ-39) (Peto et al., 1995), were depression, anxiety, RBD, 
sensation of incomplete bowel emptying, hyperhidrosis, leg swelling, diplopia, 
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impaired concentration and forgetfulness in the same study group (Duncan et al., 
2013a).  In combination, these symptoms predicted 49% of the variance in quality of 
life.       
As PD progresses, the frequency of NMS increases, with neuropsychiatric burden 
(depression, anxiety, apathy, psychosis and cognition) having a greater impact on 
quality of life than motor symptoms (Schrag et al., 2000b; Schrag et al., 2000a; 
Weintraub et al., 2004b; Slawek et al., 2005; Barone et al., 2009; Martinez-Martin et al., 
2011).  Despite this, NMS are under-recognised by clinicians and patients: the under-
reporting of NMS ranged from 31.8% (diplopia) to 65.2% (delusions) in one cross-
sectional international study (Chaudhuri et al., 2010).  Recognition of these symptoms 
is important as many are amenable to treatment, including dopaminergic therapy 
(Chaudhuri and Schapira, 2009; Zesiewicz et al., 2010; Seppi et al., 2011).  Examples of 
this include pramipexole in the treatment of depression (Barone et al., 2010; Seppi et 
al., 2011) and clozapine in the treatment of psychosis (Morgante et al., 2004; Merims 
et al., 2006; Seppi et al., 2011), both of which have been considered to be  efficacious 
in an MDS evidence based review of treatments for NMS (Seppi et al., 2011).  
The heterogeneity of NMS experienced by people with PD indicates that they are not 
all caused by the same underlying pathological substrate and suggests that dopamine 
alone is unlikely to be the sole contributor.  There is evidence that cholinergic 
dysfunction is important in the pathophysiology of cognitive impairment (Tiraboschi et 
al., 2000; Bohnen et al., 2003; Yarnall et al., 2011; Yarnall et al., 2013), depression 
(Bohnen et al., 2007; Meyer et al., 2009), hyposmia (Bohnen et al., 2010) and falls 
(Bohnen et al., 2009; Bohnen and Albin, 2011) in PD.  In addition to ACh loss, 
depression in PD has been attributed to complex interactions between dopaminergic 
loss in the SN via mesolimbic circuits, serotonergic loss from the raphé nucleus and 
noradrenergic deficits due to degeneration of neurones in the locus coeruleus 
(Aarsland et al., 2012).  Changes in inflammatory and neurotrophic factors and 
psychosocial elements may also contribute to mood disorder (Aarsland et al., 2012).           
In conclusion, NMS are common in PD, even early in the disease process.  As the 
disease progresses, the occurrence of NMS increases and impacts negatively on quality 
of life.  Symptoms may not be recognised by patients or clinicians caring for them, 
despite the fact that they may be successfully treated.  The underlying 
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pathophysiology is heterogeneous and likely to involve strategic neuronal loss and 
complex interactions between neurotransmitters throughout cortical and subcortical 
systems.   
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Table 1-3 Frequency of non-motor symptoms in PD and controls (Khoo et al, 2013); 
*denotes significant differences after Bonferroni correction for multiple tests
 Non-motor symptom PD 
N (%) 
Control 
N (%) 
 
p-value 
Gastrointestinal tract, n (%) 
Sialorrhea 
Dysphagia 
Nausea 
Constipation 
Bowel incontinence 
Incomplete bowel emptying 
Hyposmia 
Weight change (unexplained) 
 
89 (56.0) 
32 (20.1) 
4 (2.5) 
67 (42.1) 
9 (5.7) 
51 (32.1) 
71 (44.7) 
36 (22.6) 
 
6 (6.1) 
3 (3.0) 
15 (15.2) 
7 (7.1) 
5 (5.1) 
12 (12.1) 
10 (10.1) 
19 (19.2) 
 
<0.001* 
<0.001* 
0.142 
<0.001* 
1.000 
<0.001* 
<0.001* 
0.536 
Urinary tract, n (%) 
Urinary urgency 
Nocturia 
 
74 (46.5) 
42 (26.4) 
 
19 (19.2) 
17 (17.2) 
 
<0.001* 
0.095 
Sexual function, n (%) 
Sexual dysfunction 
Impaired libido 
 
33 (20.8) 
28 (17.6) 
 
10 (10.1) 
7 (7.1) 
 
0.026 
0.016 
Cardiovascular, n (%) 
Orthostatic symptoms 
Falls 
Lower limb swelling 
 
53 (33.3) 
37 (23.3) 
29 (18.2) 
 
11 (11.1) 
4 (4.0) 
11 (11.2) 
 
<0.001* 
<0.001* 
0.157 
Neuropsychiatric & Cognitive, n (%) 
Forgetfulness/ memory 
Impaired concentration 
Anxiety 
Low mood 
Loss of interest/ apathy 
Delusions 
Visual hallucinations 
 
88 (55.3) 
47 (29.6) 
68 (42.8) 
59 (37.1) 
44 (27.7) 
1 (1.0) 
35 (22.0) 
 
41 (41.4) 
2 (2.0) 
10 (10.1) 
10 (10.1) 
3 (3.0) 
0 (0.0) 
0 (0.0) 
 
0.040 
<0.001* 
<0.001* 
<0.001* 
<0.001* 
1.000 
<0.001* 
Sleep, n (%) 
Daytime somnolence 
Insomnia 
Dream re-enactment 
Vivid dream imagery 
Restless legs 
 
59 (37.1) 
28 (17.6) 
55 (34.6) 
48 (30.2) 
44 (27.7) 
 
18 (18.2) 
13 (13.1) 
8 (8.1) 
5 (5.1) 
11(11.1) 
 
0.001* 
0.385 
<0.001* 
<0.001* 
0.002 
Pain, n (%) 
Pain (unexplained) 
 
60 (37.7) 
 
3 (3.0) 
 
<0.001* 
Miscellaneous, n (%) 
Diplopia 
Hyperhidrosis 
 
16 (10.1) 
16 (10.1) 
 
3 (3.0) 
6 (6.1) 
 
0.048 
0.360 
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1.5.3 Subtypes of PD 
As discussed above, patients with PD present with a diverse range of motor and non-
motor symptoms, leading to considerable phenotypic heterogeneity.  This has led 
researchers to hypothesise that idiopathic PD comprises specific subtypes that may be 
associated with distinct underlying pathophysiological processes.  Cluster analysis of 
clinical data on prevalent and early stage PD participants recruited from separate 
centres in the UK identified three (Graham and Sagar, 1999) or four (Lewis et al., 2005) 
main subgroups.  Graham and Sagar divided participants into ‘motor only’, ‘motor and 
cognitive’ and ‘rapidly progressive’ clusters (Graham and Sagar, 1999), whilst Lewis 
and colleagues categorised those with early stage disease into: a) younger disease 
onset; b) tremor dominant; c) non-tremor dominant with cognitive impairment; and d) 
rapid disease progression without cognitive impairment (Lewis et al., 2005).  Certain 
characteristics differed across the subgroups described in the latter study, with those 
in the younger disease onset group (mean age at onset 50 years) experiencing slow 
disease progression, mild motor symptoms, motor fluctuations and less cognitive 
impairment or affective symptoms than the non-tremor dominant and rapidly 
progressive subtypes.  Tremor dominant patients were similar to the former group, 
although had more prominent tremor and were older.  Those with non-tremor 
dominant presentations displayed cognitive impairment, most notable within the 
executive domain, and more advanced motor disease, whilst those with rapid disease 
progression displayed a more aggressive motor disease course but minimal cognitive 
decline.   Clinical classification of PD into motor phenotypes is useful and has 
consistently demonstrated that those with postural instability gait difficulty (PIGD) 
phenotype have more rapid disease progression than those who persistently have 
tremor dominant symptoms (Foltynie et al., 2002; Post et al., 2007).  Importantly, this 
phenotype is also associated with accelerated cognitive decline and risk of dementia 
(Alves et al., 2006; Burn et al., 2006; Taylor et al., 2008), in agreement with Lewis and 
colleagues (Lewis et al., 2005), and may be due in part to loss of cholinergic neurons 
(Tiraboschi et al., 2000). 
These clinical findings were corroborated in part by a large retrospective 
clinicopathological study of 242 pathologically confirmed PD cases from QSBB 
(Selikhova et al., 2009).  Selikhova and colleagues confirmed that those with early 
onset shared similar characteristics to those classified by Lewis et al, with greater time 
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to falls and cognitive decline but pathologically similar LB burden to tremor dominant 
phenotypes.  Interestingly, those with tremor dominant disease did not have 
significantly longer disease duration than those with non-tremor dominant 
presentations.  The latter group was strongly associated with the development of 
cognitive impairment, had a more extensive LB disease and had greater amyloid-β 
plaque plus neurofibrillary tangle deposition than other subtypes.  Participants with 
rapid disease progression tended to be older at disease onset, were more likely to 
have early midline motor deficits plus early depression, and to present with tremor 
dominant disease.  The burden of LB disease was lower than in those who were non-
tremor dominant, but similar to those with early onset and tremor dominant disease. 
These clinicopathological findings from this group were generally consistent with those 
from an earlier study (Halliday et al., 2008), where three subtypes of PD were defined 
pathologically.  The group with younger onset had longer disease duration and 
conformed to the Braak staging hypothesis (Braak et al., 2003).  Around a quarter of 
cases were classified as having a dementia dominant syndrome, with severe 
neocortical LB pathology at disease onset, and the final subtype consisted of older age 
at onset, with shorter disease duration and a high cortical LB burden.  The latter group 
also had significant co-existent AD and cerebrovascular pathology.   
Despite these classifications, the course of clinically advanced PD seems to follow a 
typical trajectory regardless of age at death or age at disease onset, with a similar 
pathological outcome (Kempster et al., 2010).  The milestones of visual hallucinations 
(VH), frequent falls, cognitive impairment and care home placement consistently 
occurred approximately at 5, 4, 3.5 and 3 years before death, respectively.  The 
presence of VH and dementia were associated with high cortical LB burden, with 
dementia also being associated with significant amyloid-β plaque and neurofibrillary 
tangle deposition.  
In summary, there is considerable phenotypic heterogeneity within the PD diagnostic 
“umbrella”.  Clinical and pathological studies indicate that those with persistent non-
tremor dominant symptoms are at greater risk of motor progression and cognitive 
decline, and this may be due to high cortical LB counts, Alzheimer-type pathology and 
cholinergic dysfunction.  
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1.6 Parkinson’s disease dementia 
As discussed above, cognitive impairment is an important non-motor symptom in PD 
and has a considerable impact on both patients and their carers.  The development of 
PD dementia (PDD) is a frequent and distressing complication of the disease, with a 
cumulative incidence approaching 80% in community based studies (Aarsland et al., 
2003a; Buter et al., 2008; Hely et al., 2008).  PDD is associated with a twofold increase 
in mortality (Levy et al., 2002c), a loss of independence (Aarsland et al., 2000), 
increased caregiver strain (Aarsland et al., 2007a) and increased healthcare costs 
(Vossius et al., 2011), the latter largely due to the cost of institutionalisation.  Within 
PDD, neuropsychiatric symptoms including depression, anxiety, apathy and 
hallucinations affect up to 90% of patients (Aarsland et al., 2007a) and also 
significantly contribute to caregiver burden (Schrag et al., 2006).  
PDD shares many clinical, neuropsychological and neuropathological features with DLB; 
these diagnoses are separated by the timing of cognitive symptoms to motor onset.  
Those who develop cognitive dysfunction within a year of motor onset or prior to 
motor symptoms are classified as DLB, whilst those with extrapyramidal features for 
longer than one year before cognitive decline develops are designated as PDD 
(McKeith et al., 2005; Lippa et al., 2007).  PDD and DLB are likely to represent different 
phenotypes of the same underlying disease process: indeed the characteristics of 
visual hallucinations (Mosimann et al., 2004; Mosimann et al., 2006), fluctuating 
cognition, attentional-executive plus visuoperceptual deficits (Noe et al., 2004), 
neurotransmitter deficits (Klein et al., 2010), α-synuclein and Alzheimer-type 
pathology (Ballard et al., 2006), neuroleptic sensitivity (Galvin et al., 2006), REM sleep 
behaviour disorder (RBD) (Boeve et al., 1998) and autonomic dysfunction (Allan et al., 
2006) are similar across both diseases.  The major differences seen, aside from the 
temporal course, include the excess of amyloid deposition in DLB (Gomperts et al., 
2008), superior motor response to levodopa in PDD (Molloy et al., 2005) and older age 
at onset in DLB. 
1.6.1 Epidemiology of PDD 
PDD has an associated mortality risk (Levy et al., 2002c), and therefore cumulative 
prevalence is a more accurate representation of dementia frequency than cross-
sectional assessments, which may underestimate the risk of dementia.  As stated 
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above, the cumulative risk varies from 78% at eight years (Aarsland et al., 2003a), to 60% 
at 12 years (Buter et al., 2008) and 83% at 20 years (Hely et al., 2008).  The point 
prevalence of dementia in patients with PD is between 24 and 31%, with 3 to 4% of 
dementia in the population attributable to PDD (Aarsland et al., 2005b).  The 
prevalence of PDD in the general population aged 65 and over is approximately 0.2 to 
0.5% (Aarsland et al., 2005b).  Compared to subjects without PD, those with the 
disease have between a two- and six-fold increased risk of dementia (Marder et al., 
1995; Aarsland et al., 2001; Hobson and Meara, 2004; de Lau et al., 2005).  The mean 
age at diagnosis of PDD is between 71 and 78 years, with an average PD disease 
duration at that time of between 10 and 14 years (Hughes et al., 2000; Aarsland et al., 
2003a; Hely et al., 2008).  Considerable heterogeneity exists in the timescale to 
develop dementia from disease onset; some patients develop cognitive impairment 
within a few years of diagnosis, whilst others remain cognitively intact for 10 to 20 
years.  Although the risk of dementia increases as disease progresses, a degree of 
cognitive impairment may be present at diagnosis in over a third of people with PD 
(Foltynie et al., 2004).  Over a follow-up of five years, 17% of these incident cases 
developed dementia, with an incidence of 38.7 per 1000 person-years (95% confidence 
interval 23.9 – 59.3) (Williams-Gray et al., 2009a). 
1.6.2 Risk factors for PDD 
The greatest risk factor for the development of PDD is increasing age (Hughes et al., 
2000; Aarsland et al., 2001; Hobson and Meara, 2004; Aarsland et al., 2007b; Williams-
Gray et al., 2007a; Uc et al., 2009; Williams-Gray et al., 2009a).  Severity of 
parkinsonism increases risk of cognitive decline (Hughes et al., 2000; Aarsland et al., 
2001; Green et al., 2002; Uc et al., 2009), and acts synergistically with age (Levy et al., 
2002b).  Other established risk factors include the presence of hallucinations (Aarsland 
et al., 2003a; Hobson and Meara, 2004; Galvin et al., 2006), symmetry of motor 
symptoms and PIGD phenotype (Aarsland et al., 2003a; Alves et al., 2006; Burn et al., 
2006; Uc et al., 2009), RBD (Vendette et al., 2007; Postuma et al., 2012), male gender 
(Galvin et al., 2006; Uc et al., 2009) and mild cognitive impairment at baseline (Hobson 
and Meara, 2004; Janvin et al., 2006; Williams-Gray et al., 2007a; Williams-Gray et al., 
2009a).  The presence of apathy (Dujardin et al., 2009; Butterfield et al., 2010; 
Ziropadja et al., 2012), depression (Starkstein et al., 1992), disease duration (Green et 
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al., 2002; Hobson and Meara, 2004), orthostatic hypotension (Allcock et al., 2006), 
reduced educational level (Green et al., 2002), hyposmia (Bohnen et al., 2010; Baba et 
al., 2012) and gastrointestinal or urological symptoms (Uc et al., 2009) in the context 
of cognitive decline are additional potential risk factors that require further evaluation. 
The use of anticholinergic drugs to treat bladder dysfunction, mood and pain is still 
widespread, especially amongst older patients, and over-the-counter medications 
which antagonise muscarinic receptors, such as diphenyhydramine (an antihistamine), 
are also freely available.  Many PD patients with urinary urgency, low mood or pain 
may be treated with these drugs, and evidence suggests that they may accelerate 
cognitive decline (Ehrt et al., 2010).   Thus, chronic use (more than two years) of 
antimuscarinic drugs in patients with PD has been associated with more than twice the 
number of cortical plaques or tangles compared to those who had used the drugs for 
less than two years or not at all (Perry et al., 2003).  Although no difference was noted 
between those with documented confusion, it suggests that anticholinergic drugs 
increase Alzheimer pathology and hence may contribute to cognitive impairment in PD.  
It should, however, be noted that this work has not yet been replicated and therefore 
should be treated with some caution.  Additionally, pharmacological studies have 
shown a deficit in memory in those with Parkinson’s disease treated with 
anticholinergic drugs when compared to those who had not received this class of drugs 
(Dubois et al., 1987; Cooper et al., 1992), and scopolamine, a drug with potent 
antimuscarinic activity, caused a transient reversible subcortico-frontal syndrome 
when administered at subclinical doses to those with PD but not control participants 
(Bedard et al., 1999).  More recently, in a longitudinal cohort study, those PD subjects 
who had taken drugs with proven anticholinergic activity had a significant median 
decline in their Mini Mental State Examination (MMSE) score of 6.5 points over 8 years, 
compared to just 1 point in those who had not used those drugs (Ehrt et al., 2010).  
This class effect of drugs is not just limited to PD patients.  In older adults, it has long 
been recognised that anticholinergic activity is associated with delirium (Han et al., 
2001; Tune, 2001), cognitive decline (Mulsant et al., 2003) and even slowing of gait 
speed (Nebes et al., 2007).  Hence, anticholinergic drug use is likely to be an additional 
risk factor for cognitive decline in PD. 
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The majority of the risk factors discussed above have been assessed in prevalent PD 
cohorts.  In a longitudinal community-based incident PD cohort in the UK, age of 
greater than or equal to 72 combined with posterior cortical deficits (impaired 
semantic fluency and pentagon copying) had an odds ratio of 88 for dementia within 
the first 5 years of diagnosis (Williams-Gray et al., 2007a; Williams-Gray et al., 2009a).  
The strongest independent risk factor, however, for cognitive decline was the presence 
of the microtubule-associated protein tau (MAPT) H1/H1 genotype (Goris et al., 2007; 
Williams-Gray et al., 2009a), with an estimated odds ratio of 12.1.  This is supported by 
a more recent study demonstrating that the MAPT H1 haplotype was found in 
considerably more patients with PDD than controls (Seto-Salvia et al., 2011).  The 
mechanism of action is speculated to be that of protein aggregation.    
Other genes that may confer an increased risk of cognitive decline in PD have been 
investigated.  Whilst apolipoprotein E (APOE) has been established as a risk factor for 
the development of Alzheimer’s disease (AD), studies in cognitive decline in PD have 
produced conflicting results.  The three common alleles of APOE (ε2, ε3 and ε4) 
produce differing risks for AD, with ε2 being protective and ε4 both increasing the risk 
and reducing the age at onset of AD (Farrer et al., 1997).  Mechanisms by which APOE 
ε4 may operate include promoting the deposition of amyloid-β (Aβ) throughout the 
cortex, accelerating the configuration of amyloid from benign diffuse amyloid 
accumulation to neurotoxic β-pleated sheet aggregations, and increasing the 
frequency of neuritic plaque formation with associated cholinergic loss (Cummings et 
al., 1998).  Given the growing body of evidence implicating Aβ in the pathophysiology 
of PDD (Masliah et al., 2001; Pletnikova et al., 2005; Lashley et al., 2008; Clinton et al., 
2010; Siderowf et al., 2010; Compta et al., 2011b), it would seem likely that the APOE 
ε4 genotype would increase the risk of PDD.  However, the largest case-control study 
to date in 528 PD patients and 512 controls did not confirm this theory, with no 
association found between APOE ε4 carriers and cognitive decline (Williams-Gray et al., 
2009b).  The same paper included an updated meta-analysis of 4,198 PD cases and 
10,066 controls, where only a modestly increased risk of cognitive decline was found in 
APOE ε4 carriers (odds ratio 1.74, 95% confidence interval 1.36 - 2.23).  However, the 
authors cautioned against interpreting this as a positive result, citing small sample 
sizes, heterogeneous odds ratios and possible publication bias as confounding factors, 
with further longitudinal studies of several thousand participants required to draw 
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reliable conclusions (Williams-Gray et al., 2009b).  Although a more recent longitudinal 
study did find that PD patients who were APOE ε4 carriers experienced more rapid 
cognitive decline (Morley et al., 2012), the number of PD participants was relatively 
small (212) and the follow up was relatively short, with no control group included.  
Therefore, at present, there is insufficient evidence to ascertain whether APOE 
influences cognition in PD. 
Mutations in the glucocerebrosidase (GBA) gene increase the risk of PD (Sidransky et 
al., 2009) and are over-represented in other Lewy body diseases (Clark et al., 2009).  
There is also growing evidence that carriers of GBA mutations are at increased risk of 
cognitive decline (Neumann et al., 2009; Alcalay et al., 2012; Seto-Salvia et al., 2012; 
Winder-Rhodes et al., 2013).  Biological plausibility for this theory originates in mouse 
models of Gaucher’s disease (caused by homozygous loss-of-function GBA alleles), 
where an accumulation of α–synuclein/ubiquitin aggregates within the hippocampal 
neurones was noted, with a corresponding memory deficit (Sardi et al., 2011).  This is 
corroborated by post-mortem work in PD patients demonstrating more widespread 
cortical Lewy body deposition in those with GBA mutations than matched PD controls 
(Neumann et al., 2009).    
Other genes implicated in cognitive impairment in PD include butyrylcholinesterase-K 
(BuChE-K), catechol-O-methyltransferase (COMT), brain-derived neurotrophic factor 
(BDNF) and SNCA (Foltynie et al., 2005; Williams-Gray et al., 2007b; Ikeuchi et al., 2008; 
Lane et al., 2009; Williams-Gray et al., 2009a).  Duplications and triplications of SNCA 
are associated with parkinsonism and dementia (Ikeuchi et al., 2008), and variations in 
BuChE-K act synergistically with APOE in Lewy body dementias (Lane et al., 2009).  
Polymorphisms in the COMT (val158met) genotype produce differing levels of 
dopamine release in the dorsolateral prefrontal cortex and exert differing cognitive 
influences during the PD time course, with met homozygotes performing worse on 
tests of executive function in early disease and better as the disease progresses; the 
pattern is reversed for those with val/val polymorphisms (Williams-Gray et al., 2007b; 
Williams-Gray et al., 2009a).  However, COMT genotype does not influence overall 
cognitive decline and risk of dementia (Williams-Gray et al., 2009a; Morley et al., 2012). 
In summary, many risk factors have been postulated for cognitive decline in PD.  The 
most robust are increasing age, male gender, visual hallucinations, motor severity and 
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phenotype, cognitive impairment at baseline and MAPT H1/H1 haplotype.   Variations 
in risk factors are likely to partly explain the heterogeneity of cognitive impairment 
seen in PD.  
1.6.3 Profile of cognitive impairment in PDD 
Although heterogeneous in nature (Verleden et al., 2007), the cognitive profile of PDD 
differs from that of AD, with deficits in attention being one of the strongest predictors 
of PDD (Bronnick et al., 2007).  Furthermore, attentional deficit is an important 
determinant of inability to perform instrumental and physical activities of daily living, 
even after controlling for age, sex, motor function and other cognitive profiles 
(Bronnick et al., 2006).  Scores of attention also predict falls in PD (Allcock et al., 2009).  
In addition to impairments in attention, visuospatial and executive dysfunction are 
characteristic, and cognitive symptoms typically fluctuate (Troster, 2008).  Patients 
with PDD tend to perform worse than AD patients on demanding attentional tasks and 
in tasks requiring executive skills; these differences seen between the disorders 
become more pronounced as dementia progresses.  Executive problems are a common 
feature of PDD (Aarsland et al., 2003b) and lead to disturbances in adaptive, goal-
directed behaviour.  Executive dysfunction can manifest as difficulties in planning, set-
shifting, mental flexibility, abstraction, solving multiple step problems, selection of 
information, resisting cognitive interference and in the retrieval of information 
(Kehagia et al., 2010). Although many patients with PDD have a cognitive profile 
resembling that of DLB with a fronto-striatal executive syndrome and visuospatial 
deficits, a proportion may display more mnemonic and other temporo-parietal 
disturbances (Kehagia et al., 2010): this spectrum is likely to represent differing 
contributions of underlying pathologies.  The characteristics of the cognitive deficits 
seen in PDD and neuropsychological tests that may be useful are shown in Table 1-4. 
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Table 1-4 Pattern of cognitive deficits in PDD and example of tests used in diagnosis 
Cognitive 
Domain 
Description of cognitive deficit Examples of 
neuropsychological tests 
Executive ↓↓ verbal fluency,  ↓ set-shifting, 
planning & concept formation; may 
influence memory functions 
Verbal fluency (semantic & 
phonemic); ToL/SoC 
(CANTAB); WCST; Stroop 
Attention & 
Working 
Memory 
Fluctuating alertness; auditory and 
visual attentional deficits 
Digit span; Trail Making 
Test 
Memory Episodic memory less affected than 
AD; ↓ visual & verbal memory; 
recall > recognition affected early on 
Free and cued recall, e.g. 
CVLT or RAVLT 
Visuospatial & 
constructural 
function 
Globally impaired visual perception 
(predisposes to VH); impaired size 
and form discrimination; ↓ face 
recognition; marked impairment on 
clock-drawing test 
Clock-drawing test; 
Benton’s judgement of  
line orientation 
Language Less impairment than AD; less 
affected until severe disease 
Boston naming test 
ToL Tower of London test; SoC Stocking of Cambridge (both from CANTAB [Cambridge 
Neuropsychological Test Automated Battery]); WCST Wisconsin Card Sorting Test; CVLT 
California Verbal Learning Test; RAVLT Rey’s Auditory Verbal Learning Test; VH visual 
hallucinations   
1.6.4 Clinical features of PDD 
The onset of cognitive decline in PDD is insidious, with an associated slow progression 
of disease.  In a prospective study of prevalent PD in Norway, participants were 
followed longitudinally for up to eight years and compared with AD and control 
subjects (Aarsland et al., 2004).  The mean annual decline in MMSE score in all PD 
patients was 1.1 but varied widely; those who developed PDD had a mean annual 
decline of 2.3, which was similar to that seen in AD (2.6).  A comparable decline in 
MMSE score was seen in a later study of PDD and DLB, where a mean fall of 4.5 points 
(3.9 for DLB) was seen over a two-year period (Burn et al., 2006). 
Neuropsychiatric features are ubiquitous in PDD, and indeed their presence forms 
supportive criteria for the diagnosis of dementia in PD (Emre et al., 2007).  In a multi-
centre study of 537 PDD patients, 89% of subjects had at least one symptom on the 
Neuropsychiatric Inventory (NPI) and 77% had two or more symptoms (Aarsland et al., 
2007a).  Symptom burden was associated with more advanced PD and more severe 
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dementia.  Visual hallucinations (VH) occur more commonly in PDD than PD, with 
frequencies of between 30-50% for PD (Fenelon et al., 2000; Holroyd et al., 2001; 
Williams and Lees, 2005) but 45-65% in PDD (Aarsland et al., 2007a; Goetz et al., 
2008a).  VH are more common than auditory hallucinations, which in turn occur more 
frequently than tactile or olfactory hallucinations (Fenelon and Alves, 2010).  More 
benign visual phenomena such as a sense of ‘passage’ or ‘presence’ may occur early in 
PD, with subsequent illusions, simple visual hallucinations then complex formed VH as 
PDD progresses (Fenelon and Alves, 2010).  Delusions including paranoid ideation and 
phantom boarder may be present in over a quarter of patients (Goetz et al., 2008a).  
Other neuropsychiatric features commonly encountered in PDD are depression, 
anxiety and apathy (Aarsland et al., 2007a). 
Lastly, other clinical characteristics of PDD include an over-representation of the PIGD 
motor phenotype (Burn et al., 2006), autonomic dysfunction (Allan et al., 2007) and 
sleep disturbance.  RBD is a risk factor for the development of dementia in PD 
(Postuma et al., 2012), and both excessive daytime somnolence and poor sleep quality 
are commonly reported (Boddy et al., 2007). 
1.6.5 Pathogenesis 
The pathophysiology of PDD is poorly understood and may vary between individuals, 
with post-mortem studies producing conflicting findings.  Potential contributors to the 
underlying pathology include LBs and α-synuclein, Aβ plaque deposition, tau pathology, 
neuronal and synaptic loss, diffuse cerebrovascular disease and neurotransmitter 
changes, including degeneration of the cholinergic systems.  Braak hypothesised that 
as PD progresses to stages 5 and 6, LB pathology reaches the limbic and neocortical 
regions (Braak et al., 2004): indeed there is evidence that the development of 
dementia occurs with this disease progression (Braak et al., 2005).  Several studies 
have implicated these limbic and cortical LBs as the main substrate for driving 
cognitive decline in PD (Hurtig et al., 2000; Mattila et al., 2000; Apaydin et al., 2002; 
Aarsland et al., 2005a).  However, recent studies highlight the importance of Aβ 
deposition in the development of PDD (Sabbagh et al., 2009; Halliday and McCann, 
2010; Compta et al., 2011b).    Furthermore, a synergistic interaction between α-
synuclein and Aβ accumulation has been found both in vitro (Pletnikova et al., 2005; 
Lashley et al., 2008) and in transgenic mice models (Masliah et al., 2001; Clinton et al., 
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2010), with evidence that  Aβ promotes α-synuclein fibrillization and hence may 
influence the progression of cognitive decline (Masliah et al., 2001).  The observation 
that Aβ plaque burden, specifically diffuse plaque load, correlates with overall cortical 
LB burden strengthens the concept of a synergistic effect between these major 
pathological proteins (Lashley et al., 2008).  Age at disease onset and disease duration 
also contributes to the pathological findings associated with PDD (Kempster et al., 
2010), with older age at disease onset and cortical Aβ score predicting shorter time to 
dementia onset (Compta et al., 2011b).  Furthermore, older age increases the 
likelihood of age-associated pathologies; even in older subjects without PD, LB 
pathology is common and is associated with AD-type changes (Zaccai et al., 2008).  Age 
can also be associated with increased vascular burden, which in turn may contribute to 
PDD in some patients (Jellinger and Attems, 2008; Sonnen et al., 2010).  In addition, 
synaptic dysfunction in LB diseases could further influence the pathological process, as 
illustrated in a study of DLB demonstrating a post-synaptic loss of dendritic spines due 
to aggregation of pre-synaptic α-synuclein (Kramer and Schulz-Schaeffer, 2007). 
The variability and fluctuations seen in the clinical aspects of PDD suggests that at least 
some of the cognitive deficits may be the result of functional neurotransmitter 
imbalance or synaptic malfunction, rather than a structural substrate: In this context 
ACh loss almost certainly contributes to PDD.  Through modulation within open circuits 
connecting structures to the basal ganglia, the cholinergic system has widespread 
influence upon a number of functions, including cognition, attention, gait and postural 
stability (Yarnall et al., 2011).  In the brain, ACh is supplied by three main sources 
(Figure 1-2).  Neuronal loss within the pedunculopontine nucleus (PPN) and nucleus 
basalis of Meynert (nbM), in particular, are likely to be important in the pathogenesis 
of PDD.  The PPN is located in the caudal mesopontine tegmentum and comprises a 
significant population of cholinergic neurons, although other neurotransmitters in this 
structurally heterogeneous nucleus include glutamate, gamma amino-butyric acid 
(GABA) and dopamine (Jenkinson et al., 2009).  The cholinergic neurones of the PPN 
and the nbM are known loci of degeneration in PD, with the striatal cholinergic system 
remaining relatively preserved (Calabresi et al., 2006).  The nbM undergoes profound 
degeneration in PD (Arendt et al., 1983; Nakano and Hirano, 1984), with more severe 
cholinergic loss being associated with cognitive impairment (Zweig et al., 1993; 
Jellinger, 2006).        
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Figure 1-2 Schematic representation of the cholinergic output in the cortex 
 
Cholinergic interneurons in the striatum are shown in blue. The pedunculopontine nucleus 
(PPN; shown in red) provides the majority of cholinergic input to the thalamus, with other 
projections to the nucleus basalis of Meynert (nbM), striatum, substantia nigra, subthalamic 
nucleus, globus pallidus interna, cerebellum and spinal cord. The nbM (shown in green) sends 
cholinergic projections to the cerebral cortex, and also to thalamic nuclei. 
 
Further support for a cholinergic basis for cognitive impairment in PD originates from 
autopsy studies indicating that a midfrontal cholinergic deficit is more severe in 
patients with Lewy bodies than in AD (Tiraboschi et al., 2000).  Additionally, in AD with 
diffusely distributed Lewy bodies, cholinergic deficits in the caudate, frontal, temporal 
and parietal cortex are more pronounced than in pure AD (Langlais et al., 1993).  
Although previously much of the evidence for altered cholinergic transmission was 
derived in vitro, the advent of positron emission tomography (PET) offers the 
opportunity of measuring acetylcholinesterase (AChE), a surrogate marker for cortical 
cholinergic activity, in vivo.  AChE PET imaging in AD and PDD of equal global dementia 
severity demonstrated a greater reduction in cortical AChE activity in PDD compared to 
AD (Bohnen et al., 2003).   The reduction in cortical AChE activity was also greater in 
non-demented PD subjects compared to those with AD.  More specifically, a reduction 
in AChE activity correlated with poorer performance in tests of executive and 
attentional function (Bohnen et al., 2006b), hallmarks of the type of cognitive 
impairment seen in PD.  Thus forebrain cholinergic system degeneration seems to 
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occur early in PD, with deteriorating cognition associated with more severe cortical 
cholinergic loss (Bohnen et al., 2003; Shimada et al., 2009; Bohnen and Albin, 2011).    
In addition to ACh, other neurotransmitters have been implicated in the 
pathophysiology of cognitive impairment and may interact with the cholinergic system.  
Calabresi and colleagues proposed a convergent neurochemical model to explain 
cognitive deficits that occur in PD (Calabresi et al., 2006).  They suggested that 
noradrenergic and serotonergic deficits in PD (supported by post-mortem work 
(Scatton et al., 1983)) may influence dopamine and ACh release, which in turn affects 
synaptic plasticity and has a detrimental effect on the storage of neural information 
(Calabresi et al., 2006).  Neurotransmitters may also interact with other 
pathophysiological processes and influence cognition.  Evidence of a neuromodulatory 
influence of Aβ on cholinergic function has been demonstrated, with concentrations of 
Aβ negatively affecting ACh synthesis and release (Kar et al., 2004).  Serotonin 
neurotransmission has been shown to alter cortical Aβ levels, with a reduction in 
plaque load demonstrated in both a transgenic mice model of AD and in healthy older 
adults following administration of a selective serotonin reuptake inhibitor (Cirrito et al., 
2011).  In PD, a recent small imaging study demonstrated an inverse correlation 
between serotonin and amyloid binding (Kotagal et al., 2012b). 
In summary, the pathophysiological process underlying PDD is heterogeneous and is 
likely to differ between individuals.  The co-existence of α-synuclein, Aβ and tau 
deposition; neuronal loss; and neurochemical dysfunction has similarities with AD and 
suggests there may be common mechanisms triggering neurodegeneration and 
fibrillary protein aggregation (Jellinger, 2010a).  Understanding this pathogenic process 
in PDD is important for prognostication and developing appropriate therapeutic agents 
in the future.    
1.6.6 Biomarkers in PDD 
A biomarker is defined as a biological characteristic that is objectively measured and 
evaluated as an indicator of normal biological or pathologic processes or of 
pharmacologic responses to a therapeutic intervention.  There are many biomarkers 
that have been proposed as possible candidates for the development of PDD; these 
cover different modalities and are shown in Table 1-5 (Svenningsson et al., 2012).   
28 
 
Table 1-5 Studies of potential biomarkers in PDD (adapted from Svenningsson 2012)
 Biomarker Biomarker 
subtype 
Findings Reference(s) 
Imaging Structural MRI Atrophy temporal, parietal & 
occipital cortices in PDD 
 
Hippocampal plus parieto-
temporal atrophy predicted 
cognitive impairment 
(Burton et al., 2004; 
Beyer et al., 2007; Song 
et al., 2011; Weintraub et 
al., 2011; Melzer et al., 
2012) 
(Weintraub et al., 2012) 
 
18
FDG-PET Widespread cortical 
metabolism in PDD; especially 
temporal, parietal & occipital 
areas  
↓ perfusion occipital & 
posterior cingulate cortices 
predicted dementia 
(Huang et al., 2007; 
Jokinen et al., 2010; Klein 
et al., 2010) 
 
(Bohnen et al., 2011) 
 PiB PET No difference in PiB amyloid 
binding in PDD vs. PD-CN 
PiB binding at baseline 
predicted ↓ cognition during 
longitudinal follow-up 
(Foster et al., 2010; 
Gomperts et al., 2012) 
(Gomperts et al., 2013) 
 AChE PET Widespread ↓AChE activity in 
PDD: this correlated with 
attention/ executive function 
(Bohnen et al., 2003; 
Bohnen et al., 2006b; 
Shimada et al., 2009) 
 SPECT perfusion Hypoperfusion parietal/ 
occipital regions in cognitive 
impairment 
(Firbank et al., 2003; 
Nobili et al., 2009) 
CSF Aβ42 ↓ PDD>PD-MCI>PD-CN; Aβ 
correlated with memory 
impairment 
 
↓ Aβ42 predicted cognitive 
decline during longitudinal 
follow-up 
(Mollenhauer et al., 
2006b; Compta et al., 
2009; Alves et al., 2010; 
Montine et al., 2010) 
(Siderowf et al., 2010) 
 tau Mixed results (Mollenhauer et al., 
2006b; Compta et al., 
2009; Alves et al., 2010; 
Montine et al., 2010) 
 α-synuclein ↓ total α-syn in PD & DLB cf 
controls/AD 
(Hong et al., 2010; 
Mollenhauer et al., 
2011b) 
Plasma  Epidermal growth 
factor 
↓ EGF levels predicted 
cognitive decline 
(Chen-Plotkin et al., 
2011) 
Neuro- 
physiology 
EEG Low background rhythm 
frequency predicted cognitive 
decline 
(Klassen et al., 2011) 
 SAI Abnormal SAI in PDD and PD-
MCI cf controls 
(Celebi et al., 2012; 
Yarnall et al., 2013) 
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Neuroimaging methods used to predict PDD have included both structural and 
functional techniques.  These are discussed in some detail in section 1.7.4, but in brief, 
structural imaging has demonstrated that atrophy of the parietal, temporal and 
occipital cortices occur in cross-sectional studies of those with PDD or mild cognitive 
impairment (PD-MCI) compared with those with normal cognition (PD-CN) (Burton et 
al., 2004; Beyer et al., 2007; Song et al., 2011; Weintraub et al., 2011; Melzer et al., 
2012).  In a recent longitudinal study, an AD-type pattern of atrophy on MRI predicted 
long-term cognitive decline in PD subjects (Weintraub et al., 2012).   Cortical 
hypometabolism and hypoperfusion were noted in similar areas using positron 
emission tomography (PET) and single photon emission computed tomography (SPECT), 
respectively, in those with PD and cognitive impairment (Firbank et al., 2003; Huang et 
al., 2007; Nobili et al., 2009; Jokinen et al., 2010; Klein et al., 2010); with a longitudinal 
study indicating that cerebral hypometabolism in the visual association and posterior 
cingulate cortices may predict the development of dementia (Bohnen et al., 2011).  
PET imaging using radiolabelled metabolites of acetylcholinesterase (AChE) as a marker 
of ACh activity has demonstrated widespread reductions in AChE in those with PDD 
compared with AD and control participants (Bohnen et al., 2003; Shimada et al., 2009).  
Lastly, in terms of imaging, a recent study of amyloid burden detected using Pittsburgh 
Compound B (PiB) PET has shown promise in predicting cognitive decline in PD, with a 
higher baseline PiB retention and a diagnosis of PD-MCI associated with worsening 
cognition at follow-up (Gomperts et al., 2013).  Greater amyloid deposition at baseline 
also predicted executive impairment over time. 
Other biomarkers that may be used to predict PDD include cerebrospinal fluid (CSF), 
plasma proteins and neurophysiological techniques.  CSF and short latency afferent 
inhibition (SAI) as biomarkers are discussed in further detail in Chapter 3 and 4, 
respectively.  Epidermal growth factor (EGF) is a plasma protein that has been 
postulated to support dopaminergic neurons as a neurotrophic factor, and has been 
associated with both baseline cognition and an eight-fold risk of progression to 
dementia for those with EGF levels in the lowest quartile (Chen-Plotkin et al., 2011).  In 
a smaller study of de novo PD subjects followed over two years, baseline EGF levels 
predicted poorer performance in frontal and temporal cognitive function (Pellecchia et 
al., 2013).  Finally, quantitative EEG may be used as a predictive biomarker for the 
development of dementia (Klassen et al., 2011).  In a prospective study of 106 non-
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demented PD participants, those with lower than median background rhythm 
frequency were 13-times more likely to develop dementia than those with normal 
rhythms over a mean duration of 3.3 years.  The authors hypothesised that disruption 
in the default network (defined as the network of brain region activity that occurs 
during the cognitive resting state), perhaps due to amyloid deposition, could explain 
these findings (Klassen et al., 2011). 
In conclusion, many biomarkers have been studied as possible predictors of dementia 
in PD.  Due to the complexity and heterogeneity of the underlying pathophysiological 
processes it is unlikely that a single biomarker will predict PDD. But, taken together, 
these laboratory, imaging and clinical risk factors may allow clinicians to predict which 
patients are most likely to progress to this state, thus allowing better use of targeted 
interventions and improved prognostication. 
1.6.7 Diagnosis of PDD 
Based on a comprehensive literature review of the clinical, psychological and 
behavioural features of PDD, the Movement Disorder Society (MDS) Task Force 
developed clinical criteria for the diagnosis of probable and possible PDD in 2007 
(Table 1-6 and Table 1-7) (Emre et al., 2007).  The diagnosis of PDD should occur within 
the context of PD, with impairment in two or more cognitive domains (attention, 
executive, visuospatial or memory) that is severe enough to affect activities of daily 
living.  Behavioural features such as apathy, depression, anxiety, excessive daytime 
somnolence, hallucinations and delusions are supportive features but are not 
necessary for the diagnosis.  The MDS Task Force also produced recommendations in 
the same year for the operationalization of the diagnostic criteria based on two levels 
(Dubois et al., 2007).  Level I assessment can be used by any clinician and does not 
require neuropsychological expertise (Table 1-8).  MMSE score should be < 26, with 
impairment in two or more cognitive functions measured by: counting months 
backward or serial 7’s (attention); phonemic fluency or clock-drawing test (executive 
function); pentagon copying (visuospatial); or 3-word recall from the MMSE (memory).  
The presence of apathy, depressed mood, delusions or excessive daytime sleepiness, 
as measured by the four-item Neuropsychiatric Inventory, may support the diagnosis 
of probable PDD.  Level II assessment requires detailed neuropsychological testing, and 
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is recommended when there is uncertainty regarding the diagnosis or in the context of 
research or pharmaceutical trials.        
 
Table 1-6 Features associated with dementia in PD (Emre et al., 2007)
 I. Core features 
1. Diagnosis of PD according to QSBB criteria 
2. A dementia syndrome with insidious onset and slow progression, developing within the context of 
established Parkinson’s disease and diagnosed by history, clinical, and mental examination, defined as: 
• Impairment in >1 cognitive domain 
• Representing a decline from premorbid level 
• Deficits severe enough to impair daily life (social, occupational, or personal care), independent of the 
impairment ascribable to motor or autonomic symptoms 
II. Associated clinical features 
1. Cognitive features: 
• Attention: Impaired. Impairment in spontaneous and focused attention, poor performance in 
attentional tasks; performance may fluctuate during the day and from day to day 
• Executive functions: Impaired. Impairment in tasks requiring initiation, planning, concept formation, 
rule finding, set shifting or set maintenance; impaired mental speed (bradyphrenia) 
• Visuospatial functions: Impaired. Impairment in tasks requiring visual-spatial orientation, perception, 
or construction 
• Memory: Impaired. Impairment in free recall of recent events or in tasks requiring learning new 
material, memory usually improves with cueing, recognition is usually better than free recall 
• Language: Core functions largely preserved. Word finding difficulties and impaired comprehension of 
complex sentences may be present 
2. Behavioural features: 
• Apathy: decreased spontaneity; loss of motivation, interest, and effortful behaviour 
• Changes in personality and mood including depressive features and anxiety 
• Hallucinations: mostly visual, usually complex, formed visions of people, animals or objects 
• Delusions: usually paranoid, such as infidelity, or phantom boarder, delusions 
• Excessive daytime sleepiness 
III. Features which do not exclude PDD, but make the diagnosis uncertain 
• Co-existence of any other abnormality which may by itself cause cognitive impairment, but judged not 
to be the cause of dementia, e.g. presence of relevant vascular disease in imaging 
• Time interval between the development of motor and cognitive symptoms not known 
IV. Features suggesting other conditions or diseases as cause of mental impairment, which, when 
present make it impossible to reliably diagnose PD-D 
• Cognitive and behavioural symptoms appearing solely in the context of other conditions such as: 
- Acute confusion (due to systemic diseases or abnormalities; drug intoxication) 
- Major Depression according to DSM IV 
• Features compatible with “Probable Vascular dementia” criteria  
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Table 1-7 Criteria for diagnosis of probable and possible PDD (Emre et al., 2007)
 Probable PD-D 
A. Core features: Both must be present 
B. Associated clinical features: 
• Typical profile of cognitive deficits including impairment in at least two of the four core cognitive 
domains 
• The presence of at least one behavioural symptom (apathy, depressed or anxious mood, 
hallucinations, delusions, excessive daytime sleepiness) supports the diagnosis of Probable PDD 
C. None of the group III features present 
D. None of the group IV features present 
Possible PD-D 
A. Core features: Both must be present 
B. Associated clinical features: 
• Atypical profile of cognitive impairment in one or more domains, such as prominent or receptive-type 
(fluent) aphasia, or pure storage-failure type amnesia (memory does not improve with cueing or in 
recognition tasks) with preserved attention 
• Behavioural symptoms may or may not be present 
OR 
C. One or more of the group III features present 
D. None of the group IV features present 
 
Table 1-8 Algorithm for diagnosing PDD at Level I  (Dubois et al., 2007)
 1 A diagnosis of PD based on the QSBB criteria  
2 PD developed prior to the onset of dementia 
3 MMSE < 26 
4 Cognitive deficits severe enough to impact daily living (based on caregiver interview or Pill 
Questionnaire) 
5 Impairment in ≥2 of the following tests: 
Months reversed or Serial 7’s backward from 100 (≥2 incorrect responses) 
Phonemic fluency (<10 words in 60 sec) or Clock drawing 
MMSE Pentagons 
3-Word recall  
 
1.6.8 Treatment of PDD 
The initial management of PDD, after careful explanation of the diagnosis, starts with 
the withdrawal of potential contributing medications such as non-selective 
anticholinergic drugs.  Rationalisation and simplification of PD treatment by the 
gradual removal of dopamine agonists, monoamine oxidase inhibitors then catechol-O-
methyltransferase inhibitors should be done slowly to avoid worsening motor 
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symptoms.  Co-existent depression, anxiety and RBD should be treated, although no 
randomised controlled trials in these non-motor symptoms in PDD specifically have 
been reported.  If psychotic symptoms predominate, clozapine has been shown to be 
efficacious (Seppi et al., 2011), although in practice quetiapine may be used more 
commonly due to the potential risk of agranulocytosis and subsequent monitoring 
required with clozapine.   
Cholinesterase inhibitors (ChEIs) form the mainstay of treatment of PDD: A recent 
Cochrane review supports their use and showed a positive overall effect on global 
assessment, cognitive function, behavioural disturbance and activities of daily living 
(Rolinski et al., 2012).  The only two adequately powered randomised controlled trials 
of ChEIs in PDD are the EXPRESS (Emre et al., 2004) and the EDON (Dubois et al., 2012) 
study.  The EXPRESS study enrolled 541 participants with mild to moderate PDD (mean 
MMSE 19/30), who were randomised to receive either rivastigmine (3-12mg) or 
placebo for 24 weeks.  Those who received the active drug had a moderate 
improvement in the primary and secondary outcomes, with a mean improvement of 
2.1 points (out of 70) in the Alzheimer’s Disease Assessment Scale (ADAS-cog), 
compared with a 0.7 point worsening in the placebo group.  Improvements in 
executive and attentional functions, behavioural symptoms and activities of daily living 
were significantly better in the treatment group.  There were, however, marked 
variations within treatment responses.  These improvements were maintained up to 
48 weeks in an open-label extension of the study (Poewe et al., 2006).  The more 
recent EDON study recruited 550 PDD subjects (mean MMSE 21/30) and randomised 
to placebo or donepezil (5 or 10mg) for 24 weeks.  Although no difference in the 
primary endpoint, the ADAS-cog, was seen in the intention-to-treat population by the 
pre-defined statistical model, when the treatment-by-country interaction term was 
removed from the model the improvements observed were similar to the EXPRESS 
study.  Secondary end-points of global cognition using MMSE score and tests of 
executive and attention were significantly better in the donepezil group, although no 
difference was seen in activities of daily living or behavioural symptoms.  Adverse 
events in both the EXPRESS and EDON study were mild, but largely compromised 
gastrointestinal side-effects and increased tremor: there is some evidence that these 
may be reduced with administration of a rivastigmine patch instead of capsules (Emre 
et al., 2011).   
34 
 
Randomised controlled studies have investigated the effect of the partial NMDA-
receptor antagonist memantine in PDD, with generally negative results (Aarsland et al., 
2009a; Leroi et al., 2009; Emre et al., 2010).  Some improvement in cognition was 
noted and the drug was well tolerated, but the MDS Task Force have judged that as yet, 
there is insufficient evidence to recommend its use in this context (Seppi et al., 2011). 
Improving knowledge of the underlying pathogenesis of PDD should translate to 
identifying novel targets and developing new treatments for PDD.  As the disease is 
heterogeneous, different patients may benefit from different treatments.  The 
development of disease-modifying treatments that may halt or limit the progression of 
the pathology is vital to prevent the surge of dementia cases that is predicted in the 
future.  In view of the overlap of pathology between PDD and AD, work in AD may 
have direct translational benefit to PDD: One example of this is anti-amyloid strategies.  
A recent study in triple transgenic mouse models of AD demonstrated that 
subcutaneous injections of apomorphine improved memory function and decreased 
intraneuronal Aβ and phosphorylated tau levels compared with controls (Himeno et al., 
2011).  It is therefore conceivable that apomorphine, which may inhibit Aβ fibrillization 
(Lashuel et al., 2002), could be used as a modifier of amyloid deposition in PDD.  Other 
potential targets for treatment include prevention of α-synuclein aggregation, trophic 
factors and anti-inflammatory strategies.   
Lastly, in parallel with the involvement of the multidisciplinary team, the management 
of PDD should include a discussion of the cognitive and psychological benefits of 
exercise (Tanaka et al., 2009; Cruise et al., 2011) and cognitive training (Paris et al., 
2011).  These certainly deserve consideration in future clinical trials, and are likely to 
be instituted in addition to therapeutic approaches.   
1.7 Mild cognitive impairment in PD 
Mild cognitive impairment (MCI) is defined as a transitional state between normality 
and dementia, with little or no impairment in daily functioning and subjective or 
objective cognitive impairment (Petersen, 2004).  Data from epidemiological studies 
demonstrates that 10-15% of subjects with MCI per year progress to dementia, largely 
of the Alzheimer’s-type (Petersen et al., 2009).   
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The concept of mild cognitive impairment in PD (PD-MCI) has received increasing 
attention recently.  Although not analogous to the field of AD, where the significance 
of MCI may be better understood, it is now recognised that PD-MCI may represent a 
pre-dementia state and is associated with increased healthcare costs (Vossius et al., 
2011), poorer self-reported quality of life (Klepac et al., 2008; Leroi et al., 2012) plus 
subtle impairments in instrumental activities of daily living (Rosenthal et al., 2010; 
Leroi et al., 2012).   
1.7.1 Epidemiology of PD-MCI 
The prevalence of PD-MCI varies widely depending on the study population 
(community- or hospital-based, incident or prevalent cases, age and disease severity, 
use of controls), the neuropsychological tools used and the definition of MCI applied 
(Table 1-9).  Not surprisingly, studies of incident, drug-naïve patients have 
demonstrated the lowest prevalence of PD-MCI (14.8 (Poletti et al., 2012) and 18.9 % 
(Aarsland et al., 2009b)), with longer disease duration such as the work from Janvin 
and colleagues (Janvin et al., 2006) or retrospective studies (Sollinger et al., 2010) 
producing higher figures (52.8% for both).  However, the presence of PD-MCI was 57% 
in a longitudinal study of patients with relatively short disease duration (Williams-Gray 
et al., 2007a).  In an attempt to overcome methodological variation, Aarsland and 
colleagues performed a meta-analysis of over 1,000 patients encompassing eight 
centres in Europe and the USA (Aarsland et al., 2010).  A mean of 25.8% (95% CI, 23.5–
28.2) were classified as PD-MCI, based on age- and education-corrected z scores of less 
than 1.5 SD below normative values in one or more cognitive domains, although 
significant variations were seen across the separate centres studied.         
36 
 
Table 1-9 Demographic and clinical features of studies in PD-MCI 
Reference PD  Control
s 
Mean 
age 
PD 
Disease 
duration 
(years) 
Type of 
study 
Countr
y of 
origin 
MCI definition Cognitive domains 
assessed 
%MCI Cognitive 
profile 
Other comments 
1. (Pai and 
Chan, 2001) 
102 0 68 NA Cross-
sectional
; hospital 
clinic; 
prevalen
t cases  
Taiwan <1.5 SD below age- 
and educationally- 
matched groups; 
Cognitive Ability 
Screening 
Instrument (CASI) 
used (max score 
100) 
Remote memory, 
recent memory, 
attention, mental 
manipulation, 
orientation, 
abstract thinking, 
language, drawing, 
& verbal fluency 
38.2 Recent 
memory, 
verbal fluency, 
abstract 
thinking, & 
orientation all 
impaired to a 
high degree 
1. Higher educational level 
did not protect against 
cognitive decline 
2. CASI has not been 
validated in PD 
 
 
2.(Foltynie 
et al., 2004) 
159 0 70.6 NA 
Incident 
Cross-
sectional
; 
communi
ty; 
incident 
UK <1 SD below 
normative values 
for PRM and TOL 
Temporal lobe plus 
frontostriatal 
impairment tested 
with PRM and TOL, 
respectively; MMSE 
also assessed 
30.1* 9.6% fronto-
striatal 
impairment; 
8.2% temporal 
lobe deficit; 
11% global 
deficits* 
*1.Note 159 patients but 
13 had MMSE<24; in total 
36% therefore had some 
cognitive impairment 
2. Patients with global or 
frontal impairments were 
significantly older, had 
higher UPDRS motor 
scores, & lower premorbid 
IQs than CN 
3.(Muslimovi
c et al., 
2005) 
115 70 66.2 1.6 Cross-
sectional
; hospital 
clinic; 
early PD 
Nether-
lands 
<2 SD below mean 
score of matched 
controls in ≥3 
neuropsychological 
tests 
Psychomotor 
speed, attention, 
language, memory, 
executive 
functions, & 
visuospatial/constr
uctive (28 tests 
administered) 
23.5 
(4.3 
control 
group) 
Attention, 
executive & 
memory 
function most 
impaired cf 
controls 
1. Age at disease onset 
independent predictor of 
cognitive ↓ 
2. Impaired were older, 
male, had later disease 
onset, ↑ disease severity, 
↑depression scores, & 
more severe axial & speech 
symptoms 
4.(Janvin et 72 38 71.0 aMCI Longitudi Norway ≤1.5 SD below Short-time 52.8 naMCI-sd 1. 62% MCI demented at 4 
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al., 2006) 10.6; 
naMCI-sd 
11.4; 
multiple 
domains 
11.6; CN 
12.2  
nal; 
communi
ty; 
prevalen
t cases 
mean score of 
controls in 1, 2 or 3 
neuropsychological 
tests; DRS and 
MMSE also used 
visual memory 
(BVRT), visuospatial 
(JLO) & attention/ 
executive  (SWT) 
domains 
44.7%, 
multiple 
domains 
slightly 
impaired 
39.7%, 
amnestic 
15.8% 
years cf 20% cognitively 
normal (OR 4.8; 95% CI 
1.58–14.8) 
2. Single domain 
nonamnestic MCI only 
associated with 
development dementia (OR 
8.3; 95% CI 1.8 –37.5) 
5.(Caviness 
et al., 2007) 
86 0 CN 
75.2; 
MCI 
74.6; 
PDD 
79.9 
CN 5.4; 
MCI 9.2; 
PDD 16.8 
Cross-
sectional
; 
prevalen
t cases 
USA ≤1.5 SD below age 
corrected mean 
score consistently 
in 1 of 5 cognitive 
domains, plus 
subjective memory 
complaint 
Frontal/executive 
(Stroop, TMT A&B), 
amnestic (RAVLT), 
visuospatial (CDT, 
JLO), attention 
(WAIS III forward 
and backwards) & 
language (COWA, 
category fluency) 
20.9 
(25.3 
non-
demen
ted 
PDs) 
sdMCI-frontal/ 
executive 
39%; naMCI-
md 22%; 
aMCI-sd 22%; 
aMCI-md 11%; 
sdMCI-
language 6% 
Language dysfunction 
rarely seen; domains of 
visuospatial and attention 
did not reach threshold of 
dysfunction in PD-MCI 
group 
6.(Williams-
Gray et al., 
2007a) 
126 0 NA NA (‘3.5 
years’ for 
whole 
cohort) 
Longitudi
nal; 
communi
ty 
UK <1 SD below 
matched normative 
values 
Frontal (TOL, SRM, 
phonemic fluency), 
temporal (PRM, 
semantic fluency) & 
parietal function 
(pentagon copying) 
57 NA Predictors of cognitive 
decline independent of age 
were non-tremor dominant 
phenotype, impaired 
semantic fluency & 
impaired pentagon copying 
7.(Kim et al., 
2009) 
141 0 CN 
57; 
MCI 
64 
CN 3.6; 
MCI 4.0 
Cross-
sectional 
Korea <1.5 SD below the 
mean score for the 
age- and education-
matched control 
group in ≥1 of 5 
cognitive domains 
tested 
Attention (forward 
digit span); 
language (BNT); 
visuospatial (RCFT); 
memory (SVLT) & 
executive function 
(phonemic word 
association test) 
40.4 aMCI-sd 
25.9%; sd 
language 
12.3%; sd 
visuospatial 
10.5%; sd 
executive 
3.5%; md 
47.4%  
Age was significant 
predictor of all subtypes of 
MCI; domain most 
influenced by age was 
executive function 
8.(Elgh et al., 
2009) 
86 30 68.1 CN 2.1; 
MCI 1.4 
Cross-
sectional
Swede
n 
<1.5 SD below 
control means 
Episodic memory; 
working memory; 
30 30% had 
deficits in ≥1 
1.Education was the only 
independent significant 
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; newly 
diagnose
d; drug 
naive 
(matched for age/ 
sex/educational 
level if possible)  
for >50% of single 
test results within a 
domain 
visuospatial 
function; verbal 
fluency; naming 
and executive 
function 
domain, 16% 
deficits in ≥2 
domains 
predictor of severe 
cognitive impairment 
2.Included 5 patients in 
‘PD’ group with normal DaT 
9.(Mamikon
yan et al., 
2009) 
106 0 64.6 6.5 Cross-
sectional 
USA ≤1.5 SD below 
normative means 
on ≥2 tests (for 
memory and 
attention) or a 
single test 
(attention) 
Memory (HVLT-R – 
3 components), 
executive function 
(Stroop, semantic 
fluency) and 
attention (digit 
span) 
29.2 17.9% sd 
(attention 8.5, 
memory 5.7, 
executive 
3.8%); 11.3% 
md  
Predictors of  of MCI were 
↑age, ↑ Hoehn & Yahr 
stage,↑ UPDRS 
motor score, 
anti-anxiety medication use  
and a trend towards ↑ ESS 
score 
10.(Aarsland 
et al., 2009b) 
196 171 67.7 2.3 Cross-
sectional
; 
incident; 
drug 
naive 
Norway <1.5 SD below 
mean for corrected 
z score for at least 
one of the cognitive 
domains 
Verbal memory 
(CVLT-II); 
visuospatial (VOSP 
silhouettes); 
attentional/ 
executive (serial 
7’s, Stroop, 
semantic fluency) 
18.9 62.2% of MCI 
group had 
naMCI-sd; 
24.3% aMCI-
sd; 10.8% 
aMCI-md & 
2.7% naMCI-
md 
1.The largest effect size 
was found for verbal 
memory 
2.No clinical or 
demographic differences 
found between those with 
PD-MCI cf PD-CN 
11.(Sollinger 
et al., 2010) 
72 0 CN 
63.7; 
MCI 
66.0 
CN 5.8; 
MCI 8.7 
Retro-
spective 
record 
review 
USA Deficits in ≥2 tests 
within a domain; 
plus subjective & 
objective cognitive 
impairment (strict 
cut-offs not used) 
Visuospatial (JLO, 
pentagons); 
language (BNT, 
phonemic & 
semantic fluency); 
attention (digits 
forwards, TMT A); 
executive (TMT B, 
‘WORLD’ 
backwards) & 
memory (CERAD 
word list or HVLT-R) 
52.8 naMCI-sd 
36.8%, aMCI-
sd 23.7%, 
aMCI-md 
23.7% & 
naMCI-md 
15.8% 
(memory>exe
cutive>visuosp
atial>language
>attention 
deficits) 
Those with MCI had ↑ 
duration of PD and ↑ PIGD 
subscale scores 
12.(Aarsland 1,34 0 NA NA Meta- 8 <1.5 SD below Attention/ 25.8 11.3% naMCI- MCI associated with ↑age 
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et al., 2010) 6 analysis centres mean for corrected 
z score on ≥ 1 
cognitive domain 
executive; 
visuospatial; 
memory (variety of 
tests used) 
sd; 8.9% 
aMCI-sd; 4.8% 
aMCI-md & 
1.3% naMCI-
md. Memory 
(13.3%)>visuo
spatial 
(11%)>attenti
on/executive 
dysfunction 
10.1%) 
at assessment & at disease 
onset, male gender, 
depression, more severe 
motor symptoms, and 
advanced disease stage 
13.(Poletti et 
al., 2012) 
121 100 66.6 1.2 Cross-
sectional
; early 
drug 
naive 
Italy <1.5 SD scores in ≥ 
2 tests 
Memory (RAVLT, 
Rey Figure Recall); 
language (BNT, 
semantic & 
phonemic fluency); 
executive (Stroop, 
FAB, TMT A&B, 
digit span, Corsi 
test, MCST, CPM 
47); praxis (Rey 
figure copy) & 
visuospatial 
function (JLO) 
14.8 
(contro
l group 
7) 
5% naMCI-md; 
4.1% naMCI-
sd; 4.1% 
aMCI-md & 
1.7% aMCI-sd 
1.Bradykinesia, axial 
impairment &  absence of 
tremor associated with ↑ 
risk of MCI 
2.PIGD patients had higher 
proportion of MCI than TD 
(23.2 v 6.3%) 
14.(McColga
n et al., 
2012) 
132 0 NA 1.1 Incident; 
commmu
nity 
UK <1 SD in ≥2 tests 
plus subjective or 
objective decline 
NA (included ACE-
R, TOL, PRM, SRM, 
PAL, semantic & 
phonemic fluency) 
22 NA 1.ACE-R good screening 
test of MCI (score <89) 
2.MCI older & less 
educated than CN 
15.(Yu et al., 
2012) 
94 84 61.6 4.0 Cross-
sectional
; early; 
mild 
disease 
Taiwa
m 
<1.5 SD in ≥1 
cognitive domain  
Executive; category 
fluency; memory 
function; 
psychomotor 
speed; visuospatial; 
attention; language 
46.8 
(PDD 
9.6) 
naMCIsd 
25.5%; 
aMCImd 7.4%; 
naMCImd 
7.4%; aMCIsd 
6.4% 
1.Executive most common 
domain affected (29.5%), 
then visuospatial then 
memory (15.9 & 13.6%). 
2.MCST greatest effect size 
of cognitive tests 
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PRM pattern recognition memory; SRM spatial recognition memory; TOL tower of London task; PAL paired associates learning; BVRT Benton visual retention test; 
JLO judgement of line orientation test; SWT Stroop word test; TMT Trails making test; RAVLT Rey auditory verbal learning test; CDT clock drawing test; WAIS 
Wechsler Adult Intelligence Scale; COWA controlled oral word association; BNT Boston naming test; RCFT Rey Complex Figure Test; SVLT Seoul Verbal Learning 
Test; HVLT-R Hopkins verbal learning test-revised; CVLT-2 California verbal learning test 2; VOSP visual object and space perception battery; FAB frontal 
assessment battery; MCST modified card sorting test; CPM 47 Raven coloured progressive matrices; ACE-R Addenbrooke’s Cognitive Examination-Revised; na 
amnestic; a amnestic; sd single domain; md multiple domain; CN cognitively normal; ESS Epworth sleepiness scale; PIGD postural instability gait difficulty; TD 
tremor dominant 
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Prior to 2012, there were no consensus criteria for the diagnosis of PD-MCI.  Of the 15 
studies in Table 1-9, ten used neuropsychological test scores of less than 1.5 standard 
deviations (SD) below control values or normative means, three used a cut-off of 1 SD 
(all three studies by the same group), one used 2 SD and the last used no strict cut-off. 
This explains in part the variation in frequencies of MCI reported.  As per the definition, 
16% and 2.5% of subjects will fall below 1 and 2 SD of the mean, respectively, of a 
normally distributed test, and hence a less stringent cut-off could lead to a higher 
likelihood of false positive MCI cases.  This was succinctly demonstrated by researchers 
in New Zealand, who evaluated 143 PD participants and 50 matched controls on 20 
neuropsychological measures (Dalrymple-Alford et al., 2011).  The prevalence of PD-
MCI was 14% when a cut-off of two test scores within one domain less than 2 SDs 
below normative values was used, but increased to 89% when one score less than 1 SD 
was used.  The authors recommended that two scores less than 1.5 SD either within a 
single domain or in two separate domains should be used as criteria for PD-MCI 
(Dalrymple-Alford et al., 2011).  Variations are also attributable to whether subjective 
cognitive impairment was included as part of the diagnostic criteria; there is however, 
evidence that this may not be a reliable discriminator of MCI, with subjective memory 
complaints commonly reported in those who are cognitively normal (PD-CN) and 
under-reported in those with impairments (Caviness et al., 2007).   In addition, the 
differences in frequencies of MCI may be due to the number of neuropsychological 
tests used by study participants, with larger numbers of tests increasing the probability 
of false-positives.  This can be avoided to some extent by defining MCI using 
impairment in more than one test, or standardising impairments within tests within 
separate cognitive domains.      
1.7.2 Profile of cognitive impairment in MCI 
As different neuropsychological tests cannot be fully separated on their 
neuroanatomical basis, it can be difficult to classify cognitive deficits based on 
impairments in each test, and therefore discrepancies are seen in the cognitive deficits 
reported in PD-MCI.  Furthermore, researchers’ interpretations can mean that tests 
may be categorised in different domains, which affects study analysis.  For example, 
semantic fluency has been categorised as a test of executive (Aarsland et al., 2009b; 
Mamikonyan et al., 2009) and language function (Sollinger et al., 2010; Poletti et al., 
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2012).  These differences and the cognitive heterogeneity of PD mean that it is difficult 
to generalise findings to the PD-MCI population overall.  However, a significant 
number of studies have found that nonamnestic single-domain MCI (naMCI-sd) is the 
most common subtype (Janvin et al., 2006; Caviness et al., 2007; Aarsland et al., 2009b; 
Mamikonyan et al., 2009; Aarsland et al., 2010; Sollinger et al., 2010; Goldman et al., 
2012a; Yu et al., 2012).  This is in contrast to the general population, where amnestic 
MCI is the most common subtype.   
Early studies, largely from researchers in Cambridge, in cognitively impaired but non-
demented PD participants focussed on a fronto-striatal dysexecutive syndrome that 
was driven by dopaminergic deficits, but which may also be precipitated by 
medications due to dopamine ‘overdosing’ in the caudate nucleus and ventral striatum 
(Kehagia et al., 2010).  Prominent frontal/executive deficits have been found in a 
number of studies in PD-MCI (Foltynie et al., 2004; Muslimovic et al., 2005; Caviness et 
al., 2007; Mamikonyan et al., 2009; Yu et al., 2012).  There is evidence that these 
deficits may impact on other neuropsychological domains, with one study 
demonstrating that executive deficits explained a significant proportion of memory 
deficits (Bronnick et al., 2011).  Some studies have suggested that executive 
dysfunction may predict cognitive decline (Levy et al., 2002a; Woods and Troster, 2003; 
Janvin et al., 2005); however, findings from a larger, less heterogeneous and well-
characterised cohort in the UK established that fronto-striatal deficits at baseline were 
associated with a better prognosis and did not increase the likelihood of progression to 
dementia (Williams-Gray et al., 2007a; Williams-Gray et al., 2009a).  Mnemonic deficits 
(in both retrieval and encoding) were prominent findings for a number of groups and 
signifies an important aspect of early cognitive dysfunction (Aarsland et al., 2009b; 
Elgh et al., 2009; Kim et al., 2009; Aarsland et al., 2010; Sollinger et al., 2010).  
Amnestic impairments were present even after controlling for attention/executive 
dysfunction (Aarsland et al., 2010).  There is considerable heterogeneity within the 
memory deficits in PD, which have traditionally been thought to comprise deficits in 
retrieval; that is, problems with recall of learned information but with sparing of 
encoding, storage and recognition (Poletti et al., 2011).  However, recent studies 
indicate that there is diversity in memory profiles affected, which include encoding and 
retention in addition to retrieval (Weintraub et al., 2004a; Whittington et al., 2006; 
Bronnick et al., 2011).  Other domains affected in PD-MCI are psychomotor speed, 
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attention and visuospatial function (Muslimovic et al., 2005; Mamikonyan et al., 2009; 
Aarsland et al., 2010; Aarsland et al., 2011; Barone et al., 2011; Goldman et al., 2012a), 
with language function less likely to be affected (Caviness et al., 2007).  
Therefore, within PD-MCI there are substantial variations in the cognitive construct.  
Deficits are present in early disease, even in de novo patients, and the differences seen 
may represent differing underlying pathological mechanisms.          
1.7.3 Risk factors and course 
As discussed above, the heterogeneity of PD-MCI suggests that cognitive correlates 
may not be generalizable to the whole population.  Nevertheless, increased age 
(Foltynie et al., 2004; Muslimovic et al., 2005; Williams-Gray et al., 2007a; Kim et al., 
2009; Mamikonyan et al., 2009; Aarsland et al., 2010; McColgan et al., 2012), motor 
disease severity (Foltynie et al., 2004; Muslimovic et al., 2005; Mamikonyan et al., 
2009; Aarsland et al., 2010), non-tremor-dominant motor phenotype (Muslimovic et 
al., 2005; Williams-Gray et al., 2007a; Sollinger et al., 2010; Poletti et al., 2012) and 
lower educational levels (Foltynie et al., 2004; Elgh et al., 2009; McColgan et al., 2012) 
all seem to be robustly associated with MCI risk.  Other possible associations include 
presence of depression (Muslimovic et al., 2005; Aarsland et al., 2010), male gender 
(Aarsland et al., 2010) and anti-anxiety medication use (Mamikonyan et al., 2009).  In 
addition, one recent study examined the predictors of separate MCI subtypes in PD 
(Goldman et al., 2012a).  In keeping with previous studies, naMCI-sd was the most 
common subtype in 128 PD-MCI participants, but within the naMCI-md participants, 
significantly greater scores on axial functioning/gait subset of the Unified PD Rating 
Scale (UPDRS) motor score were observed, compared with the aMCI-sd subtype 
(Goldman et al., 2012a).  The authors postulated that non-dopaminergic deficits may 
link these specific motor and cognitive phenotypes.  
To date, only three studies have published data on longitudinal outcomes in PD-MCI.  
Janvin and colleagues studied 72 non-demented PD participants with a mean age at 
baseline of 71 years and a disease duration of between 10 and 12 years, of whom 59 
completed assessments four years later (Janvin et al., 2006).  Presence of MCI at 
baseline assessment was significantly associated with cognitive decline at follow-up, 
with 62% of those with PD-MCI versus 20% of those who were cognitively normal 
developing dementia.  After controlling for age, sex, disease stage and education in a 
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logistic regression model, MCI at baseline was strongly associated with development of 
dementia (odds ratio 5.1; 95% CI, 1.51–16.24).  The only subtype that was associated 
with later dementia was naMCI-sd (odds ratio 8.3; 95% CI, 1.8 –37.5); however, the 
small numbers within the subgroups means that definitive conclusions cannot be 
drawn. 
The CamPaIGN cohort is another longitudinal study which has explored the evolution 
of cognitive dysfunction (Foltynie et al., 2004; Williams-Gray et al., 2007a; Williams-
Gray et al., 2009a).  Although MCI was not studied specifically, over a mean of 5.2 
years, 17% of incident PD cases developed PDD, with increasing age, impairments in 
semantic fluency and visuospatial function and MAPT H1/H1 genotype all significantly 
associated with a more rapid cognitive decline (Williams-Gray et al., 2007a; Williams-
Gray et al., 2009a).  COMT genotype and impairments in frontally-based tasks were not 
associated with deteriorating cognition, lending support to the hypothesis that more 
posteriorly based cognitive deficits increase the risk of subsequent decline due to a 
more posterior deposition of Lewy bodies, combined with the ageing process plus 
cholinergic dysfunction. Most recently, follow-up of MCI cases from the ParkWest 
Study (Aarsland et al., 2009b) demonstrated that a diagnosis of MCI vs. non-MCI at 
baseline visit had a relative risk for dementia of 39.2 at three years (Pedersen et al., 
2013).  27% of those with MCI progressed to dementia over follow-up compared to 0.7% 
of those who were cognitively normal, although it should be noted that 21.6% of those 
with MCI reverted to normal cognition.   
1.7.4 Pathogenesis 
The exact underlying pathophysiology of PD-MCI remains the subject of debate, largely 
due to the scarcity of neuropathological data.  Structural and functional imaging, 
neurophysiological techniques and CSF analysis provides some in vivo evidence of the 
mechanisms underlying MCI.  Only one neuropathological study in well-characterised 
PD-MCI in which participants were followed prospectively has been reported (Adler et 
al., 2010).  Eight cases were examined, of who four were classified as amnestic and 
four as nonamnestic MCI.  The neuropathology was heterogeneous, with five cases 
exhibiting limbic or neocortical Lewy body (LB) pathology and the remainder 
predominantly consisting of brainstem LB pathology.  Diffuse amyloid plaques were 
seen in the majority of cases (Adler and Beach, 2010), with two of the amnestic MCI 
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subgroup meeting neuropathological criteria for AD.  Cerebrovascular pathology was 
frequently seen.  In correspondence relating to this study, Kurt Jellinger reported on a 
further eight cases of MCI, where four cases were defined as aMCI-sd, three were 
naMCI-sd and one MCI multiple-domains (Jellinger, 2010b).  Again the neuropathology 
was heterogeneous, with most patients having limbic or neocortical LB deposition, and 
some displaying Alzheimer-type pathology.  These studies provide evidence that the 
neuropathology underlying PD-MCI may be similar to, but less advanced than, that 
found in PDD.  
Changes seen in structural and functional imaging provide further evidence of the 
possible underlying pathogenesis of PD-MCI.  Extensive grey matter loss on structural 
magnetic resonance imaging (MRI) is a consistent finding in PDD (Burton et al., 2004; 
Melzer et al., 2012); in MCI, a more selective loss has been observed (Bruck et al., 2004; 
Beyer et al., 2007; Song et al., 2011; Melzer et al., 2012).  Atrophy was noted in frontal 
(Beyer et al., 2007; Song et al., 2011; Melzer et al., 2012), prefrontal (Bruck et al., 2004; 
Song et al., 2011; Weintraub et al., 2011), temporal (Beyer et al., 2007; Melzer et al., 
2012), hippocampal (Bruck et al., 2004; Weintraub et al., 2011; Melzer et al., 2012), 
amygdala (Melzer et al., 2012), parietal (Weintraub et al., 2011) and occipital (Song et 
al., 2011; Weintraub et al., 2011) regions, and may be attributable to neuronal and 
synaptic loss from LB and/or AD-type pathology.   It has been postulated that 
hippocampal atrophy may be a biomarker of early cognitive decline in PD (Weintraub 
et al., 2011), with longitudinal follow-up indicating that hippocampal plus parieto-
temporal atrophy predict cognitive impairment (Weintraub et al., 2012).  However, a 
study in de novo incident PD cases did not demonstrate significant grey matter loss, 
perhaps due to the shorter disease duration, arguing for functional neurotransmitter 
loss rather than structural grey matter loss as a pathological basis for MCI (Dalaker et 
al., 2010). 
Functional imaging using 18F-fluorodeoxyglucose (FDG) PET has demonstrated 
metabolic abnormalities associated with PD-MCI, with metabolic reductions 
demonstrated in frontal and parietal association areas plus relative increases in the 
cerebellar vermis and dentate nuclei (Huang et al., 2007).  This pattern predicted 
performance in memory and visuospatial domains, with a more recent PET study by 
the same authors revealing a difference in parietal and prefrontal metabolism in those 
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with multiple-domain MCI compared to PD-CN participants (Huang et al., 2008).  Other 
studies have demonstrated cerebral hypometabolism in posterior cortical regions in 
participants with PD-MCI compared to those with PD and normal cognition (Hosokai et 
al., 2009; Pappata et al., 2011).  Taken together, neurotransmitter deficits in PD-MCI 
may explain the PET findings, with dopaminergic dysfunction accounting for frontal 
hypometabolism and subcortical cholinergic loss leading to posterior changes.  The 
former presupposition is strengthened by a functional imaging study which used 
functional MRI (fMRI) and dopamine transporter binding SPECT scanning to assess 
brain responses during a working memory task in early drug naïve PD-MCI participants 
(Ekman et al., 2012).  Compared to PD-CN subjects, those with PD-MCI had markedly 
reduced recruitment of the right caudate nucleus, bilateral anterior cingulate cortex 
and to a lesser extent the right dorsolateral prefrontal cortex.  These findings 
correlated with working memory function, and lend support to dopaminergic 
dysfunction as a basis for the functional changes seen.  
Other potential mechanisms that may underpin the pathophysiology of MCI in PD 
include cholinergic dysfunction and abnormal processing of the amyloid precursor 
protein.  Cholinergic loss is an established feature of PDD (Tiraboschi et al., 2000; 
Bohnen et al., 2003) and may contribute to PD-MCI: Evidence from a PET study 
demonstrating a reduction in nicotinic ACh receptors  in the midbrain, pons, and 
cerebellum in PD subjects with MCI support this hypothesis (Meyer et al., 2009).  In 
addition, short latency afferent inhibition (SAI) is abnormal in PD-MCI (Yarnall et al., 
2013).  SAI is a non-invasive neurophysiological technique that relies on cholinergic 
excitability in the cerebral cortex, and hence can be used as a proxy measure of 
cholinergic activity.  This theory of a cholinergic basis to MCI has biological plausibility 
in terms of the Braak hypothesis: at Braak Stage 3, where the motor disease may 
become apparent, there is already destruction of the basal forebrain cholinergic nuclei 
and consequent ACh loss.  Lastly, abnormal Aβ deposition and fibrillization due to 
altered amyloid precursor processing may contribute to PD-MCI.  Reduced CSF levels 
of Aβ42, a marker of amyloid deposition and aggregation, were found in those with PD 
and who were cognitively impaired but not demented (Montine et al., 2010).  Reduced 
CSF Aβ42, 40 and 38 levels also correlated with memory function in early de novo PD 
participants (Alves et al., 2010).  However, detection of amyloid-β deposition using PET 
imaging with Pittsburgh Compound B (PiB) in PD-MCI has been less convincing.  In two 
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small cross-sectional studies, PiB retention did not differ between groups with PD and 
normal cognition, PD-MCI or PDD (Foster et al., 2010; Gomperts et al., 2012), although 
in more recent longitudinal work, amyloid burden at baseline predicted cognitive 
decline during follow-up (Gomperts et al., 2013).  In a further cross-sectional study of 
40 PD participants with risk factors for the development of dementia (30 defined as 
MCI), cortical PiB binding was below that expected for older individuals and for those 
at risk of AD; PiB retention was, however, correlated with global cognitive function and 
a tests of executive function (Petrou et al., 2012). 
In conclusion, the pathogenesis of PD-MCI is heterogeneous and may differ between 
individuals and between subtypes.  Lewy body deposition, amyloid deposition and 
neurotransmitter deficits are all likely to contribute, although to a lesser degree than 
those changes seen in PDD.  Further in vivo and post-mortem studies will facilitate 
future work. 
1.7.5 Definition of PD-MCI 
Due to the increasing research in PD-MCI and a lack of standardization in defining the 
disorder, the Movement Disorder Society (MDS) commissioned a Task Force to 
evaluate the literature (Litvan et al., 2011) and propose criteria (Litvan et al., 2012) for 
the diagnosis of PD-MCI.  The criteria are shown in Table 1-10. They require the 
diagnosis of PD, subjective or objective cognitive decline and the demonstration of 
cognitive deficits that do not interfere with functional independence.  The Task Force 
defined both a level I category, for an abbreviated assessment, and a more 
comprehensive level II assessment for more diagnostic certainty and for use in a 
research setting.  Strict cut-offs were not defined, with impairment in performance in 
neuropsychological tests of 1 to 2 SDs.  The Task Force also gave examples of global 
cognitive scales and neuropsychological tests that could be used.  With time these 
criteria may be refined further, although it should be noted that PD-MCI is a 
contentious term and may not necessarily be useful in terms of prognostication.  
Reasons to contend this include the fact that MCI was extrapolated from the AD 
literature, and this may not be analogous to PD; that there is considerable 
heterogeneity in PD-MCI; and that PD-MCI may represent a fluid state, with some 
returning to normal cognition over time in addition to converting to dementia. 
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Table 1-10 Diagnostic criteria for PD-MCI 
I. Inclusion criteria 
 Diagnosis of PD 
 Cognitive decline, in context of established PD, reported by patient/carer/treating 
physician 
 Cognitive deficits on either formal neuropsychological testing or a scale global 
cognitive abilities 
 Cognitive deficits not severe enough to interfere with functional independence, 
although subtle impairments me be present 
II. Exclusion criteria 
 PDD 
 Other primary explanation for cognitive impairment (e.g. stroke, major depression, 
delirium) 
 Other PD-associated comorbid conditions (e.g. motor impairment,  
severe anxiety, psychosis) that may significantly influence cognitive testing 
III. Specific guidelines for PD-MCI level I and level II categories 
A. Level I (abbreviated assessment) 
 Impairment on a scale of global cognitive abilities validated for use in 
PD (MoCA, SCOPA-COG, PD CRS, MDRS)* or 
 Impairment on at least two tests, when a limited battery of neuropsychological 
tests is performed 
B. Level II (comprehensive assessment) 
 Neuropsychological testing that includes 2 tests within each of the 
5 cognitive domains (attention and working memory, executive, 
language, memory, and visuospatial) 
 Impairment on ≥ 2neuropsychological tests (either 2 impaired tests in 1 cognitive 
domain or 1 impaired test in 2 different cognitive domains) 
 Impairment on neuropsychological tests may be demonstrated by: 
o Performance approximately 1 to 2 SDs below appropriate norms or 
o Significant decline demonstrated on serial cognitive testing or 
o Significant decline from estimated premorbid levels 
IV. Subtype classification for PD-MCI (optional, requires two tests for each of the 
five cognitive domains assessed) 
-  PD-MCI single-domain—abnormalities on two tests within a single cognitive 
domain (specify the domain), with other domains unimpaired or 
-  PD-MCI multiple-domain—abnormalities on at least one test in two or more 
cognitive domains (specify the domains) 
*MoCA Montreal Cognitive Assessment; SCOPA-COG Scales for Outcomes of Parkinson’s 
disease Cognition; PD CRS PD Cognitive Rating Scale; MDRS Mattis Dementia Rating Scale 
 
1.7.6 Treatment 
To date, there have been no randomised controlled trials in PD-MCI.  A small study of 
Atomoxetine, a selective norepinephrine reuptake inhibitor, produced an 
improvement in global cognition in non-demented PD patients, although cognition was 
only a secondary outcome measure (Weintraub et al., 2010).  Trials of cholinesterase 
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inhibitors in PD-MCI and mild dementia, such as the MUSTARDD-PD study 
(www.clinicaltrials.gov: NCT01014858), are on-going and should inform future practice.  
The continued investigation of the pathogenesis underlying PD-MCI is important for 
the development of new therapeutic targets, including the reduction of insoluble 
amyloid-β accumulation or the inhibition of oligomeric α-synuclein accumulation.  
Finally, non-pharmacological interventions such as cognitive intervention programmes 
(Jean et al., 2010; Naismith et al., 2013) or physical exercise should be investigated 
further (Hindle et al., 2013). 
1.8 Study summary, objectives and hypotheses 
In summary, PD is a complex neurodegenerative disorder with impairments of 
movement, gait, mood and cognition.  The incidence of dementia is six times higher 
than that expected in controls, with a cumulative prevalence approaching 80% in 
community studies.  Moreover, up to a quarter of people with Parkinson’s disease will 
have subtle cognitive deficits (mild cognitive impairment) at diagnosis.  The cognitive 
profile of PDD differs from that of AD, with deficits in attention being one of the 
strongest predictors of PDD.  Overall, executive function and visuospatial deficits are 
more prominent in PDD, but it is not known which pattern of deficit is associated with 
a more rapid rate of cognitive decline.  Although the pathophysiology underlying these 
deficits is likely to be varied, deposition of amyloid within the cortex and cholinergic 
loss throughout the frontal cortex are likely to contribute.   CSF may be a potential 
biomarker for cognitive decline in PD, with previous studies indicating that low levels 
of amyloid-β 1-42 are associated with memory impairment.  A surrogate marker of 
cortical cholinergic status is short latency afferent inhibition, a simple 
neurophysiological technique that has been shown to be abnormal in AD and DLB, 
where cholinergic loss is a fundamental neurophysiological component.  
Aims and objectives:  
The overarching aim of this thesis was therefore to define and characterise cognitive 
subtypes early Parkinson’s and to determine the interplay between putative markers 
of protein deposition and neurochemical dysfunction. 
This aim was achieved through the following objectives: 
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1) To investigate cognition in early Parkinson’s disease. 
2) To investigate the relationship between amyloid-β and cognition (including 
specific cognitive domains) in early Parkinson’s disease. 
3) To investigate the relationship between short latency afferent inhibition (SAI) 
and cognition in early Parkinson’s disease. 
Hypotheses: 
1. Cognitive deficits will be frequently observed, even in a very early cohort of 
Parkinson’s disease patients. 
2. Low CSF amyloid-β in early PD will be associated with cognitive decline. 
3. Low CSF amyloid-β in early PD will be associated with impaired mnemonic 
function, that is, a more "posterior" mediated function. 
4. Abnormal short latency afferent inhibition (SAI) will be associated with low 
baseline CSF amyloid-β levels, reflecting greater underlying cholinergic 
dysfunction and Alzheimer-related pathology. 
5. Abnormal short latency afferent inhibition will correlate with cognitive 
impairment. 
6. Abnormal SAI will be associated with more posteriorly mediated cognitive 
functions. 
7. Executive dysfunction at baseline will not be associated with CSF or SAI 
abnormalities. 
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Chapter 2 Cognition in early Parkinson’s disease – the ICICLE-PD study 
2.1 General ICICLE-PD Methodology 
The Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation-PD 
(ICICLE-PD) study is a twin centre longitudinal observational study, the aim of which is 
to better understand the anatomical, biochemical and genotypic mechanisms 
underlying the evolution of PDD from disease onset.  Through centres in Newcastle 
and Cambridge, participants are followed up every 18 months, where the diagnosis of 
PD is reassessed and further clinical, neuropsychological, imaging and laboratory 
measures are performed. 
2.2 Baseline Assessment 
Between June 2009 and December 2011, we attempted to identify all newly diagnosed 
PD patients from outpatient clinics in Newcastle-upon-Tyne/Gateshead and 
Cambridgeshire, UK.  A total of 166 primary care practices were identified and 
encouraged to refer patients with suspected parkinsonism.  We also informed 
colleagues in secondary care and invited them to refer all patients with suspected 
parkinsonism.  This group included neurologists (n=48), geriatricians (n=17), and 
Parkinson’s disease nurse specialists (n=14).  PD was diagnosed by a movement 
disorder specialist according to the UK Brain Bank criteria for idiopathic PD (Hughes et 
al., 1992).  Exclusion criteria comprised: Parkinsonism diagnosed prior to the onset of 
the study; insufficient working knowledge of English (defined as insufficient to perform 
the neuropsychological assessments or questionnaires in the opinion of the assessor); 
significant memory impairment at presentation (defined as MMSE score < 24), or 
meeting DSM IV (Association, 2000) or the MDS criteria for dementia (Emre et al., 
2007); subjects who did not have the capacity to give informed consent (as assessed by 
criteria laid out in the MHA code of practice, section 4-3); history consistent with DLB 
(McKeith et al., 2005), atypical parkinsonian syndromes (including multiple system 
atrophy or progressive supranuclear palsy, diagnosed according to accepted criteria 
(Litvan et al., 2003)) repeated strokes or stepwise progression of symptoms, leading to 
a diagnosis of ‘vascular parkinsonism’; and, exposure to dopamine receptor blocking 
agents at the onset of symptoms.  
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To control for the effects of normal ageing and to generate normative values for 
cognitive tests, unrelated controls of similar age and sex to patients were recruited 
through local advertising (including primary care settings), word of mouth and 
community groups.  Carers and spouses of patients with PD were not used as controls 
to limit bias; for example, sleep disruption or mood disorder in a patient could 
influence carer response.  None of the controls had a history of major psychiatric 
disorders, cognitive impairment, stroke or a movement disorder, but were not pre-
screened for memory problems to ensure that this was a representative sample.  All 
control subjects underwent clinical and neuropsychological testing, and were given the 
option of participating in laboratory and MRI studies.  Global cognitive scores in 
control participants were comparable to published age- and educationally-matched 
normative data for the MMSE (Crum et al., 1993) and Montreal Cognitive Assessment  
(MoCA) (Dalrymple-Alford et al., 2010).  
The study was approved by the Newcastle and North Tyneside Research Ethics 
Committee and performed according to the Declaration of Helsinki, with all subjects 
providing written informed consent. 
2.3 Clinical Assessment 
Clinical and demographic data collected comprised a detailed history of disease onset; 
disease duration; comorbidities; family history of neuropsychiatric disease; level of 
education and medication use. Clinical assessments were performed by trained 
examiners and included a standardised neurological assessment, the MDS-revised 
Unified Parkinson’s Disease Rating Scale (MDS UPDRS) (Goetz et al., 2008b) and Hoehn 
and Yahr stage (Hoehn and Yahr, 1967).  Depressive symptoms were assessed using 
the Geriatric Depression Scale-15 (GDS-15) score (Yesavage et al., 1983) and functional 
status and well-being were measured by the Parkinson’s disease Quality of Life 
Questionnaire (PDQ-39) (Peto et al., 1995).  Motor phenotype was calculated using the 
MDS-UPDRS revision (Goetz et al., 2008b) of the method described by Jankovic  
(Stebbins et al., 2013) whereby patients are categorised into tremor dominant (TD), 
postural instability with gait difficulty (PIGD), or indeterminate (ID) motor subtypes 
based on the ratio between mean tremor score versus and mean postural instability 
gait difficulty score.  Ratios of ≥ 1.15 were classified as TD and ≤ 0.90 as PIGD (Stebbins 
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et al., 2013).  Levodopa equivalent daily dose (LEDD) was calculated for all 
dopaminergic medications (Tomlinson et al., 2010).  Participants underwent baseline 
assessments, with planned evaluation every 18 months until the end point of dementia 
(diagnosed according to the Movement Disorder Society criteria (Emre et al., 2007)) or 
death.  
2.4 Neuropsychological Assessment 
Global cognitive function was assessed with the MMSE (Folstein et al., 1975) and 
Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005; Zadikoff et al., 2008).  
Although traditionally used as a screening test for cognitive impairment in the wider 
population, the MMSE has not been validated in PD and problems such as accuracy, 
sensitivity (especially in early cognitive impairment) and “ceiling effect” have called 
into question its use (Hobson and Meara, 1999; Athey et al., 2005; Zadikoff et al., 2008; 
Nazem et al., 2009).  One study demonstrated that over half of those who were 
classified as “normal” cognition by MMSE were impaired on the MoCA (Nazem et al., 
2009).  In addition, executive and visuospatial domains are poorly represented by the 
MMSE.  Originally developed as a brief screening tool to detect mild cognitive 
impairment (MCI) as a precursor to AD with a score of less than 26/30 being predictive 
of MCI (Nasreddine et al., 2005), the MoCA has been shown to be valuable in screening 
for both dementia and MCI in PD (Hoops et al., 2009; Dalrymple-Alford et al., 2010).  
At a score of <21/30, the MoCA has a 81% sensitivity, 95% specificity, negative 
predictive value of 92% and a positive predictive value of 87% for the diagnosis of PDD,  
with the corresponding figures for MCI at a score of <26/30 of 90, 75, 61 and 95%, 
respectively (Dalrymple-Alford et al., 2010).  Although other scales of global cognition, 
such as the Addenbrooke’s Cognitive Examination-Revised (ACE-R) are available and 
have shown to be useful screening tools for PD-MCI (McColgan et al., 2012), the MoCA 
can be completed in 10 minutes and is one of the recommended global screening tools 
by the Movement Disorder Society Task Force on MCI (Litvan et al., 2012).   
Premorbid IQ was estimated with the National Adult Reading Test (NART) (Nelson and 
O'Connell, 1978).  Where relevant, subjects were assessed ‘on’ dopaminergic 
medication, although due to the short disease duration, motor and cognitive 
fluctuations were not problematic in this study.  Participants were asked to refrain 
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from drinking caffeine or smoking for one hour prior to appointments, to reduce the 
risk of confounding due to stimulant effects and to standardise neuropsychological 
testing. 
Five cognitive domains were assessed as part of the neuropsychological battery.  
Attention and working memory were measured using the Cognitive Drug Research 
(CDR) computerised battery (Ballard et al., 2002; Wesnes et al., 2002).  Scores of 
simple reaction time, choice reaction time and digit vigilance mean time (all in 
milliseconds (msec)) were summed to produce a Power of Attention (PoA) score, with 
a higher score indicating more severe impairment (Wesnes et al., 2002) (Table 2-1).  
PoA has been used as both a primary and secondary outcome of attentional function in 
acetylcholinesterase inhibitor (AChE-I) studies in PDD and DLB (Wesnes et al., 2002; 
Emre et al., 2004; Wesnes et al., 2005; Rowan et al., 2007), and as a measure of 
attention when correlated with clinical characteristics (Taylor et al., 2008; Allcock et al., 
2009).  Digit vigilance accuracy was also evaluated as part of this domain, which was 
chosen due to its large effect size when compared with controls.   Memory was 
assessed with Pattern Recognition Memory (PRM), Spatial Recognition Memory (SRM) 
[sensitive to impairment of temporal and frontal lobe function, respectively (Owen et 
al., 1995b)] and Paired Associates Learning (PAL) from the computerised Cambridge 
Neuropsychological Test Automated Battery (CANTAB) (Sahakian et al., 1988; Robbins 
et al., 1994; Owen et al., 1995a) (Table 2-1).  As this battery requires touch screen 
testing, participants were initially screened for visual, motor and comprehensive 
deficits using a motor screening test (MOT).  Paired associates learning is a visuospatial 
test of learning and memory that is sensitive to both temporal and frontal damage and 
has been shown to predict Alzheimer's disease with a high degree of accuracy 
(Swainson et al., 2001; Blackwell et al., 2004).  Executive function was determined 
using the modified ('one touch') version (OTS) of the Tower Of London task from the 
CANTAB battery, a test of planning requiring working memory (Owen et al., 1995a) 
that has been shown to activate fronto-parietal-caudate circuitry (Baker et al., 1996; 
Cheesman et al., 2005); phonemic fluency (words beginning with F, A and S in one 
minute) (Benton, 1968) and semantic fluency (animals in 90 seconds) (Goodglass, 
1972), tests sensitive to fronto-striatal and fronto-parietal dysfunction (Miller, 1985).  
For phonemic fluency, Cambridge participants (n=61) only underwent testing of words 
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beginning with F, and this data was therefore combined with the Newcastle data to 
produce an aggregate score.  In line with previous studies in PD assessing cognition 
using the CANTAB battery (Sahakian et al., 1988; Lewis et al., 2003; Foltynie et al., 
2004; Williams-Gray et al., 2007a; Williams-Gray et al., 2009a), scores of total number 
correct for PRM (maximum 24) and SRM (maximum 20) were used, with OTS assessed 
using the total number of problems solved on first attempt (maximum 20).  For PAL, 
the parameters measured were stages completed (score 0-8), total number errors, 
total number of trials and mean trials to success.  Previous studies using PAL have used 
a combination of these parameters.  After discussion with the CANTAB team in 
Cambridge and after inspecting the distributions of the data, mean trials to success 
was included, with a higher score indicating a greater degree of impairment.  The 
pentagon copying item within the MMSE was graded using a modified 0-2 rating scale 
(Ala et al., 2001; Williams-Gray et al., 2007a) as a measure of visuospatial function.  
Language domain was assessed using the naming (0-3) and sentence (0-2) subsets of 
the MoCA test.   
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Table 2-1 Computerised battery tests 
Cognitive test Description Measure 
CDR   
Simple reaction time 
(SRT) 
Subject instructed to press ‘YES’ button as quickly 
as possible every time the word ‘yes’ appeared 
on computer screen. 30 stimuli delivered at 
varying inter-stimulus intervals. 
Response time (ms); 
response time variability 
(%) 
Choice reaction time 
(CRT) 
Either the word ‘no’ or the word ‘yes’ randomly 
appeared on screen, and the patient instructed 
to press the corresponding button as quickly as 
possible.  30 stimuli delivered at varying 
intervals. 
Response time (ms); 
response time variability 
(%); % of accurate 
responses 
Digit vigilance A target digit was randomly selected and 
constantly displayed to the right of the screen. A 
series of digits was then presented in the centre 
of the screen at the rate of 150 per minute and 
the subject told to press the ‘YES’ button as 
quickly as possible every time the digit in the 
series matched the target digit. 
Response time (ms); 
response time variability 
(%); % of accurate 
responses; number of 
errors 
CANTAB   
Pattern recognition 
memory (PRM) 
Subjects were initially shown a series of coloured 
patterns inside a box in the centre of the screen.  
In the next stage, pairs of patterns were shown in 
the centre, & the subject was asked to touch the 
pattern they had already seen during the initial 
phase. 
Number correct (max 
24); % correct; latency 
to correct (ms) 
Spatial recognition 
memory (SRM) 
In the 1
st
 phase, unfilled white squares were 
shown at different locations on the screen.  
During the 2
nd
 phase, 2 squares appeared 
simultaneously on the screen and the subject had 
to select the correct location had been used 
before in the 1st phase. 
Number correct (max 
20); % correct; latency 
to correct (ms) 
Paired associates 
learning (PAL) 
Initially 6 boxes were placed in different locations 
on the screen and were ‘opened’ one at a time, 
with 1 displaying a coloured pattern.  The pattern 
then appeared in the screen centre, & the 
subject was asked to touch which box had 
contained the pattern.  This was repeated with 2, 
3 & up to 6 patterns.  Finally the number of boxes 
was increased to 8 with 8 patterns to identify. 
Stages completed (max 
8); total errors; total 
trials; mean trials to 
success 
One touch stockings 
of Cambridge (OTS) 
2 sets of 3 stockings were displayed on the touch 
screen, with the subject asked to rearrange the 
balls in the bottom display to match the position 
in the top of the screen.  
Problems solved on 1
st
 
choice (max 20); mean 
choices to correct; 
latency to correct (ms) 
 
MoCA was not performed on the first 24 participants as it was introduced slightly later 
in the study.  A small number of subjects did not undergo all 11 neuropsychological 
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tests and were coded as missing data.  For example, CDR could not be completed in 
two PD patients due to technical issues (Table 2-2). 
Mild cognitive impairment was determined using the recently published Movement 
Disorder Society criteria (Litvan et al., 2012).  The ICICLE neuropsychological battery 
was devised prior to the publication of the MDS PD-MCI guidelines.  Therefore, the 
visuospatial domain was not as well covered as we would have anticipated.  Other 
domains were, however, well covered.  Subjects were classified as level 1 MCI 
(abbreviated assessment, possible MCI) if they scored <26 on the MoCA.  Level 2 
criteria (comprehensive assessment) necessitated impairment on at least two 
neuropsychological tests, represented by either two impaired tests in one cognitive 
domain or one impaired test in two different domains.  A test score was considered 
‘impaired’ if it was 1, 1.5 or 2 standard deviations (SDs) below the mean score of the 
control subjects which was approximately normally distributed.  For non-normally 
distributed data, even after transformation (pentagon, naming, language and digit 
vigilance scores), cut-offs were used that gave approximately the correct percentage of 
people impaired (according to the normal distribution) for that corresponding SD.  For 
example, the mean plus 1 SD cut-off for naming was 2 or less as 14% of controls scored 
0, 1 or 2.  Subjects were further classified as single- or multiple-domain amnestic or 
nonamnestic according to the criteria.  
Table 2-2 Missing cognitive data 
 MoCA MMSE CDR CANTAB Verbal 
fluency 
Pentagon Language 
Control 
no. 
missing 
2 0 5 5 1 0 2 
Reason 
for 
missing 
data 
Missing 
data 
 Equipment 
failure 
(n=3), 
missing 
data (n=2) 
Visual 
impairment 
(n=4), 
missing 
data (n=1) 
Missing 
data 
 Missing 
data 
PD no. 
missing 
24 0 2 12 3 0 24 
Reason Introduced 
later in 
study 
 Equipment 
failure 
Visual 
impairment 
(n=3), 
missing 
data (n=9) 
Missing 
data 
 Introduced 
later in 
study 
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2.5 Statistical Analysis 
Statistical analyses were performed with SPSS 19.0 (SPSS, Chicago, IL).  Data were 
examined for normality with visual histograms and Kolmogorov-Smirnov test.  Means 
and SDs for general characteristics and cognitive test scores were calculated.  The 
primary statistical analysis consisted of descriptive statistics comparing those classified 
as MCI level 1 or level 2 with the PD-cognitively normal (CN) groups, and within MCI 
level 2, whether they met the criteria at 1, 1.5 or 2 SD below normative values.  Means 
were compared using Student t-tests or ANOVA for normally distributed and Mann-
Whitney or Kruskal-Wallis test for data that were non-normally distributed.  Pearson 
correlation (parametric distributions) or Spearman’s rank correlation (non-parametric) 
coefficients were calculated to assess the bivariate association between cognitive and 
clinical or biochemical parameters.  A linear regression model was used to control for 
covariates including age and education; logistic regression was used for binary 
dependent variables.  Collinearity diagnostics were inspected to test for multi-
collinearity, with an average variance inflation factor (VIF) greater than one considered 
problematic.  The Durbin–Watson statistic was used to identify autocorrelation (values 
less than one or greater than three were a cause for concern).  In all regression models, 
standardised residuals were inspected to ensure they were approximately normally 
distributed and between ±3.0.  Cook’s distances were used to check for cases exerting 
undue influence in any model.  Mixed linear modelling was used with age as a 
covariate to compare neuropsychological tests between groups (controls versus PD 
participants).  The effect size of each cognitive test was calculated using Glass’s delta, 
by calculating the mean difference (mean cognitive test score of controls – mean 
cognitive test score of PD participants) divided by the SD.  A priori correction for 
multiple comparisons was not made due to the exploratory nature of the investigation; 
if a parameter was significant, even if by chance, it was felt it merited further analysis 
(Rothman, 1990; Perneger, 1998; Feise, 2002).   However, if multiple corrections were 
required for defining clinical significance, a Bonferroni correction was applied for 
multiple comparisons.  Pearson Chi-square tests were used to compare between-group 
distribution of proportions, with Fisher’s exact test used if the expected frequency in 
any group was < 5.  For parametric tests, all p values reported are two-tailed.  A p 
value of < 0.05 was deemed as significant. 
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2.6 Results – cognition in early Parkinson’s disease 
2.6.1 Baseline characteristics of study participants 
682 patients with parkinsonism were approached and, of these, 226 with idiopathic PD 
consented (Figure 2-1).  Seven were subsequently excluded (one due to a diagnosis of 
dementia; one due to insufficient command of the English language; one due to 
vascular parkinsonism and four due to normal Dopamine Transporter scans (FP-CIT 
SPECT)).  Those that declined to take part (n=312) were older than those who 
participated (71.5 vs. 65.9 years, p<0.001, unpaired t-test).  101 age- and sex-matched 
controls were also recruited, with two excluded (one due to a diagnosis of essential 
tremor and one because of a glioblastoma multiforme incidentally found on MRI).  
Therefore, 219 PD subjects and 99 controls participated.  With the exception of a 
statistically significant difference in disease duration (6.0 vs. 4.3 months) which was 
not clinically significant, PD participants from Newcastle and Cambridge were well-
matched (Table 2-3).  Baseline characteristics are shown in Table 2-4.  In keeping with 
early PD, mean disease duration was less than six months (mean 5.5 months) with 
relatively mild motor disease (mean MDS UPDRS score 27.1) and 83% of participants 
were Hoehn and Yahr Stage 1 or 2.  PD participants scored significantly lower on the 
MoCA and MMSE and higher on the GDS-15 than the controls, but there were no 
differences in the years of education.  Control participants tended to be older, and 
although this did not reach statistical significance, age was included as a covariate in all 
analyses.  Mean LEDD was 178 mg/day in PD subjects, with only 16.4% of participants 
being treatment naive.  The most commonly medication prescribed was a dopamine 
agonist, and there was no significant difference in the number of PD participants 
versus controls who were taking antidepressants.     
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Figure 2-1 Flow diagram of PD participants and assessments 
 
 
Table 2-3 Comparison of Newcastle and Cambridge PD participant demographics 
Characteristic Newcastle (n=158) Cambridge (n=61) P value 
Age 66.5 (10.3) 64.4 (7.8) 0.103a 
Male gender 104 (65.8) 36 (59.0) 0.347b 
Disease duration (mo) 6.0 (4.5) 4.3 (6.0) <0.001 
MDS UPDRS III 27.1 (12.1) 28.8 (11.2) 0.373 
LEDD (mg/d) 177.8 (146.9) 178.3 (171.3) 0.849 
Education (years) 12.8 (3.9) 12.8 (3.0) 0.450 
NART 114.6 (10.8) 113.4 (9.1) 0.143 
GDS-15 2.9 (2.6) 3.0 (2.9) 0.888 
MoCAc 25.1 (3.6) 25.8 (2.7) 0.499 
MMSE 28.6 (1.4) 29.0 (1.0) 0.120 
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Table 2-4 Demographics and clinical characteristics of PD and control participants 
(unadjusted) 
Characteristic Controls (n=99) PD (n=219) p value 
Age (years) 67.9 (8.2, 48.0 – 88.2) 65.9 (9.7, 35.0 – 87.3) 0.057a 
Male gender 54 (54.5%) 140 (63.9%) 0.112b 
Education (years) 13.1 (3.4) 12.8 (3.6) 0.356 
Disease duration 
(months) 
- 5.5 (5.0) - 
Hoehn & Yahr stage I - 57 (26.0%) - 
Hoehn & Yahr stage II - 125 (57.1%) - 
Hoehn & Yahr stage III - 36 (16.4%) - 
Hoehn &Yahr stage IV - 1 (0.5%) - 
MDS UPDRS part 3 - 27.6 (11.9) - 
Levodopa equivalent 
dose (mg/d)  
- 178.0 (153.7) - 
Treatment naive - 36 (16.4%) - 
Levodopa use  - 64 (29.2%) - 
Dopamine agonist use - 83 (37.9%) - 
Monoamine oxidase 
inhibitor 
- 78 (35.6%) - 
Amantadine  - 3 (1.4%) - 
Antidepressant use 10 (10.1%) 35 (16.0%) 0.164b 
NART 116 (8.7) 114 (10.3) 0.366 
MoCAc 27.0 (2.5) 25.3 (3.4) <0.001 
MMSE 29.0 (1.2) 28.7 (1.3) 0.010 
GDS 15 1.0 (1.5) 2.9 (2.7) <0.001 
Data are mean (SD) or number (%), and range for age. MDS UPDRS=Movement Disorder 
Society Unified Parkinson's Disease Rating Scale; NART=National Adult Reading Test; 
MoCA=Montreal Cognitive Assessment; MMSE=Mini Mental State Examination; GDS 
15=Geriatric Depression Scale-15; aUnpaired t-test; b Pearson Chi-square test; the remainder 
used Mann-Whitney test; cn=292 (controls=97;PD=195). 
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2.6.3 Cognitive profile of early PD 
The cognitive profile of control and PD participants are shown in Table 2-5.  Cognitive 
test scores on all domains, apart from language, were significantly lower in PD than 
control participants, even after controlling for age using ANCOVA. The greatest effect 
sizes for cognitive tests between PD and control participants were seen in tests of 
attention and OTS, a test of executive function. 
 
Table 2-5 Cognitive profiles of all controls versus PD participants.  Comparisons 
performed using ANCOVA with age as a covariate; values are adjusted means (SD)  
 Characteristic Controls 
(n=99) 
PD all 
(n=219) 
p value Effect size 
of 
cognitive 
test 
MoCA 27.1 (2.5) 25.2 (3.4) <0.001 0.76 
MMSE 29.1 (1.2) 28.7 (1.3) 0.006 0.35 
Power of attention (msec) 1272.2 
(136.0) 
1381.8 
(233.7) 
<0.001 0.81 
Digit vigilance accuracy (%) 96.3 (5.8) 92.0 (12.8) 0.002 0.75 
Pattern recognition memory 20.8 (2.5) 19.6 (3.1) 0.001 0.48 
Spatial recognition memory 16.2 (1.8) 15.3 (2.2) <0.001 0.51 
Paired associates learning 1.8 (0.5) 2.0 (0.8) 0.009 0.42 
One touch stockings 16.6 (2.5) 14.4 (4.2) <0.001 0.84 
Phonemic fluency 13.1 (4.7) 11.8 (4.7) 0.024 0.28 
Semantic fluency 24.2 (6.1) 21.0 (6.6) <0.001 0.52 
Pentagon copying 2.0 (0.2) 1.8 (0.4) 0.009 0.51 
Naming 2.8 (0.4) 2.9 (0.3) 0.365 0.09 
Sentence 1.7 (0.6) 1.6 (0.6) 0.104 0.22 
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81 out of 195 PD participants who completed the MoCA (41.5%) scored less than 26 
and therefore met the criteria for level 1 MCI, compared with 22.7% in the control 
group.  Those who met the criteria for level 1 MCI were older, had a longer disease 
duration, fewer years of education, higher depression scores and were on higher doses 
of dopaminergic medications than those with PD who were cognitively normal (PD-CN) 
(Table 2-6).  After adjusting for age and education in an ANCOVA, cognitive scores 
were worse in all tests apart from PoA in those with MCI.  Level 2 criteria were met by 
144 (65.8%) of PD participants at 1 SD below normative values, 93 (42.5%) at 1.5 SD 
and 49 (22.4%) at 2 SD.  The corresponding figures for controls were 43 (43.4%) at 1 SD, 
21 (21.2%) at 1.5 SD and 9 (9.1%) at 2 SD.  PD participants who met level 2 criteria 
were older, completed fewer years of education, had greater motor disability and 
scored higher on the GDS than those who were cognitively normal (Table 2-7).  
Cognitive scores were poorer in all tests in those with level 2 MCI, even after adjusting 
for age and education in an ANCOVA.  54.5% of those classified as level 2 MCI at 1 SD 
also met criteria for level 1 MCI, with the corresponding figures for 1.5 and 2 SD 65.5 
and 73.3%, respectively.  Conversely, 90.1% of those with a MoCA score of less than 26 
were impaired at level 2 criteria at 1 SD, 70.4% at 1.5 SD and 40.7% at 2 SD.  
When PD participants were dichotomised by motor phenotype into those who were 
tremor dominant (TD) and non-TD, there was no difference in the proportions who 
were represented in the MCI groups either at level 1 (Table 2-6) or level 2 (Table 2-7) 
compared with PD-CN.  Those who were non-TD scored significantly worse on 
semantic fluency than TD participants (adjusted mean score 19.6 vs. 22.5, p=0.002 
after Bonferroni correction); but otherwise there were no significant differences 
between the groups.   
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Table 2-6 Cognitive profile of PD participants according to level 1 MCI criteria 
Characteristic Level 1 PD-
CN (n=114) 
Level 1 MCI 
(n=81) 
p value Adjusted p 
valuea 
Age (years) 64·1 69 <0.001 - 
Male gender (n) 72 53 0.764 - 
Education (years) 13.8 11.5 <0.001 - 
Disease duration (mo) 4.7 6.4 0.022 - 
MDS UPDRS part 3 26.4 29.7 0.54 - 
Proportion non-TD phenotype 
(%) 
45.6 51.9 0.390 - 
LEDD (mg/d)  157.1 203.5 0.039 - 
MoCA 27.7 21.9 <0.001 <0.001 
MMSE 29.1 28.2 <0.001 <0.001 
GDS 15 2.6 3.3 0.023 0.027b 
Power of attention (msec) 1361.5 1417.2 0.02 0.311 
Digit vigilance accuracy (%) 94.2 88.3 <0.001 0.018 
Pattern recognition memory 20.6 18.1 <0.001 <0.001 
Spatial recognition memory 15.7 14.8 0.006 0.043 
Paired associates learning 1.8 2.3 <0.001 <0.001 
One touch stockings 15.8 12.4 <0.001 <0.001 
Phonemic fluency 13.2 10 <0.001 <0.001 
Semantic fluency 22.6 18.7 <0.001 0.004 
Pentagon copying 1.9 1.7 <0.001 0.007 
Naming 3 2.8 <0.001 <0.001 
Sentence 1.8 1.4 <0.001 0.001 
Values are mean (SD); aCognitive scores adjusted for age and years of education; bGDS 
adjusted for age; non-TD=non tremor dominant motor phenotype; LEDD=levodopa equivalent 
dose 
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Table 2-7 Cognitive profiles of PD participants according to level 2 MCI criteria 
Characteristic Level 2 
PD-CN 
(n=75) 
Level 2 MCI 
1 SD (n=51; 
cumulative 
n=144)  
Level 2 MCI 
1.5 SD 
(n=44; 
cumulative 
n=93) 
Level 2 MCI 
2 SD (n=49; 
cumulative 
n=49) 
p 
value 
Adjusted 
p valuea 
Age (years) 61.2 67.3 68.9 69 <0.001 - 
Male gender (n) 42 35 29 34 0.356 - 
Education (years) 14.4 13.1 11.2 11.4 <0.001 - 
Disease duration (mo) 5.3 6.2 5.8 4.8 0.43 - 
MDS UPDRS part 3 22.8 27.2 31.7 31.6 <0.001 - 
Proportion non-TD 
phenotype (%) 
53.3 39.2 54.5 49.0 0.384 - 
LEDD (mg/d)  177.5 149.2 202.4 186.8 0.362 - 
MoCA 27.4 26.1 24.5 22.3 <0.001 <0.001 
MMSE 29.3 28.8 28.4 27.9 <0.001 <0.001 
GDS 15 2.3 2.8 2.9 4 0.016 <0.001b 
Power of attention 
(msec) 
1266 1310 1403.9 1601.9 <0.001 <0.001 
Digit vigilance accuracy 
(%) 
97.5 96.7 92.2 78.9 <0.001 <0.001 
Pattern recognition 
memory 
21.8 19.9 19.2 16.9 <0.001 <0.001 
Spatial recognition 
memory 
16.9 15.3 14.9 13.4 <0.001 <0.001 
Paired associates 
learning 
1.6 1.8 2.2 2.6 <0.001 <0.001 
One touch stockings 16.9 14.8 14.1 11.1 <0.001 <0.001 
Phonemic fluency 14.3 11.8 9.7 9.8 <0.001 <0.001 
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Semantic fluency 25 21.5 19.1 16.7 <0.001 <0.001 
Pentagon copying 2 1.9 1.8 1.6 <0.001 <0.001 
Naming 3 2.9 2.8 2.8 0.009 0.021 
Sentence 1.9 1.6 1.5 1.4 0.001 0.003 
aCognitive scores adjusted for age and years of education; bGDS adjusted for age; non-TD=non 
tremor dominant motor phenotype; LEDD=levodopa equivalent daily dose 
 
2.6.4 MCI subtypes 
Among the five cognitive domains, memory impairment was the most common 
domain affected in PD participants at 1, 1.5 and 2 SD below normative values (24.2, 
15.1 and 5.5%, respectively).  This was followed by executive dysfunction in 24.7, 11.0 
and 4.1% of participants and attention/working memory impairment in 20.1, 12.3 and 
5.5%, respectively (Figure 2-2).  Visuospatial impairment occurred in 13.2, 13.2 and 
1.8%.  Only 5.0% of participants were impaired in the language domain at 1 SD below 
the control mean.  In control participants, the memory domain was also the most 
common domain affected at 1, 1.5 and 2 SD below normative values (12.1, 8.1 and 
2.0%, respectively).  This was followed by executive dysfunction in 9.1, 3.0 and 1.0% 
and attention in 7.1, 3.0 and 1.0%, respectively.  Visuospatial dysfunction was seen in 
5.1% at 1 and 1.5 SD only, with 6.1, 1.0 and 1.0% impaired in language domain at 1, 1.5 
and 2 SD, respectively (Figure 2-2).  When level 2 MCI criteria were applied at 1.5 SD, 
12.8% of those with PD were classified as nonamnestic single-domain MCI (naMCI-sd), 
7.7% had amnestic (aMCI-sd), 5.0% were nonamnestic multiple-domain (naMCI-md) 
and 8.2% had aMCI-md (Figure 2-3).  For controls, the corresponding figures were 8.1% 
for naMCI-sd, 5.1% for aMCI-sd, 0% for naMCI-md and 3.0% for aMCI-md (Figure 2-3).  
The remainder of those classified as MCI had mixed deficits and did not fall within one 
classification.  This included subjects who were impaired in just two tests but in 
different domains, meaning that there was no “pure” domain impairment.    
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Figure 2-2 Graphical representation of percentage of PD and control participants impaired according to single cognitive domain 
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Figure 2-3 Graphical representation of PD and control participants impaired according to subtypes of MCI 
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2.7 Discussion – cognition in early PD 
This study has shown that in a large community-acquired cohort of early PD 
participants, PD-MCI is common, with 42.5% meeting level 2 MDS criteria at 1.5 SD 
below normative means.  The clinical profile of these subjects differed from those with 
normal cognition, being significantly older, with greater motor impairment and 
depression.  This is the first study to apply the new MDS PD-MCI criteria to a cohort of 
early PD.   
Previous studies of patients with early or untreated PD have shown frequencies of PD-
MCI between 14.8 and 36% (Foltynie et al., 2004; Muslimovic et al., 2005; Aarsland et 
al., 2009b; Poletti et al., 2012).  A critical review of PD-MCI with a comprehensive 
literature review found a mean frequency of 26.7% (Litvan et al., 2011), and an earlier 
large meta-analysis 25.8% (Aarsland et al., 2010).  However, very recent work using the 
MDS PD-MCI criteria in a prevalent PD cohort found a similar rate of 41%, when level 2 
criteria were used at 1.5 SDs below normative values and the authors did not include 
cognitive complaint as part of the criteria (Marras et al., 2013).  The higher prevalence 
of PD-MCI in this study may be explained by our adoption of the new MDS PD-MCI 
criteria, which are generally considered to be less conservative than other definitions 
of MCI.  In addition, by using two computerised test systems we may have increased 
the precision of measuring cognition.  Further work is required to validate the new 
MDS MCI criteria in longitudinal assessments, and to determine the optimum type and 
number of cognitive tests that will best predict future cognitive decline.  In addition, 
future studies should also determine the prognostic utility of MCI in PD and whether 
this diagnosis does predict future cognitive decline.  A recent longitudinal study 
suggests that a diagnosis of MCI at baseline assessment is associated with a relative 
risk of dementia during follow-up of 39, although it should be noted that a significant 
proportion (21.6%) of those diagnosed with MCI reverted to normal cognition over 
three years  (Pedersen et al., 2013).  Furthermore, the sensitivity and specificity of the 
screening tests used to determine level 1 PD-MCI should be further examined, as 27% 
of PD participants classified here as level 2 MCI at 2 SDs below normative values had 
normal MoCA scores.  In keeping with our work, the aforementioned study found 
similar performance of the MoCA, with a specificity of only 44% in those who scored 
26 or less (Marras et al., 2013). 
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In common with a number of studies , we found that nonamnestic single-domain was 
the most common PD-MCI subtype (Janvin et al., 2006; Caviness et al., 2007; Aarsland 
et al., 2009b; Mamikonyan et al., 2009; Aarsland et al., 2010; Sollinger et al., 2010; 
Litvan et al., 2011; Goldman et al., 2012a).  This is in contrast to the general population, 
where amnestic MCI is the most common subtype.  MCI in the general population is 
generally less common than in PD, with prevalence rates of between 14 to 18% in 
those aged 70 and over; indeed, the annual progression to dementia in these patients 
may only be between 6-10% (Petersen et al., 2009).  The sub-optimal sensitivity of the 
MMSE in detecting cognitive impairment in PD is consistent with earlier studies 
(Nasreddine et al., 2005; Zadikoff et al., 2008).   
The largest effect sizes seen for individual cognitive tests in PD participants were OTS 
and PoA from the frontal-executive and attention domains, respectively.  These are 
likely to represent differing underlying pathophysiology, with PoA dependent on 
cortical cholinergic function and OTS with dopamine-dependent fronto-parietal-
caudate function. 
Motor phenotype did not come up as a determinant of MCI, which is somewhat 
surprising in view of its well-established association with dementia (Alves et al., 2006; 
Burn et al., 2006; Williams-Gray et al., 2007a; Taylor et al., 2008).  It is recognised that 
motor phenotype does change over the course of the disease, with the majority of the 
transition seen from TD to PIGD (Alves et al., 2006); it is therefore possible that our 
participants were at such an early disease stage that the true influence of motor 
phenotype has not yet emerged.  Also, motor phenotype was calculated using the new 
MDS-UPDRS scale (Stebbins et al., 2013), which does require further validation in 
larger, longitudinally assessed cohorts of PD subjects.  Participants with non-TD disease 
did score worse on semantic fluency that those with TD disease, however, and this test 
has been previously identified as a predictor of future dementia (Williams-Gray et al., 
2007a; Williams-Gray et al., 2009a).    
The principal strengths of this hypothesis-driven prospective study are its multimodal 
design and recruitment of a large community cohort with early disease.  Through 
future longitudinal evaluation, we will determine whether those participants currently 
classified as PD-MCI at baseline are at increased risk of PDD, and the subtypes that 
ultimately predict cognitive decline.  Previous cross-sectional studies of MCI have been 
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limited by small sample sizes and disease heterogeneity.  Our sample is further 
strengthened by a matched control group who underwent detailed assessments.   
Limitations include the fact that not all of the participants were treatment-naïve, 
which may limit the generalizability to all early stage PD patients, but arguably this 
makes the findings more relevant to clinicians and researchers.  A large number of 
patients declined to take part in the study, which may limit how we translate the 
findings to the wider PD population.  Participants who declined to take part in the 
study were older, were often caring for frail relatives, may have had a greater number 
of co-morbidities and thus are potentially more likely to develop dementia.  These 
participants may have reflected the inclusion of geriatric medicine clinics as sources of 
referral which we believe enhanced our ability to include patients who may have 
otherwise not contributed.  Apathy and depression may also have played a role in the 
refusal to participate, as both have been shown to be common in early disease (Khoo 
et al., 2013).  The population was largely recruited from the community, which may 
have introduced bias towards an increase in those with cognitive impairment.  
Certainly we noted that a significant proportion of our control participants also met 
the criteria for MCI, which is likely to represent the fact that we did not pre-screen for 
cognition.  Again we would argue that this suggests that these controls were more 
representative of the wider global community.  In terms of the cognitive measures 
used, domains of attention, memory and executive function were well covered, but 
testing of visuospatial function and language was limited, which may be one 
explanation for the low frequency of impairment observed in these domains and limit 
to absolute applicability of the MDS criteria.  However, inability to copy intersecting 
pentagons has been shown to be a significant predictor of dementia risk (Williams-
Gray et al., 2009a), and there is evidence from other studies that language function is 
less likely to be affected in early cognitive dysfunction in PD (Caviness et al., 2007). 
In summary, the ICICLE-PD study has shown that mild cognitive impairment is more 
common than previously reported in patients with newly diagnosed PD.  Future 
longitudinal assessment will determine whether those participants are at increased 
risk of PDD, allowing for identification of disease modification strategies and targeted 
treatment options. 
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Chapter 3 Cerebrospinal fluid as a biomarker for cognitive decline in 
Parkinson’s disease 
3.1 Rationale for cerebrospinal fluid as a biomarker in neurodegenerative disease 
Although the diagnosis of different neurodegenerative diseases may be based on 
clinical findings and imaging markers, often the earliest pathological alterations may be 
undetected before clinical findings become apparent.  There is evidence that in 
Alzheimer’s disease (AD), the earliest changes seen are in amyloid deposition, followed 
by neurodegeneration and cell loss.  These precede detectable cognitive changes by 
many years (Jack et al., 2010)(Figure 3-1).    
Figure 3-1 Changes in biomarkers in AD (adapted from Jack et al, 2010)  
 
Earlier recognition of these patients with neurodegenerative disorders and 
biochemical abnormalities using biomarkers is important because it allows 
prognostication with early and accurate diagnosis, allows identification of those 
patients who may be selected for neuroprotective or disease-modifying therapies and 
it offers insight into the underlying pathophysiology of the disease.  Furthermore, 
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sensitive and specific biomarkers that permit the detection of preclinical disease could 
also offer objective measures of disease progression and outcome in clinical trials.  
Potential biomarkers in such diseases include structural or functional imaging, genetic 
markers, blood or cerebrospinal fluid (CSF).  As shown in Figure 3-1, imaging changes 
may not be seen until late in the disease process; therefore, CSF may be a more 
suitable alternative.  
CSF bathes the central nervous system (CNS) and may reflect brain pathology and brain 
metabolic systems more accurately than plasma or serum, although CSF proteins are 
derived from both blood and brain tissue (Pan et al., 2007; van Dijk et al., 2010).  
Proteins derived from blood enter the CSF via the choroid plexus, and follow the flow 
of CSF to the ventricles and subarachnoid space, thus creating an increasing protein 
gradient from ventricular to lumbar CSF (van Dijk et al., 2010).  This has implications 
for the site of CSF withdrawal, as does a traumatic tap with subsequent blood 
contamination (Teunissen et al., 2009).  Some CSF proteins are also influenced by 
circadian rhythm.  In view of these variations, a standardised protocol for the 
collection of CSF has been produced (Teunissen et al., 2009). 
The most widely studied peptides in neurodegenerative diseases and dementia are 
amyloid-β and tau.  More recently, α-synuclein has been investigated as a potential 
biomarker for synucleinopathies.  These proteins are discussed in further detail below. 
3.1.1 Amyloid-β 
Amyloid-β (Aβ) proteins are a key component of extracellular amyloid plaques and 
cerebrovascular amyloid that form part of the pathological hallmark of AD (Glenner 
and Wong, 1984; Selkoe, 1996; Verbeek et al., 2003).   Aβ is derived from the 
proteolytic cleavage of Aβ precursor protein (APP), with the subsequent peptide 
production dependent on the length of amino acid chain produced by the enzymes β- 
then γ-secretases at the C-terminus.  The peptides produced from this cleavage vary in 
their ability to aggregate, depending on their length and the degree of post-
translational oxidation (Mollenhauer and Trenkwalder, 2009).  The longer 42-amino 
acid form, Aβ42, is a major constituent of neuritic amyloid plaques, and is highly prone 
to oligomerization and aggregation into fibrils (Jarrett et al., 1993; Selkoe, 1996; 
Verbeek et al., 2003; Irvine et al., 2008).  It is this conformation of oligomers and fibrils 
that precipitate neurotoxicity.  Aβ40, containing 40 residues, is more abundantly 
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produced than Aβ42 and is also found within neuritic amyloid plaques, although there 
is some evidence that Aβ42 is the more toxic of the species (Jarrett et al., 1993).  Aβ40 
is not found within diffuse plaques, which are not fibrillar and contain almost 
exclusively Aβ42 proteins; these are thought to represent precursors of mature, 
neuritic plaques (Irvine et al., 2008).  Aβ is found within the CSF (Seubert et al., 1992; 
Shoji et al., 1992), with a robust inverse correlation found between CSF Aβ and ante- 
and post-mortem amyloid plaque pathology in AD (Clark et al., 2003; Strozyk et al., 
2003; Fagan et al., 2006; Grimmer et al., 2009; Jack et al., 2010).  AD, DLB and PDD 
participants with positive PiB PET imaging consistently demonstrate low CSF Aβ42 
levels (Fagan et al., 2006; Grimmer et al., 2009; Maetzler et al., 2009), with 
neuropathological amyloid plaque numbers in the neocortex and hippocampus 
strongly associated with lower CSF Aβ42 levels (Strozyk et al., 2003).  The reason for 
reduced Aβ in CSF is thought to be due to sequestration within the parenchyma of 
senile plaques, with subsequently lower circulating levels available to diffuse into the 
CSF, although other reasons include the non-detection of Aβ oligomers and its binding 
to other proteins (Irvine et al., 2008).  Reduced circulating CSF Aβ42 levels have been 
found in other conditions, including Creutzfeldt-Jakob disease, where plaque 
pathology may be part of prion disease but does not form a major extent of the 
disease burden (Mollenhauer et al., 2011a).  Hence it has been postulated that Aβ42 
may be a more non-specific measure of neurodegeneration.  Although CSF Aβ42 and 
Aβ40 have demonstrated considerable variation in hour-to-hour sampling over a 36-
hour period in non-demented control participants (Bateman et al., 2007), this was not 
replicated in a small number of mildly impaired older adults sampled every 6 hours 
over the same time period (Moghekar et al., 2012).  Overall, however, low CSF Aβ is 
likely to represent a suitable biomarker of cortical Aβ plaque load.    
3.1.2 Tau 
Tau operates as a microtubule-associated protein, stabilising microtubules that are 
required for the axonal transport of cytoplasmic organelles within the neuron (Verbeek 
et al., 2003).  Tau is usually only mildly phosphorylated in health, but in AD becomes 
hyperphosphorylated, precipitating tau aggregation, accumulation of insoluble paired 
helical filaments and tangle formation, ultimately leading to neuronal cell death and 
leakage of tau into the CSF (Verbeek et al., 2003).  Hence, although total tau is 
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measured, phosphorylated tau levels in addition may be a more specific marker of 
tangle formation.  In AD, intracellular neurofibrillary tangles are found in close 
proximity to Aβ plaques, lending support to the concept of Aβ induced neurotoxicity 
(Irvine et al., 2008), although tau pathology is also found in other neurodegenerative 
disorders without Aβ pathology, including progressive supranuclear palsy, 
frontotemporal dementia and corticobasal degeneration.  Tau is phosphorylated at a 
number of sites, including threonine 181, 205 and 231.  Assays that detect tau 
phosphorylated at threonine 181 (P181-tau) are commonly used in clinical practice as 
a measure of phosphorylated tau.  Neither total- or P181-tau were found to 
significantly vary in repeated measures over a 36-hour time period (Moghekar et al., 
2012), and these markers of tau plus Aβ42 remained stable over a 6 month assessment 
period in subjects with AD (Blennow et al., 2007).  In AD, increased CSF levels of total 
and phosphorylated tau correlated with neuropathological neurofibrillary tangle scores 
(Tapiola et al., 1997; Buerger et al., 2006; Tapiola et al., 2009), suggesting that CSF tau 
measurements may be an appropriate antemortem measure of tangle deposition.  
However, tau levels are greatly elevated in Creutzfeldt-Jakob disease (CJD) (Otto et al., 
2002) and increased in acute stroke (Hesse et al., 2001), suggesting that tau may also 
be a marker of general neuronal loss.  
3.1.3 α-synuclein 
As discussed in Chapter 1,   pre-synaptic α-synuclein is the major constituent of Lewy 
bodies and Lewy neurites, and is found in PD and other synucleinopathies.  Like 
amyloid, α-synuclein proteins first coalesce as soluble oligomers, then aggregate as 
protofibrils before forming insoluble fibrils (El-Agnaf et al., 2003).  There is evidence 
that these intermediate soluble oligomers and protofibrils may be the pathogenic 
species causing neuronal death and neurodegeneration (El-Agnaf et al., 2003).  α-
synuclein can be detected in plasma, CSF and within blood cells (Henchcliffe et al., 
2011).  To date, most studies have demonstrated lower total CSF α-synuclein in PD 
patients compared to controls (Tokuda et al., 2006; Mollenhauer et al., 2008; Hong et 
al., 2010; Mollenhauer et al., 2011b; Shi et al., 2011) and compared to AD subjects 
(Mollenhauer et al., 2011b; Tateno et al., 2012), although others have shown no 
difference (Borghi et al., 2000; Ohrfelt et al., 2009; Reesink et al., 2010).  Reduced α-
synuclein has been detected even in de novo PD patients (Mollenhauer et al., 2013).  
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Synucleinopathies have generally been shown to have reduced CSF α-synuclein 
compared with tauopathies (Ballard et al., 2010; Mollenhauer et al., 2011b; Shi et al., 
2011), and in the largest study to date on CSF biomarkers in neurodegenerative 
disease, α-synuclein levels of less than 1.6 pg/µL had a positive predictive value of 
90.7 % for a synucleinopathy (Mollenhauer et al., 2011b).  The explanation for the 
decrease in CSF α-synuclein could be due to intracellular aggregation, resulting in 
reduced extracellular release, alterations in gene transcription or a greater clearance 
of the protein from CSF (Mollenhauer and Trenkwalder, 2009).  There is some evidence 
that α-synuclein increases with age (Hong et al., 2010) and decreases with PD severity 
(Tokuda et al., 2006), although this has not been consistently shown.  α-synuclein is 
affected by blood contamination of the CSF and therefore red cell count should be 
controlled for (Hong et al., 2010).  As stated above, it has been postulated that 
oligomeric not total α-synuclein may be the toxic species in PD, and more recent 
studies that measured CSF oligomeric α-synuclein have found increased levels in PD 
(Tokuda et al., 2010) and DLB (Paleologou et al., 2009).  To date there has been little 
investigation of α-synuclein and cognition, although one small study in DLB found that 
lower α-synuclein levels correlated with lower scores on MMSE and verbal fluency 
(Reesink et al., 2010).  Therefore, in view of conflicting results to date, definitive 
conclusions cannot be drawn on whether CSF measurement of α-synuclein in PD is a 
useful potential cognitive marker. 
3.1.4 Other CSF proteins 
Other CSF proteins that have been explored in neurodegenerative diseases include 
markers of inflammation such as interleukins, neuropeptides, neurofilaments and 
oxidative stress markers (Hu et al., 2010; van Dijk et al., 2010; Henchcliffe et al., 2011).  
A further protein product indicative of oxidative stress and mitochondrial dysfunction 
is DJ-1, which has shown promise as a possible biomarker of PD (Hong et al., 2010).  In 
a large well conducted study, decreased DJ-1 levels in the CSF were found in PD 
compared with AD and control participants, with a sensitivity and specificity for 
patients with PD versus controls of 90 and 70%, respectively.  Further work is required 
to validate these findings in wider neurodegenerative populations.    
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3.2 Cerebrospinal fluid in Alzheimer’s disease and other dementias 
The typical pattern of CSF findings in AD is well established (Verbeek et al., 2003), and 
more recently, this pattern of decreased Aβ42 with increased total-tau (T-tau) and 
P181-tau has been recommended as supportive criteria for the diagnosis of AD (Dubois 
et al., 2010).  General patterns of CSF biomarkers in other forms of cognitive 
impairment are shown in Table 3-1. Changes seen in mild cognitive impairment (MCI) 
are similar to those seen in AD and predict the development of future AD (Mattsson et 
al., 2009; Visser et al., 2009), although it is likely that longitudinal cognitive decline 
only occurs in those with increased P181-tau levels  (Desikan et al., 2012).  In DLB, the 
pattern of CSF markers is similar to that found in AD and has been hypothesised to be 
due to the burden of AD pathology (Parnetti et al., 2008).  However, DLB may be 
differentiated from AD by increased Aβ40 and reduced α-synuclein levels, thought to 
be due to disease-specific mechanisms of amyloid deposition driven by interactions 
with α-synuclein pathology (Bibl et al., 2006).  Changes seen in frontotemporal 
dementia include raised tau levels that are greater than in PD and controls, but less 
than changes seen in AD (Parnetti et al., 2011).  In addition, a modest reduction in 
Aβ42 and increase in Aβ40 has been found, with a more specific and marked reduction 
in Aβ38; this may be due to a disease specific phenomenon, masking of epitopes to 
antibodies or an upregulation of other Aβ peptides (Bibl et al., 2007).  Lastly, 
Creutzfeldt-Jakob disease is characterised by a massive increase in tau levels due to 
neuronal death, with reduced Aβ42 despite the relative absence of plaque pathology.  
It has been hypothesised that this may be due to the influence of prion proteins 
impeding Aβ metabolism, or a possible common chaperone complex that shows a high 
affinity binding and epitope masking of Aβ42 (Mollenhauer et al., 2011a).   
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Table 3-1 CSF markers in cognitive impairment 
Diagnosis T-tau P-Tau Aβ42 Aβ40 Aβ42: 
Aβ40 
Other 
comments 
References 
AD ↑↑ ↑↑ ↓↓ ↔↓ ↓ ApoE4 ↓ 
Aβ42 levels 
(Verbeek et al., 
2003; Vemuri et 
al., 2009) 
MCI-AD ↑ ↑ ↓ - ↓  (Shaw et al., 2009; 
Vemuri et al., 
2009; Koyama et 
al., 2012) 
DLB ↑ ↑ ↓ ↑ - ↓ αsyn (Mollenhauer et 
al., 2005; Bibl et 
al., 2006; Bibl et 
al., 2010; 
Andersson et al., 
2011; Mollenhauer 
et al., 2011b) 
FTD ↑ ↑ ↔↓ ↑ - ↓↓ Aβ38 (Bibl et al., 2007; 
Parnetti et al., 
2011) 
CJD ↑↑↑ ↑↑↑ ↓↓ ↔ - ↑ αsyn (Otto et al., 2002; 
Mollenhauer et al., 
2008; Mollenhauer 
et al., 2011a) 
AD = Alzheimer’s disease; MCI = mild cognitive impairment; DLB = dementia with Lewy bodies; 
FTD = frontotemporal dementia; CJD = Creutzfeldt-Jakob disease 
3.3 CSF amyloid and tau as biomarkers of cognition in Parkinson’s disease 
In recent years, there has been an exponential increase in the number of studies 
assessing potential CSF biomarkers that may be predictive of AD, DLB, PD, PDD and 
atypical parkinsonian disorders.  Differences in definition of the neurodegenerative 
disorder, differing CSF protein measurement systems (for example, enzyme linked 
immunosorbent assay (ELISA) versus bead-based approach in the Luminex platform) 
and diverse reading techniques (namely spectrometry versus luminescence) result in 
difficulties drawing comparisons in specific protein levels across studies.  The majority 
of this chapter will discuss studies that have specifically looked at cognition and/or 
phenotypes in Parkinson’s disease (highlighted in yellow in Table 3-2).  In non-
demented PD (PDND) participants, most studies have not demonstrated a significant 
difference in total tau levels between PDND and controls (Molina et al., 1997; Steur et 
al., 1998; Kanemaru et al., 2000; Sjogren et al., 2000; Lins et al., 2004; Parnetti et al., 
2008; Compta et al., 2009; Alves et al., 2010; Parnetti et al., 2011).  The results are 
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similar for P181-tau, although only later studies specifically measured this protein 
(Parnetti et al., 2008; Compta et al., 2009; Alves et al., 2010; Parnetti et al., 2011).  One 
recent small study did demonstrate increased total tau, total tau/Aβ42 ratio and 
clusterin (a glycoprotein released under cytotoxic conditions) levels in PD participants 
with a short disease duration compared to controls; the authors postulated that the 
findings may be due to high levels of neurodegeneration in early disease (Vranova et 
al., 2010). In contrast, two large biomarker studies found that both total and P181-tau 
were lower in PD participants compared with controls (Shi et al., 2011; Hall et al., 
2012), although it should be noted that both of these studies were designed to assess 
the accuracy of a number of CSF biomarkers across a number of neurodegenerative 
diseases, and not specifically to compare PD with other groups.  In terms of amyloid 
markers and PDND participants, early studies plus one recent study did not 
demonstrate differences in Aβ42 levels compared to controls (Kanemaru et al., 2000; 
Sjogren et al., 2000; Holmberg et al., 2003; Lins et al., 2004; Parnetti et al., 2011), 
whereas later studies have found consistently decreased Aβ42 levels in PDND subjects 
(Parnetti et al., 2008; Compta et al., 2009; Alves et al., 2010; Shi et al., 2011).  Aβ40 
and Aβ38 are also lower in these patients (Alves et al., 2010).  These changes may be 
present even before clinical PD manifests.  In a recent study of asymptomatic and 
symptomatic LRRK2 carriers, there was a trend towards lower CSF analytes in those 
with clinical disease compared to those with asymptomatic mutations, although this 
did not reach statistical significance (Aasly et al., 2012).  In the group overall, reduced 
CSF Aβ42 and tau levels correlated with lower striatal dopaminergic function as 
determined by PET tracers, with a significant association between Aβ42 and 18F-6-
fluoro-L-dopa uptake. 
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Table 3-2 Summary of studies assessing amyloid and tau CSF biomarkers in PD 
Reference Patients Biomarkers Results Other notes 
(Molina et al., 1997) C=25 (62.8 yrs); PDND=26 (66 yrs) 
 
Total tau (ELISA 
Innogenetics) 
Mean PD=132.8 vs C=159.9 pg/ml 
(not significant) 
Tau not correlated with age, age onset 
PD, disease duration, UPDRS or H&Y 
stage. 
(Steur et al., 1998) C=16 (58 yrs); PDND=67; PDD=48 
(all PD mean age 62 yrs)   
Total tau (ELISA 
Innogenetics), AST 
Tau=155, 199, 204 ng/L (C, PDND, 
PDD) (not significant) 
Tau & AST not correlated with MMSE, 
disease duration, dementia duration, age 
or sex.  
PDD defined MMSE<26. 
(Kanemaru et al., 2000) C=19 (74.7 yrs); PDND=15 (72.9 
yrs); DLB=11 (75.1 yrs); AD=24 
(75.8 yrs) 
Aβ42, total tau (ELISA 
Innotest) 
Aβ42=713.6, 617.1, 349.2, 284.1 
pg/ml (C, PD, DLB, AD) 
Tau=115.1, 116.6, 137.5, 460.1 
pg/ml 
Aβ42 signif ↓ in DLB & AD; tau signif ↑ 
in AD. 
(Sjogren et al., 2000) C=32 (71.5 yrs); PDND=23 (70.7 
yrs); AD=60 (66 yrs); FTD=17 
(62.4 yrs) 
Aβ42, total tau (ELISA 
Innogenetics), GAP-43 
Aβ42=772, 610, 381, 553 pg/mL (C, 
PD, AD, FTD) 
Tau=307, 313, 743, 366 pg/mL 
Aβ42 & tau no different in PD & controls 
but ↑ & ↓ cf AD, respectively. 
(Holmberg et al., 2003) C=32 (65.9); PD=48 (62.3); 
MSA=36 (63.7); PSP=15 (68.5) 
Aβ42 (ELISA Innotest) Aβ42=800, 812, 552, 729 pg/mL (C, 
PD, MSA, PSP) 
Signif ↓ Aβ42 in MSA only cf controls 
(Lins et al., 2004) C=12 (62.8 yrs); PDND=12 (69.3 
yrs); NPH=12 (75 yrs); AD=12 
(71.8 yrs); VD=12 (76.4 yrs) 
Aβ42, total tau (ELISA 
Innogenetics) 
Aβ42=648, 598, 403, 454, 580 
pg/mL (C, PD, NPH, AD, VD) 
Tau=224, 227, 267, 729, 280 pg/mL 
Aβ42 & tau no different cf controls or VD. 
(Bibl et al., 2006) C=23 (68.5 yrs); PDD=21 (72.4 
yrs); DLB=21 (71.5 yrs); AD=23 
(69.5 yrs) 
Aβ37, 38, 39, 40 & 42 (Aβ-
SDS–PAGE/immunoblot 
analysis) 
Signif ↓ Aβ42 in AD & DLB cf 
controls; PDD not signif 
DLB ↑ Aβ40
ox
; Aβ42/37 accurately 
discriminated between dementias & 
controls. 
PDD diagnosed using DSM IV criteria for 
dementia 
(Mollenhauer et al., 2006b) C=41 (70yrs); PDND=23 (72 yrs); 
PDD=73 (72 yrs) 
Aβ42, total tau (ELISA 
Innogenetics), ApoE 
genotyping 
Aβ42=641, 559, 466 pg/ml (C, PD, 
PDD); signif ↓PDD vs PD & C 
Tau=148, 216, 214 pg/ml; signif 
Aβ42 & tau not correlated with age, 
disease duration, UPDRS, H&Y or MMSE. 
Changes marked in those with ApoE3/3. 
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PDD vs C only PDD diagnosed MMSE<25 
(Parnetti et al., 2008) C=20 (60 yrs); PD=20 (62 yrs); 
PDD=18 (65 yrs); DLB=19 (70 yrs); 
AD=23 (70 yrs) 
Aβ42, total tau, P tau (ELISA 
Innogenetics) 
MMSE, MODA, NPI 
Aβ42=1014, 788, 647, 373, 544 
pg/mL (C, PD, PDD, DLB, AD) 
Total tau=177, 160, 286, 508, 960 
pg/mL 
P tau=42, 37, 52, 55, 119 pg/ml 
 
Aβ42 signif ↓ in all groups cf controls; no 
difference between PD & PDD. 
No signif difference in total tau in 
controls, PD or PDD (↑DLB & AD). 
P tau ↑ in AD only. 
DLB only, trend towards ↓ Aβ42 & ↑ 
disease duration & ↑ total tau & 
↓MMSE/MODA scores 
*(Compta et al., 2009) C=30 (71.1 yrs); PDND=20 (69.1 
yrs); PDD=20 (72.5 yrs) 
Aβ42, total tau, P tau (ELISA 
Innogenetics) 
Neuropsychological 
Assessment 
Aβ42=638, 539, 410 pg/mL (C, 
PDND, PDD) 
Total tau=220, 247, 463 pg/mL 
P tau=31, 29, 46 pg/ml 
Signif ↑ T & P tau in PDD vs PDND 
& controls. 
Signif linearity in Aβ42 between 3 
groups. 
No correlation with UPDRS or H&Y. 
MANOVA- age signif ass with total 
tau & P tau. 
All PD- T & P tau signif associated with 
recall, recognition, naming & 
visuoperceptive deficits. Aβ42 signif ↓ in 
those with phonemic & semantic deficits 
& positive correlation with semantic 
fluency. 
PDND- Aβ42 signif ↓ in px with impaired 
phonemic fluency & positively correlated 
with this variable. 
PDD- T & P tau signif associated with 
impaired recognition & naming. 
(Montine et al., 2010) C=115 (68 yrs); aMCI=24 (68 yrs); 
AD=49 (68 yrs); PD=41 (64 yrs); 
PD-CIND=58 (66 yrs); PDD=11 (71 
yrs) 
Aβ42, total tau, P181 tau 
(AlzBio3 Luminex kits from 
Innogenetics) 
Aβ42=378, 322, 313, 220 pg/mL (C, 
PD, PD-CIND, PDD) 
Total tau=60, 54, 53, 33 pg/mL 
P tau=25, 20, 20, 17 pg/ml 
 
PD-CIND defined as clinical dementia 
rating of 0.5 but without dementia. 
Aβ42 signif ↓ in PD-CIND & PDD cf 
controls. 
T tau levels unchanged in 3 PD groups. 
P tau signif ↓ in PD & PD-CIND cf 
controls. 
15% PD, 29% PD-CIND & 45% PDD 
abnormal ↑ P tau/ Aβ42, cf >90% aMCI & 
AD. 
(Bibl et al., 2010) C=40 (64.5 yrs); PDD=21 (73.2); 
DLB=15 (71.4); AD=45 (70.9) 
Aβ42, total tau (ELISA 
Innotest); Aβ peptide 
patterns Aβ-SDS-
PAGE/immunoblot 
Aβ42=0.79, 0.51, 0.37, 0.41 ng/mL 
(C, PDD, DLB, AD) 
Total tau=0.23, 0.31, 0.37, 0.62 
ng/mL 
PDD signif ↓ Aβ42 & Aβ42%  & ↑ Aβ40% 
cf controls. 
↑ Aβ40% & ↓ Aβ42 in DLB vs PDD. 
Low Aβ42/tau sensitive marker for AD. 
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Aβ42%=11.7, 7.5, 7.1, 4.4 
Aβ40%=0.8, 1.1, 1.8, 0.9 
↑ Aβ40% potential marker of DLB. 
(Vranova et al., 2010) C=30 (58.8 yrs); PD=32 (59.9) Aβ42, total tau (ELISA 
Biosource, 
Innogenetics);cystatin C, 
clusterin ELISA, Biovendor) 
Total tau=194 vs 225 ng/L (C vs PD) 
Clusterin=9004 vs 4668 IU/L 
Signif ↑ tau PD vs C. 
Signif ↑ tau, tau/ Aβ42 & clusterin in PD 
with symptoms <2 yrs cf > 2 yrs. May be 
due to high levels of neurodegeneration. 
(Alves et al., 2010) C=36 (66.4 yrs); PD=109 (67.2); 
AD=20 (68.5) 
Aβ38, 40 & 42 (Meso Scale 
Discovery kit by 
electrochemiluminiscence); 
Total & P181 tau (ELISA, 
Innogenetics); Full 
neuropsychological testing 
Aβ42=445, 362, 208 pg/mL (C, PD, 
AD) 
Aβ40=7070, 5973, 6104 pg/mL 
Aβ38=629, 484, 514 pg/mL 
Total tau=228, 224, 435 pg/mL 
P tau=51, 58, 89 pg/ml 
Drug-naïve PD patients. 
Signif ↓ Aβ42, Aβ40 & Aβ38 in PD cf 
controls.  No difference in tau (ANCOVA 
with age, sex & education as covariates). 
Signif ass between Aβ42, Aβ40 & Aβ38 
and memory in multiple sequential 
regression (not attentional-executive or 
visuospatial domains).  Tau did not 
correlate with cognitive scores. 
(Siderowf et al., 2010) PDND=45 (73 yrs) Aβ42, total tau, P181 tau 
(Luminex platform with 
Innogenetics); Longitudinal 
f/u and DRS-2 
Baseline Aβ42= 224 pg/mL 
Total tau=52 pg/mL 
P tau=18 pg/mL 
All patients had 1 year f/u, 20 had 2 
year f/u and 3 evaluated at 3 years. 
At baseline, no association between CSF 
& cognition. 
↓ Aβ42 strongly associated with 
cognitive ↓ over time.  
Aβ42 ≤ 192 had ↓in DRS score that was 
6.1 points greater than those > 192. 
Largest effect size for attention, then 
conceptualization then memory 
subscore. 
↓ Aβ42 in ApoE4 carriers. 
(Mulugeta et al., 2011b) C=12 (73.5 yrs); PDD=20 (73); 
DLB=23 (74); AD=30 (75.5) 
Aβ38, 40 & 42 (Meso Scale 
Discovery kit by 
electrochemiluminiscence); 
Total & P181 tau (ELISA, 
Innogenetics) 
Aβ42=337, 287, 223, 192 pg/mL (C, 
PDD, DLB, AD) 
Aβ40=8286, 5036, 5507, 5461 
pg/mL 
Aβ38=635, 404, 385, 440 pg/mL 
Total tau=250, 303, 303, 382 pg/mL 
P tau=58, 57, 60, 86 pg/ml 
No difference between PDD & DLB. 
Aβ42/Aβ38 strongest marker for 
differentiation of AD & DLB. 
Age & MMSE score correlated with total 
tau, Aβ38 & Aβ40 in all subjects. 
Aβ38 correlated with disease duration.  
Aβ42 correlated with UPDRS. 
(Shi et al., 2011) C=137 (58.9 yrs); PD=126 (63.8); 
AD=50 (68.1); MSA=32 (60.3) 
Aβ42, total tau, P tau (ELISA 
Innogenetics); Flt3 ligand, 
Aβ42=404, 333, 209, 312 pg/mL (C, 
PD, AD, MSA) 
T & P tau tended to ↑ with age.  
Aβ42 & T/P tau ↓ in PD & MSA cf 
   
 
83 
 
fractalkine, DJ-1, α-syn Total tau=62, 55, 95, 47 pg/mL 
P tau=29, 21, 57, 22 pg/ml 
controls. 
Fractalkine/Aβ42 ↑ with UPDRS score. 
↑Flt3 differentiated PD from MSA. 
(Mulugeta et al., 2011a) C=12 (74.1 yrs ); PDD=21 (73.6); 
DLB=24 (74 yrs ); AD=50 (74.4) 
Aβ38, 40 & 42 (Meso Scale 
Discovery kit by 
electrochemiluminiscence); 
Total & P181 tau (ELISA, 
Innogenetics); sAPPα & 
sAPPβ 
Aβ42=479, 264, 262, 275 pg/mL (C, 
PDD, DLB, AD) 
Aβ40=7835, ?, 5833, 5297 pg/mL 
Aβ38=785, 366, 384, 814 pg/mL 
Total tau=269, 308, 297, 600 pg/mL 
P tau=58, 66, 63, 89 pg/ml 
No signif differences in APP between 
groups, but APP correlated with MMSE. 
In LBD, signif correlations between sAPPα 
and sAPPβ with all Aβ species & T-Tau, 
but not P-tau. 
(Andersson et al., 2011) PDD=17 (73 yrs ); DLB=47 (76); 
AD=150 (75) 
Aβ42, total tau, P tau (ELISA 
Innogenetics) 
Aβ42=566, 402, 409 (PDD, DLB, AD) 
ng/L 
T tau=314, 434, 625 ng/L 
P tau=51, 56, 78 ng/L 
DLB ↑ T tau & ↓ Aβ42 cf PDD. 
In DLB, not PDD, CSF proteins correlated 
with MMSE memory scores. 
*(Compta et al., 2011a) C=9 (70 yrs); PDND=19 (69); 
PDD=19 (73) 
Aβ42, total tau, P tau (ELISA 
Innogenetics); tau 
genotypes 
Aβ42=667, 570, 389 pg/mL (c, 
PDND, PDD) 
T tau=248, 217, 358 pg/mL 
P tau=34, 28, 35 pg/mL 
rs242557 tau gene polymorphism 
associated with ↑ T & P tau but only in 
those with Aβ42 < 500pg/mL. 
H1/H1 carriers ↑ P tau in PDD only. 
No signif difference in Aβ42 levels in 
ApoE4 carriers and non-carriers. 
(Parnetti et al., 2011) C= 32 (61.9 yrs); PD=38 (69.3); 
DLB=32 (71.4); AD=48 (68.7); 
FTD=31 (64.3) 
Aβ42, total tau, P tau (ELISA 
Innogenetics); αsyn 
(SuperSignal ELISA) 
Aβ42=69, 43, 18, 35, 15 (C, PD, 
DLB, AD, FTD) ng/mL 
T tau=190, 232, 341, 734, 424 
pg/mL 
P tau=35, 42, 49, 98, 59 pg/mL 
αsyn=69, 43, 18, 35, 15 mg/mL 
αsyn levels signif ↓ in pathological 
groups cf controls. 
Inverse correlation between αsyn & T 
tau. 
In PD, Aβ42, T & P tau levels not different 
to controls. 
T tau/αsyn & P tau/αsyn ↓ showed best 
discrimination of PD. 
(Mollenhauer et al., 2011b) C=23 (73 yrs); PD=273 (72); 
DLB=66 (72); MSA=15 (70); PSP=8 
(72) 
Aβ42, total tau  (ELISA 
Innogenetics); αsyn (ELISA 
system mSA1/Syn1-BB) 
Aβ42=499, 474, 378, 460, 529 (C, 
PD, DLB, MSA, PSP) pg/mL 
T tau=267, 180, 192, 146, 154 
pg/mL 
αsyn=2.2, 1.3, 1.3, 1.1, 1.8 µg/µL  
αsyn signif different across groups. The 
only signif predictor for αsyn was clinical 
diagnosis. 
αsyn < 1.6 µg/µL predicted 
synucleinopathies with 90.7% accuracy. 
(Leverenz et al., 2011) PDND=22 (68.7 yrs) Aβ42, total tau  (Luminex-
based MAP); BDNF; 
Aβ42=544 pg/mL 
T tau=137 pg/mL 
Correlation between processing speed & 
Aβ42, Aβ42/t-tau & BDNF. 
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Neuropsychological testing BDNF=285 pg/mL Signif association between semantic 
fluency (vegetable) & Aβ42/t-tau. 
Effects attenuated by age. 
(Hall et al., 2012) C=107 (70 yrs); PD=90 (63); 
PDD=33 (76); DLB=70 (74); AD=48 
(78); PSP=45 (70); MSA=48 (64); 
CBD=12 (71) 
 Aβ42, T-tau, P tau & αsyn 
(Luminex MAP); NFL 
Aβ42=630, 612, 559, 447, 362, 576, 
589, 595 ng/mL (C, PD, PDD, DLB, 
AD, PSP, MSA, CBD) 
T tau= 473, 371, 365, 413, 840, 
429, 528, 611 ng/mL 
P tau=49, 46, 52, 51, 103, 43, 42, 
46 ng/mL 
αsyn= 67, 55, 59, 59, 94, 70, 56, 56 
ng/mL 
NFL associated with disease severity. 
Age correlated with αsyn in PD, controls 
& MSA. 
PDD ↑ P tau & NFL cf PD. 
PD & PDD ↓ T tau cf controls; PD ↓P tau. 
PD, PDD, DLB & MSA signif ↓ αsyn cf 
controls; AD signif ↑ cf other groups. 
NFL ↑ PSP, MSA & CBD cf others. 
*(Compta et al., 2012) C=12 (71.5 yrs); PDND=18 (69); 
PDD=15 (73) 
Aβ42, total tau, P tau (ELISA 
Innogenetics); MRI 
Aβ42=659, 579, 348 pg/mL (C, 
PDND, PDD) 
Total tau=237, 218, 395 pg/mL 
P tau=33, 28, 35 pg/ml 
Signif negative association between grey 
matter volume & T/P tau; signif positive 
association for grey matter volume & 
Aβ42 in whole PD group for mostly 
frontal & temporal structures. 
(Aasly et al., 2012) Asymptomatic LRRK2 carriers=18 
(51 yrs); LRRK2 + PD=8 (67) 
Aβ42, total tau, P tau (ELISA 
Innogenetics); Dopaminergic 
PETs 
Aβ42=601 vs 504 (carriers vs 
LRRK2+PD) pg/mL 
T tau=36 vs 24 pg/mL 
P tau=21 vs 17 pg/mL 
↓ Aβ42 & tau correlated with ↓ striatal 
DA function on PET. 
Signif association between Aβ42 & 18F-6-
fluoro-L-dopa uptake. 
(Jellinger, 2012) C=17 (68.7 yrs); PD-NT=6 ; PD-
TD=6 (mean age all PD 63.2); 
AD=27 (68.7) 
Aβ42, total tau (ELISA 
Innogenetics) 
Aβ42=658, 394, 147, 376 pg/mL (C, 
PD-NT, PD-TD, AD) 
T tau=223, 147, 193, 760 pg/mL 
Tau/ Aβ42=29, 45, 19.3, 49.5 
Cortex tau/Aβ42 signif ↑ in PD-NT & AD 
cf controls and TD-PD.  Note- difficult to 
see how this calculated, & also Aβ42 ↓ in 
PD-TD (lower than AD & PD-NT). 
(Vranova et al., 2012) C=19 (56.2 yrs); PD-EDO=17 
(48.9); PD-NT=16 (65.6); PD-
TD=15 (67.3); AD=18 (68.4) 
Aβ42, total tau (ELISA 
Innogenetics); tau/ Aβ42 
Aβ42=830, 809, 631, 791, 423 ng/L 
(C, PD-EDO, PD-NT, PD-TD, AD) 
T tau=209, 235, 435, 263, 554 ng/L 
Tau/ Aβ42=0.28, 0.29, 0.55, 0.34, 
1.5 
PD-NT signif ↑ tau & tau/ Aβ42 cf 
controls, PD-EDO & PD-TD. 
In PD-NT, tau correlated with H&Y stage. 
No signif difference between AD & PD-NT 
in terms of tau or tau/ Aβ42. 
(Alves et al., 2013) PD-PIGD=39 (67 yrs); PD-TD=60 
(67.5) 
Aβ38, 40 & 42 (Meso Scale 
Discovery kit by 
electrochemiluminiscence) 
Aβ42=307 vs 408 pg/mL (PIGD vs 
TD) 
Aβ40=5664 vs 6453 pg/mL 
Aβ38=390 vs 578 pg/mL 
PIGD signif ↓ Aβ42 & Aβ38 cf TD. 
PIGD signif ↓ all Aβ peptides cf controls. 
PIGD severity inversely associated with 
Aβ42 & Aβ38. 
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Aβ42 & Aβ38 associated with lower limb 
bradykinesia. 
C= Controls; PDND= PD non-demented; PDD= PD dementia; PD-CIND= PD cognitively impaired non-demented; PD-NT= PD non tremor-dominant; PD-TD= PD 
tremor dominant; PD-EDO= early disease onset; PIGD= postural instability gait difficulty; DLB= dementia with Lewy bodies; AD= Alzheimer’s disease; MSA= 
multiple system atrophy; PSP= progressive supranuclear palsy; FTD= frontotemporal dementia; NPH= normal pressure hydrocephalus; VD= vascular dementia; 
aMCI= amnestic mild cognitive impairment; UPDRS= Unified PD Rating Scale; H&Y= Hoehn & Yahr stage; MMSE= mini mental state examination; MODA= Milan 
Overall Dementia Assessment; NPI= Neuropsychiatric Inventory; DRS-2= Dementia Rating Scale; AST= aspartate aminotransferase; ApoE= apolipoprotein; sAPP= 
soluble isoforms of amyloid precursor protein; NFL= neurofilament light chain; DA= dopamine; *= studies with patients from same cohort; cf=compared with. 
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With respect to cognitive impairment in PD, there is consistent evidence that there are 
differences in CSF markers in those with PDD compared to controls or PDND subjects, 
although one small early study that only measured total tau and aspartate 
aminotransferase (AST) did not find differences between these groups (Steur et al., 
1998).  In DLB and PDD, CSF findings in DLB were similar to that in AD, with higher T-
tau and lower Aβ42 in DLB than PDD, lending support to the hypothesis that these 
patients may have a larger AD burden (Andersson et al., 2011).  In addition, Aβ42 and 
T-tau levels may to be related to dementia severity and duration in DLB but not PDD, 
with one study reporting a negative association between CSF Aβ42 and disease 
duration and T-tau and cognitive scores (Parnetti et al., 2008).   
The first study to accurately characterise Aβ42 and T-tau in a cohort with PDD was in 
2006, where Aβ42 was significantly lower and tau levels were higher compared to 
PDND and control subjects and to controls, respectively (Mollenhauer et al., 2006b).  
This pattern was most marked in the subgroup of PDD patients who were carriers of 
the ApoE3 genotype; this is in contrast with findings in the general population, where 
ApoE4 genotype predicts lower Aβ42 levels (Morris et al., 2010), and may have been 
due to the small numbers studied.  Of note, however, PDD was diagnosed only with a 
MMSE score of less than 25 (Mollenhauer et al., 2006b).  In the next study that 
compared Aβ42, total and P181-tau in controls, PDND, PDD (n=18), DLB and AD 
subjects, Aβ42 was decreased in all groups compared with controls, but no difference 
was seen between PDND and PDD.  Total and P181-tau were not significantly different 
between the control, PD or PDD groups, with no correlations between measures of 
global cognitive function and CSF markers (Parnetti et al., 2008).  In contrast, a further 
study found associations between neuropsychological deficits and CSF markers 
(Compta et al., 2009).  In addition to a graduation in Aβ42 levels from high (controls) to 
intermediate (PDND) to low (PDD) and greater total plus P181-tau in PDD compared to 
PDND subjects, increased tau levels were associated with memory, naming and 
visuospatial deficits, with lower Aβ42 found in those with impairments of verbal 
fluency (Compta et al., 2009).  Aβ42 correlated with phonetic fluency in PD patients 
with and without dementia (PDND), leading the authors to postulate that underlying 
Alzheimer-type pathology in PD was associated with cortical cognitive function, and 
that low CSF Aβ42 with impaired phonetic fluency in PDND could represent an early 
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marker of cognitive dysfunction.  In the same group of patients, certain tau gene 
polymorphisms defined raised total and P181-tau levels, but only in the presence of 
low CSF Aβ42 values (Compta et al., 2011a), with greater tau levels negatively 
correlated with frontal and temporal grey matter volume on MRI (Compta et al., 2012).  
These changes are consistent with findings from the AD literature (Buongiorno et al., 
2011).  In a community cohort of 109 de novo PDND patients, CSF Aβ42, Aβ40 and 
Aβ38 levels were reduced compared to controls, although no difference in tau was 
found (Alves et al., 2010).  In contrast to the results from Compta et al, these early 
stage PD subjects did not display correlations between tau and neuropsychological 
assessments, but Aβ peptides were significantly associated with impairments on the 
memory domain in multiple sequential regression, implying that Aβ metabolism is 
altered early in the disease course and may influence the heterogeneity of the pattern 
and course of cognitive decline associated with PD (Alves et al., 2010).  In comparison, 
a more recent study with 22 non-demented PD patients showed no correlations 
between Aβ42 or total tau and memory, processing speed or executive function after 
controlling for age, but did demonstrate a significant association between category 
fluency (naming vegetables) and Aβ42/T-tau ratio (Leverenz et al., 2011).  These 
results should be interpreted with caution due to the small sample size and the 
possible inconsistencies in the results, with category fluency (naming animals) 
revealing no relationship with any CSF parameters.  A much larger cross-sectional 
study of 345 individuals compared CSF Aβ42, T-tau and P-tau levels in controls, 
amnestic MCI, AD, PD, PD cognitively impaired not demented (PD-CIND) and PDD 
patients (Montine et al., 2010).  Progressively lower Aβ42 levels were found in PD, PD-
CIND and PDD patients, whereas average T-tau was unchanged and P181-tau levels 
were decreased compared to controls.  One-third of PD-CIND and a half of PDD 
patients had the biomarker “signature” of AD (with an increased P181-tau/Aβ42 ratio) 
compared to over 90% of those with amnestic MCI or AD, leading the authors to 
propose that abnormal Aβ42 metabolism may be a common mechanism for PD-CIND 
and PDD. 
The only published longitudinal study to date to look at the relationship between CSF 
biomarkers and cognitive decline in PD showed a strong association between reduced 
Aβ42 and cognitive decline over one year follow-up (Siderowf et al., 2010).  No 
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association was seen between T-tau and P-tau and cognitive decline.  Although at 
baseline assessment there was no association between biomarkers and cognition, 
subjects with baseline CSF Aβ42 levels of ≤ 192 pg/mL (measured using Luminex 
platform) were at greatest risk of deterioration in cognitive scores over time, exhibiting 
a decline of an average of 5.8 more points per year on the Mattis Dementia Rating 
Scale (DRS-2) compared to subjects above this cut-off, after adjusting for age, disease 
duration and baseline cognitive status.  Low CSF Aβ42 was associated with decline in 
multiple subscales of the DRS-2, with the largest effect size seen for attention, then 
conceptualization, then memory subscores.  An accompanying editorial highlighted the 
need for longitudinal studies and better defined more homogeneous cohorts to 
validate these findings (Aarsland and Ravina, 2010). 
Lastly, very recent studies in PD have examined the relationship of different 
phenotypes and CSF parameters (Alves et al., 2010; Jellinger, 2012; Vranova et al., 
2012; Alves et al., 2013).  PD participants with a non-tremor dominant phenotype 
seem to have a pattern of CSF markers similar to changes seen in AD, with significantly 
higher T-tau levels and T-tau/Aβ42 ratio compared to tremor-dominant (TD) disease, 
early-onset disease or control participants (Vranova et al., 2012).  In non-tremor 
dominant participants, T-tau correlated with disease severity, as measured by Hoehn 
and Yahr scale (Vranova et al., 2012).  Although there was a trend towards reduced 
Aβ42 in this phenotype, this did not reach statistical significance.  In comparison, 
newly diagnosed unmedicated PD participants with the postural instability gait 
difficulty (PIGD) phenotype at diagnosis had lower Aβ42 and Aβ38 levels compared 
with a TD presentation (Alves et al., 2013).  These Aβ peptides were associated with 
PIGD subscore severity and lower limb bradykinesia, suggesting that Aβ metabolism 
may influence motor function in addition to cognitive consequences even in early 
stage disease (Alves et al., 2013).  Tau levels were not reported in this study.  
In conclusion, studies of CSF in PD have been largely cross-sectional in nature (with the 
exception of Siderowf’s study), and frequently limited by small sample size and 
heterogeneous study groups.  Overall, low CSF Aβ42 levels have consistently been 
associated with cognitive impairments in non-demented PD subjects, possibly related 
to AD and temporal lobe pathology.  Results for tau and cognition have been 
conflicting, with some studies suggesting an increase, others no change and some 
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suggesting lower tau levels in those with PD and cognitive impairment.  Alzheimer-type 
changes in the CSF seem to correlate with neuropsychological assessments of 
posteriorly mediated cortical impairments, although further work is required to clarify 
these findings with longitudinal evaluation over time. 
Therefore, as part of the ICICLE-PD study, we aimed to determine whether certain CSF 
parameters may predict cognition in a homogeneous, well-defined cohort of early PD 
patients.  We hypothesised that low CSF amyloid-β would be associated with cognitive 
decline, and that low CSF amyloid-β would be associated with more posteriorly-
mediated cognitive dysfunction.  
3.4 Specific CSF methodology 
Lumbar puncture (LP) was performed on a subset of consenting participants as part of 
the ICICLE-PD study, within a four month period after the initial assessment.   To 
standardise collections, all LPs were performed between 8 and 10am after an 
overnight fast and whilst withholding Parkinson’s mediations, as some biomarkers may 
be altered by circadian rhythms and by medication use (Teunissen et al., 2009).  LPs 
were performed in the left lateral or sitting position, depending on the flexibility of the 
patient and presence of tremor.  After appropriate local anaesthesia with lignocaine, a 
20 gauge needle in L3-L5 was used to collect up to 10ml of CSF.  Samples that were 
free of visual contamination by blood were centrifuged within 15 minutes of collection 
at 2000g at 4⁰C for 10 minutes, with the supernatant then divided into aliquots of 
0.25mL and frozen at -80⁰C in labelled polypropylene cryovials.  These cryovials have 
low protein binding potential and should not influence biomarker outcome (Teunissen 
et al., 2009).  Matched serum samples were taken simultaneously and centrifuged at 
4000g at 19⁰C for 10 minutes.  CSF analysis was kindly provided by Professor Brit 
Mollenhauer and her team in Gottingen, Germany.  Frozen samples were transported 
on dry ice without thawing, and immediately analysed for Aβ42, Aβ40, T-tau, tau 
phosphorylated at amino acid 181 (P181-tau) and total α-synuclein (αsyn).  Samples 
were analysed using commercially available assays (tau protein: INNOTEST hTAU 
Antigen; p-tau: INNOTESTTM PHOSPHO-TAU(181P); Aß42: INNOTEST TH ß-AMYLOID 
(1-42) all Fujirebio Inc/Innogenetics, Gent, Belgien; p-tau and Aß40: hAmyloid ß40 Elisa 
ABETA GmbH, Heidelberg, Germany) (Mollenhauer et al., 2006a).  CSF αsyn values 
were determined as published previously with slight modifications (Mollenhauer et al., 
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2008; Kruse et al., 2012).  Capture antibody MJF-1 clone 12.1 (kindly provided by Liyu 
Wu, Epitomics, Burlingame, CA, USA) was used at 3µg/ml. Detection was performed 
using Anti-α-Synuclein clone 42/α-Synuclein (BD Biosciences, Heidelberg, Germany) at 
1µg/ml.  An electrochemiluminescence-based detection system as developed by Meso 
Scale Discovery™ was used instead of classical ELISAs, due to its higher sensitivity and 
smaller amount of CSF required (Kruse et al., 2012).  αsyn standards were used in the 
range of 6 - 25000 pg/ml, with lower limits of detection was less than 10pg/ml.  Intra-
assay coefficients of variation were usually less the 20%, in most cases even less than 
10%. 
3.5  Statistical analysis 
Statistical analyses were performed using SPSS 19.0 (SPSS, Chicago, IL). Data were 
examined for normality with visual histograms and the Kolmogorov-Smirnov test.  
Means were compared using unpaired t-tests if normally distributed or the Mann-
Whitney test for non-normally distributed data.  Pearson Chi-square tests were used to 
compare between-group distribution of proportions. Pearson correlation (for normally 
distributed data) or Spearman’s rank correlation coefficients (non-normal) were 
calculated to assess bivariate associations between neuropsychological tests and CSF 
parameters.  If these were significant or reached near-significance, correlations were 
examined using scatter plots to determine whether the relationship was linear.  A 
linear regression model (forced entry) was then used to control for age and education, 
as these co-variates are known to influence cognition.  Due to exploratory nature of 
the study, we did not adjust for multiple comparisons; if a parameter was significant, 
even if by chance, it was felt that it merited further analysis (Rothman, 1990; Perneger, 
1998; Feise, 2002). 
In the second step of analysis, regression models were used to examine the 
contribution of CSF markers (independent variables) to cognition (dependent variable) 
and to determine whether CSF markers were an independent predictor of cognition.  
MoCA (global cognitive function), One Touch Stockings (OTS) of Cambridge (executive 
function), semantic fluency (executive domain), Power of Attention (PoA, attention 
domain), pattern recognition memory (PRM), paired associates learning (PAL) (both 
memory domains), pentagon score (visuospatial function) and total language score 
were analysed separately.  Generally, one test from each domain was examined, 
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although semantic fluency was investigated in addition to OTS as there is evidence that 
impairment in this test predicts subsequent PDD (Williams-Gray et al., 2007a).  Both 
PAL plus PRM were assessed as part of the memory domain, as PRM was associated 
with Aβ42 using bivariate correlations and has been shown to be sensitive to temporal 
lobe damage, thus more ‘posteriorly’ mediated (Owen et al., 1995b).  PAL was also 
explored as part of the memory domain as  this test is sensitive to both temporal and 
frontal damage and has been shown to predict Alzheimer's disease with a high degree 
of accuracy (Swainson et al., 2001; Blackwell et al., 2004).  Age (Hughes et al., 2000; 
Aarsland et al., 2001; Hobson and Meara, 2004; Aarsland et al., 2007b; Williams-Gray 
et al., 2007a; Uc et al., 2009; Williams-Gray et al., 2009a) and education ( Green et al., 
2002) influence cognition in PD and in the general population.  Other potential 
contributors to cognition include motor phenotype (Aarsland et al., 2003a; Alves et al., 
2006; Burn et al., 2006; Uc et al., 2009), disease severity (Hughes et al., 2000; Aarsland 
et al., 2001; Green et al., 2002; Uc et al., 2009), dopaminergic medication (Kehagia et 
al., 2010) and presence of depression (Starkstein et al., 1992).  Therefore, age and 
education were controlled for in each model, and the associations of each cognitive 
test with motor phenotype score, UPDRS III score, LEDD and GDS were examined using 
bivariate correlation and controlled for if there was a significant or near significant 
association (p<0.1).  These clinical predictors were entered in the first level of the 
model using forced entry, then Aβ42, Aβ40, P-tau and α-synuclein (‘mechanistic’ 
predictors) were entered in the second level using a stepwise method, to determine 
which, if any of the CSF parameters made a significant independent contribution to 
cognition.  Collinearity diagnostics were inspected to test for multi-collinearity, with an 
average variance inflation factor (VIF) greater than one considered problematic.  The 
Durbin–Watson statistic was used to identify autocorrelation (values less than one or 
greater than three were a cause for concern).  In all regression models, standardised 
residuals were inspected to ensure they were approximately normally distributed and 
between ±3.0. There was no evidence of cases exerting undue influence in any model, 
as evidenced by Cook’s distances (D<1). 
In the final stage of analysis, the cases who were defined as level 2 mild cognitive 
impairment (PD-MCI) at 1.5 standard deviations (SDs) as per the methods outlined in 
Chapter 2 were compared to those who were cognitively normal (PD-CN) with respect 
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to the CSF values.  The mean values of Aβ42, Aβ40, T-tau, P-tau and α-synuclein in 
those with PD-MCI versus PD-CN were initially compared using t-test or Mann-Whitney 
test, depending on the distribution of the parameters.  A binary logistic regression 
model (forced entry) was then used to control for age and education.  For the model to 
be a significant fit of the data, the -2 x log-likelihood statistic and its associated chi-
square statistic were < 0.05.  Residuals were examined to ensure model fit, and 
standardised residuals > 3 were inspected.  There was no evidence of cases exerting 
undue influence in any model, as evidenced by Cook’s distances (D<1).  Model fit was 
reported using Cox & Snell’s R2 and Nagelkerke’s R2.   
3.6 Results 
3.6.1 General and clinical characteristics 
67 PD participants consented to lumbar puncture, 56 from Newcastle and 11 from 
Cambridge.  Comparison with those who did not consent is shown in Table 3-3.  The 
sample was representative with the exception of years of education and depression 
scores.  Those who did not consent scored slightly worse on digit vigilance, paired 
associates learning and pattern recognition memory cognitive tests.  No samples were 
discarded due to blood contamination. 
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Table 3-3 Characteristics of participants who did and did not consent to lumbar 
puncture 
Characteristic CSF +ve (n=67) CSF –ve (n=152) P value 
Age (years)a 64.5 (9.4) 66.6 (9.8) 0.141 
Male genderb 39 (58.2%) 101 (66.4%) 0.242 
Disease duration (mo) 5.3 (5.6) 5.6 (4.7) 0.249 
MDS UPDRS III 26.8 (11.8) 27.9 (11.9) 0.513 
LEDD (mg/d) 140.3 (98.1) 194.6 (170.3) 0.071 
Education (years) 13.5 (3.9) 12.5 (3.5) 0.035 
GDS-15 2.4 (2.5) 3.1 (2.7) 0.025 
MoCAc 25.2 (3.3) 25.5 (3.7) 0.314 
MMSE 28.8 (1.1) 28.6 (1.3) 0.439 
Phonemic fluency 11.3 (4.6) 12.0 (4.8) 0.386 
Semantic fluency 22.0 (5.8) 20.7 (7.0) 0.062 
PoA 1341.7 (163.0) 1396.1 (257.9) 0.261 
Digit vigilance 94.4 (11.1) 91.0 (13.3) 0.003 
PAL 1.82 (0.7) 2.1 (0.9) 0.004 
PRM 20.7 (2.6) 19.2 (3.3) 0.001 
SRM 15.6 (2.1) 15.2 (2.3) 0.331 
OTS 14.5 (3.8) 14.5 (4.3) 0.798 
Pentagon 1.9 (0.4) 1.8 (0.4) 0.219 
Language 4.5 (0.7) 4.5 (0.7) 0.507 
Data shown are mean (SD) or number (%). aUnpaired t-test, bPearson Chi-Square; the 
remainder used Mann-Whitney test. cMoCA completed in 195 PD participants. PoA= power of 
attention; PAL= paired associates learning; PRM= pattern recognition memory; SRM= spatial 
recognition memory; OTS= one touch stockings of Cambridge. 
 
Scatter plots of the CSF analytes with age are shown in Figure 3-2.  It was noted that 
there were two outliers in the α-syn data.  One of these was noted to be a ‘reddish 
sample’ at analysis, and therefore analysis was performed with and without this to 
determine whether this unduly influenced the statistics.  The findings below are with 
the outlier included, and any differences in the significance levels without it are 
reported in addition.  The lower limit of detection for T-tau was <75 pg/ml, therefore 
these samples were coded as 0 pg/ml.   
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Figure 3-2 Scatter plots demonstrating the relationship between age and CSF markers 
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As expected, there were significant positive correlations between Aβ42 and Aβ40 
(r=0.698, p<0.001, Pearson’s correlation coefficient) and T- and P181-tau (0.902, 
p<0.001, Spearman’s rho).  α-syn also correlated with Aβ42 (r=0.264, p=0.031), Aβ40 
(r=0.455, p<0.001), T-tau (r=0.530, P<0.001) and P181-tau (r=0.571, p<0.001) (all 
Spearman’s rho).  In keeping with previous studies, there were significant correlations 
between age and T-tau and P181-tau (r=0.412 and r=0.466, respectively, p<0.001, 
Spearman’s rho), age and Aβ40 (r=0.315, p=0.009, Pearson’s correlation coefficient) 
and age and αsyn (r=0.278, p=0.023, Spearman’s rho) (Parnetti et al., 2011; Shi et al., 
2011; Hall et al., 2012).  None of the CSF markers correlated with measures of disease 
duration or severity, the latter as measured by the MDS-UPDRS.  15 subjects (22.4%) 
had pathological P181-tau levels above normal (>60 pg/ml), and five (7.5%) had Aβ42 
<500 pg/ml.  Raw CSF values are displayed in Table 3-4, including all PD participants 
and separate values for males and females.  With the exception of α-syn, which 
showed a slightly higher mean value in females compared to males, there were no 
significant differences between each gender. 
  
Table 3-4  Raw CSF marker values in all PD participants, and males vs females 
 PD all (n=67) Male (n=39) Female (n=28) P value (M vs F) 
Age (years) 64.5 (9.4) 65.7 (10.5) 62.7 (7.3) 0.181a 
Aβ42 (pg/ml) 930.5 (299.7) 935.2 (285.0) 923.8 (324.3) 0.879a 
Aβ40 (pg/ml) 10203 (4092) 10102 (3833) 10342 (4497) 0.815a 
T-tau (pg/ml) 130.4 (93.2) 127.4 (95.9) 134.6 (90.8) 0.358 
P-tau (pg/ml) 47.8 (19.1) 47.0 (19.7) 48.9 (18.6) 0.620 
αsyn (pg/ml) 110.2 (100.2) 100.3 (83.7) 124.0 (119.8) 0.033 
Values are mean (SD). 
a
Unpaired t-test, the remainder used Mann-Whitney test. 
3.6.2 CSF and cognition 
Associations between CSF analytes and cognitive variables were then examined using 
simple bivariate correlations, and are shown in Table 3-5.  If a significant or near 
significant value was found, scatter plots were examined and a linear regression model 
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was used to control for age and education to determine if this significance remained 
(Table 3-6).   
There was a significant association between Aβ42 and PRM (r=0.285, p=0.021, 
Spearman’s rho), and there was a trend towards an association between Aβ42 and 
MoCA and Aβ42 and phonemic fluency (r=0.226, p=0.075, Spearman’s rho; r=-0.220, 
p=0.073, Pearson’s correlation coefficient, respectively).  Further trends were found 
between Aβ40 and total language score (r=0.218, p=0.085, Spearman’s rho) and P-tau 
and semantic fluency (r=-0.211, p=0.086, Spearman’s rho).  Scatter plots of these 
associations are shown in Figure 3-3.   
 
Table 3-5 Bivariate analysis for CSF and cognitive variables 
     CSF      
 Aβ42 
ra 
p Aβ40 
ra 
p T-tau 
rb 
p P-tau 
rb 
p 
 
αsyn 
rb 
p 
MoCAb .226 .075 .107 .405 -.196 .124 -.132 .303 .033 .799 
PoAa -.110 .374 -.020 .871 .124 .316 .126 .311 .097 .435 
Digit 
vigilanceb 
.029 .814 -.044 .723 -.072 .565 -.108 .386 -.107 .387 
Phonemica -.220 .073 -.110 .374 .090 .471 .030 .809 .001 .996 
Semantica .131 .292 -.072 .561 -.169 .171 -.211 .086 .017 .891 
OTSb .102 .418 .114 .367 .007 .955 .009 .942 .060 .636 
PRMb .285 .021 .188 .134 -.054 .671 -.023 .855 -.058 .648 
SRMa .182 .146 .126 .317 -.036 .778 -.061 .631 -.149 .235 
Pentagonsb .061 .624 .015 .901 -.087 .483 -.111 .372 -.026 .832 
Languageb .188 .141 .218 .085 -.024 .854 .038 .765 .172 .177 
aNormally distributed data; bnon-normally distributed; r value using Pearson’s correlation 
coefficient if both variables are normally distributed and Spearman’s rho if not. MoCA= 
Montreal Cognitive Assessment; PoA= power of attention; phonemic= phonemic fluency; 
semantic= semantic fluency; OTS= one touch stockings of Cambridge; PRM= pattern 
recognition memory; SRM= spatial recognition memory; language= total language score. 
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Figure 3-3 Scatter plot demonstrating relationships between CSF markers and cognitive 
assessments 
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Table 3-6 Predictors of association between cognition and CSF biomarkers 
Regression B SE β p 
MoCA  
Linear regression model (df=3, n=62), p = 0.002, R2 = .215 
Age -.105 .049 -.253 0.037 
Education .277 .107 .302 0.012 
Aβ42 .003 .002 .245 0.041* 
PRM  
Linear regression model (df=3, n=64), p = 0.003, R2 = .207 
Age -.060 .032 -.217 0.064 
Education .191 .080 .273 0.021 
Aβ42 .003 .001 .316 0.008* 
Phonemic fluency 
Linear regression model (df=3, n=66), p <0.001, R2 = .259 
Age .030 .054 .061 0.580 
Education .541 .128 .461 <0.001 
Aβ42 -.003 .002 -.205 0.064 
Language 
Linear regression model (df=3, n=62), p = 0.056*, R2 = .119 
Age -.018 .011 -.215 0.115 
Education .034 .023 .187 0.137 
Aβ40 .000055 .000 .296 0.031* 
Semantic fluency 
Linear regression model (df=3, n=66), p = 0.035, R2 = .127 
Age -.170 .081 -.275 0.040 
Education .296 .178 .200 0.101 
P-tau .001 .041 .003 0.982 
 
In a linear regression model that allowed the co-variates of age and education to be 
controlled for, Aβ42 was associated with global cognition, as measured by MoCA (β 
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standardised coefficient=0.245, p=0.041).  Together, age, education and Aβ42 
explained 21.5% of the variance in MoCA score (p=0.002).  Similarly, Aβ42 remained 
associated with PRM, a test of temporal lobe function (β standardised 
coefficient=0.316, p=0.008), with this CSF marker plus age and education explaining 
20.7% of the variance in PRM score (p=0.003).  By contrast, the significant associations 
between Aβ42 and phonemic fluency and P-tau and semantic fluency were lost after 
controlling for the aforementioned variables in the model (β standardised coefficient=-
0.205, p=0.064 and β=0.003, p=0.982, respectively). Although the overall model did 
not explain the variance in language (R2=0.119, p=0.056), reduced Aβ40 was correlated 
with poorer language score (β=0.296, p=0.031).  However, it can be seen from the 
scatter plots in Figure 3-3 that the relationship between language and Aβ40 was not 
linear, and therefore firm conclusions cannot be drawn from these statistics. 
To further explain cognition using CSF parameters, tests from each cognitive domain 
were entered into a linear regression model as the dependent variable and are shown 
below: 
1. Global cognition (Montreal Cognitive Assessment) 
Table 3-7 Regression model statistics and coefficients of variables for MoCA score in 
PD (n=63)
 Independent β P-value 
Model 1   
Age -.220 0.070 
Education .250 0.051 
UPDRS 3 -.178 0.156 
R2 = .185; P-value of change = 0.007   
Model 2   
Age -.261 0.030* 
Education .250 0.045* 
UPDRS 3 -.165 0.176 
Aβ42 .237 0.046* 
R2 = .239 ; P-value of change = 0.046   
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In a bivariate analysis, MoCA score demonstrated a negative association with motor 
severity score which reached near significance (r=-.0.240, p=0.058, Spearman’s rho); 
therefore UPDRS plus age and education were entered into the regression model.  A 
greater level of Aβ42 was an independent determinant of MoCA score and explained 
5.4% of variability (Table 3-7).  In the final model, age, education and Aβ42 were 
independent determinants, explaining 24% of variability in MoCA.  Motor severity was 
not significant, and the remainder of the CSF parameters were excluded from the 
model as they were also not significant. 
2. Executive function (One Touch Stockings of Cambridge) 
Table 3-8 Regression model statistics and coefficients of variables for OTS score (n=61)
 Independent β P-value 
Model 1   
Age -.280 0.024 
Education .160 0.207 
UPDRS 3 -.246 0.053 
Motor phenotype score .096 0.431 
R2 = .197; P-value of change = 0.014   
Model 2   
Age -.261 0.006* 
Education .250 0.123 
UPDRS 3 -.165 0.093 
Motor phenotype score .075 0.528 
Aβ40 .237 0.047* 
R2 = .253 ; P-value of change = 0.047   
   
In addition to age and education, OTS displayed a significant negative association with 
UPDRS 3 score (r=-0.268, p=0.031), with a trend towards a positive correlation with 
motor phenotype score (a greater score indicating more tremor-dominant features, 
r=0.213, p=0.099).   A larger Aβ40 value was an independent determinant of OTS score, 
explaining 5.6% of variability (Table 3-8).  The final model explained 25% of variability 
in OTS, with age and Aβ40 independent determinants.  As there was only a trend 
   
 
102 
 
towards significance between OTS and motor phenotype score and the latter value 
was not significant in either model, the analysis was repeated without motor 
phenotype being entered into the initial step.  This changed the model, with the final 
model explaining 24% of variability in OTS (P-value of change=0.030), and age (β=-
0.391, p=0.003) plus P-tau (β=0.284, p=0.003) independent determinants. 
3. Executive function (semantic fluency) 
Table 3-9 Regression model statistics and coefficients of variables for semantic fluency 
(n=67)
 Independent β P-value 
Model 1   
Age -.285 0.015* 
Education .211 0.069 
LEDD -.253 0.029* 
R2 = .191; P-value of change = 0.004   
  
In a bivariate analysis for explanatory variables for semantic fluency, levodopa 
equivalent daily dose (LEDD, mg/day) negatively correlated with test score (r=-0.253, 
p=0.039).  LEDD plus age and education explained 19% of variance in semantic fluency, 
with age and LEDD significant independent predictors in the final model.  None of the 
CSF parameters added to the final model and were therefore not included, although 
Aβ42 showed a trend towards significance (β=.197, p=0.086). 
4. Attention (Power of Attention) 
Table 3-10 Regression model statistics and coefficients of variables for PoA (n=66)
 Independent β P-value 
Model 1   
Age .203 0.073 
Education -.177 0.116 
GDS .427 <0.001* 
R2 = .251; P-value of change < 0.001   
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PoA score is a sum of reaction times, with a higher score indicating more impairment, 
and showed a positive correlation with GDS score (r=0.341, p=0.005) in bivariate 
analysis.  Again there were no CSF markers that added to the model with age, 
education and GDS explaining 25% of variance in PoA.  Only GDS was an independent 
determinant (β=0.427, p<0.001). 
5. Memory (pattern recognition memory) 
Table 3-11 Regression model statistics and coefficients of variables for PRM (n=65)
 Independent β P-value 
Model 1   
Age -.202 0.073 
Education .148 0.200 
UPDRS 3 -.404 0.001 
R2 = .261; P-value of change < 0.001   
Model 2   
Age -.225 0.035* 
Education .173 0.113 
UPDRS 3 -.401 <0.001* 
Aβ42 .312 0.004* 
R2 = .357; P-value of change = 0.004   
 
PRM was negatively associated with UPDRS (r=-0.371, p=0.002).  Aβ42 was an 
important determinant of PRM score, explaining nearly 10% variability in the final 
model (Table 3-11).  Age, education, motor severity score and Aβ42 together 
accounted for 36% variability in PRM score, with age, UPDRS and Aβ42 independent 
predictors.  
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6. Memory (paired associates learning) 
Table 3-12 Regression model statistics and coefficient variables for PAL (n=65)
 Independent β P-value 
Model 1   
Age .372 0.002 
Education -.239 0.039 
R2 = .212; P-value of change = 0.001   
Model 2   
Age .521 <0.001* 
Education -.292 0.009* 
P-tau -.354 0.005* 
R2 = .310; P-value of change = 0.005   
 
Paired associates learning (PAL) ‘mean trials to success’ was used as the score within 
this test (with a greater score indicating worse performance), as this was used in 
Chapter 2 as part of the definition of mild cognitive impairment.  No other clinical 
variables correlated with PAL score apart from age and education, and in the final 
model, these plus P-tau explained 31% of variance in PAL score.  All variables were 
independent determinants, with increasing P-tau levels predicting a better test score.  
However, it was noted that the model did not meet one of the assumptions required 
for generalisation, with a maximum standardised residual value of > ±3.0 (one value 
was 4.4).  Therefore, the model was repeated with this case excluded.  This did not 
change the overall model (R2=31%, p=0.005), with age (β=.533, p<0.001), education 
(β=-.279, p=0.014) and P-tau (β=-.359, p=0.005) remaining independent contributors 
to PAL score.  The model of PAL was also repeated using PAL ‘total errors’ (again a 
higher score indicating more impairment) and the same variables, as total error score 
has been shown to was very sensitive to the testing of an MCI (non-PD) group and also 
the prediction of AD (Swainson et al., 2001; Blackwell et al., 2004).  In the final model, 
only age and education were included and both were significant contributors, 
explaining 24% of PAL total error score, but P-tau was no longer significant (p=0.082).  
The standardised residuals were almost within ± 3.0 (one residual was 3.3).  
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7. Visuospatial function (pentagon score) 
Table 3-13 Regression model statistics and coefficient variables for pentagon score 
(n=67)
 Independent β P-value 
Model 1   
Age -.173 0.160 
Education .119 0.356 
UPDRS -.130 0.312 
R2 = .275; P-value of change = 0.172   
 
Pentagon score demonstrated a trend towards an association with UPDRS on bivariate 
analysis (r=-0.211, p=0.086).  The final model, although explaining 28% of variance in 
pentagon score, was not significantly better at predicting pentagon score than using 
the mean pentagon score, with no clinical or CSF characteristics independent 
determinants of visuospatial function.  In addition, the assumptions for generalisation 
of the model were not met, with the standardised residual scores ranging from -5.2 to 
0.927.  
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8. Language 
Table 3-14 Regression model statistics and coefficient variables for language (n=62)
 Independent β P-value 
Model 1   
Age -.135 0.274 
Education .153 0.237 
UPDRS 3 -.065 0.628 
GDS -.169 0.206 
LEDD -.283 0.027 
R2 = .189; P-value of change = 0.034   
Model 2   
Age -.271 0.037* 
Education .197 0.113 
UPDRS 3 .012 0.929 
GDS -.133 0.298 
LEDD -.364 0.004* 
Aβ40 .356 0.010* 
R2 = .283; P-value of change = 0.010   
     
Language score was significantly inversely associated with both LEDD (r=-0.327, 
p=0.009) and GDS (r=-0.291, p=0.022), with a trend towards correlation with UPDRS 
(r=-0.210, p=0.098).  These plus age and education were therefore entered into the 
first step of the model, with these clinical variables plus Aβ40 explaining 28% of 
variability in language score.  In the final model, younger age, lower LEDD and 
increased Aβ40 were independent determinants of language score, with Aβ40 
explaining 9% of the variance.  Aβ42 was also a significant predictor (partial 
correlation=.268, p=0.044), but was forced out by Aβ40 and hence not included in the 
final model.  As motor severity showed only a trend towards significance in association 
with language score and did not independently contribute to either model, the model 
was repeated with this variable removed.  This did not alter the final model, which 
explained 28% variability with age, LEDD and Aβ40 being independent predictors of 
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language score.  Below is a summary table of the contributors to cognition discussed in 
this section, using clinical and CSF parameters in regression models. 
Table 3-15 Summary table of independent contributors to cognitive assessments 
 MoCA OTS Semantic 
fluency 
PoA PRM PAL Pentagon Language 
Age X X X  X X  X 
Education X     X   
UPDRS 3     X    
LEDD   X     X 
GDS    X     
Aβ42 X    X    
Aβ40  X*      X 
P-tau  X*    X   
X=significant determinant of cognition in the final regression model; *Differing CSF parameters 
included, depending on whether motor phenotype included in model 
3.6.3 CSF and MCI 
To further examine CSF and its relationship with MCI, participants were dichotomised 
into those who met the criteria for level 2 MCI at 1.5 standard deviations (SDs) and 
those who were cognitively normal (see Chapter 2 for description of methods as to 
how MCI was defined).  CSF values according to cognitive status are shown in Table 
3-16.  PD participants who met criteria for level 2 MCI (PD-MCI, n=21) had significantly 
fewer years of education than those who were cognitively normal (PD-CN, n=46) (11.2 
vs. 14.5 years, p<0.001, Mann-Whitney test).  The PD-MCI cohort had significantly 
lower mean Aβ40 levels compared with PD-CN (8781 vs. 10,852 pg/ml, p=0.029, t-test), 
and there was a trend towards reduced Aβ42 in the MCI group (840.2 vs. 971.6 pg/ml, 
p=0.096, t-test).  Initially there was no significant differences in T-tau or P-tau in either 
group (p=0.456 and p=0.425, respectively, Mann-Whitney test).  
A binary logistic regression model was used to control for age and education, as 
increased age is associated with risk of MCI (Foltynie et al., 2004; Muslimovic et al., 
2005; Williams-Gray et al., 2007a; Kim et al., 2009; Mamikonyan et al., 2009; Aarsland 
et al., 2010; McColgan et al., 2012) and there was a significant difference between the 
number of years of education between the two groups.  After controlling for these 
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variables, significant differences in all CSF parameters remained between the two 
cognitive groups, with the exception of α-synuclein.  T-tau, P-tau, Aβ42 and Aβ40 
values were all significantly lower in the PD-MCI groups (p=0.032, p=0.039, p=0.041 
and p=0.009, respectively) (Figure 3-4 and Table 3-17 to Table 3-20).  Inspection of 
residuals revealed that two cases (case 23 and 43, both from the PD-MCI group) had 
standardised residuals > 3.  The analysis was therefore repeated with these cases 
excluded, which did not change the significance of the models or CSF parameters 
(p=0.020, p=0.035, p=0.017 and p=0.005 for T-tau, P-tau, Aβ42 and Aβ40, respectively).   
Of the five participants with Aβ42 levels less than 500 pg/ml, only one was classified as 
PD-MCI, with a corresponding figure of three out of 15 subjects with P-tau levels 
greater than 60 pg/ml.  Three of the low Aβ42 and six of the high P-tau group scored 
less than 26 on the MoCA, thus meeting the criteria for level 1 MCI. 
 
Table 3-16 CSF profile according to cognitive status 
  Level 2 PD-
CN 
Level 2 MCI 1.5 
SD 
Unadjust-
ed p  
adjusted pb 
No. patients 46 21   
Age (yrs) 63.6 (9.7) 66.3 (8.7) 0.291 - 
Education (yrs) 14.5 (4.0) 11.2 (2.8) <0.001a - 
CSF T-tau (pg/ml) 135.2 (92.1) 119.9 (97.1) 0.456a 0.032 
CSF P-tau (pg/ml) 49.2 (19.8) 44.8 (17.4) 0.425a 0.039 
CSF Aβ42 (pg/ml) 971.6 (319) 840.2 (234.6) 0.096 0.041 
CSF Aβ40 (pg/ml) 10852 (4369) 8781 (3035) 0.029 0.009 
αsyn (pg/ml) 119.3 (116.6) 90.3 (43.9) 0.358a 0.182 
Values are mean (SD); aMann-Whitney test; remainder unpaired t-test; 
bAdjusted for age and education in a binary logistic regression model.  
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Figure 3-4 Scatter plot of (A) CSF Aβ42 and (B) CSF Aβ40 levels (pg/ml) in PD-CN and 
PD-MCI at 1.5 SD below normative values 
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Table 3-17 Binary logistic regression statistics for MCI and T-tau 
 B (SE) P-value Exp (B) 95% CI for Exp (B) 
Lower              Upper 
Age .069 (.041) 0.088 1.072 .990 1.160 
Education -.401 (.128) 0.002* .670 .521 .860 
T-tau -.009 (.004) 0.032* .991 .983 .999 
R2 = .249 (Cox & Snell), .350 (Nagelkerke); Model Chi-squared (3) = 19.17, p < 0.001  
 
Table 3-18 Binary logistic regression statistics for MCI and P-Tau 
 B (SE) P-value Exp (B) 95% CI for Exp (B) 
Lower              Upper 
Age .069 (.041) 0.094 1.071 .988 1.161 
Education -.377 (.124) 0.002* .686 .537 .875 
P-tau -.042 (.020) 0.039* .959 .922 .998 
R2 = .247 (Cox & Snell), .347 (Nagelkerke); Model Chi-squared (3) = 19.02, p < 0.001 
 
Table 3-19 Binary logistic regression statistics for MCI and Aβ42 
 B (SE) P-value Exp (B) 95% CI for Exp (B) 
Lower              Upper 
Age .035 (.036) 0.326 1.036 .966 1.111 
Education -.376 (.131) 0.004* .687 .531 .887 
Aβ42 -.002 (.001) 0.041* .998 .996 1.000 
R2 = .241 (Cox & Snell), .339 (Nagelkerke); Model Chi-squared (3) = 18.50, p < 0.001 
 
Table 3-20 Binary logistic regression statistics for MCI and Aβ40 
 B (SE) P-value  Exp (B) 95% CI for Exp (B) 
Lower              Upper 
Age .087 (.046) 0.058 1.090 .997 1.192 
Education -.394 (.131) 0.003* .675 .522 .871 
Aβ40 -3.10x10-4 
(1.18x10-4) 
0.009* .9997 .9995 .9999 
R2 = .301 (Cox & Snell), .422 (Nagelkerke); Model Chi-squared (3) = 23.96, p < 0.001   
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Lastly, the CSF parameters of those with level 2 PD-MCI (n=21) were then examined 
further in an exploratory analysis.  Due to the small numbers impaired in each 
cognitive domain, participants were instead dichotomised into those with single- or 
multiple-domain MCI and those with amnestic vs. nonamnestic impairments.  No 
significant differences between mean CSF levels were seen in single- (n=9) vs. multiple- 
(n=12) domain MCI (Aβ42: 792.3 vs. 876.2, p=0.400; Aβ40: 8207.3 vs. 9210.9, p=0.468; 
T-tau: 134.8 vs. 108.7, p=0.556; P-tau: 44.3 vs. 45.2, p=0.917; asyn: 87.2 vs. 92.6, 
p=0.788, respectively).  Interestingly, PD subjects with amnestic MCI (n=11) had 
significantly lower T-tau levels compared with nonamnestic MCI (n=10; 77.8 vs. 166.1, 
respectively, p=0.034).  P-tau levels showed a trend towards significance (amnestic 
38.7 vs. nonamnestic 51.5, p=0.093).  The amnestic and nonamnestic participants did 
not differ significantly in mean Aβ42 (837.1 vs. 843.7, respectively, p=0.951), Aβ40 
(8214.1 vs. 9404.2, p=0.383) or asyn levels (79.5 vs. 102.2, p=0.248).  When these 
values were entered into a binary logistic regression model, however, with 
amnestic/nonamnestic as the dependent variable, and age, education plus T-tau or P-
tau as co-variates, neither T-tau nor P-tau were significant determinants.  Furthermore, 
the model chi-square was not significant, indicating that the addition of the variables 
to the model did not significantly affect its predictive power (for T-tau model chi-
square statistic (3) = 7.54, p>0.05; B=.019, p=0.052.  For P-tau, model chi-square 
statistic (3) = 5.64, p>0.05; B=.086, p=0.108).     
3.7 Discussion: CSF as a biomarker for cognition in PD 
In line with previous studies, CSF Aβ42 and Aβ40 levels were found to be significantly 
lower in those with impaired cognition (Mollenhauer et al., 2006a; Compta et al., 2009; 
Montine et al., 2010), with no differences in αsyn levels.  It should be noted, however, 
that only total αsyn and not oligomeric αsyn was measured; the latter has been 
postulated to be the pathogenic species that may precipitate neuronal degeneration 
(Paleologou et al., 2009).  Aβ42 correlated with both global cognition and visual PRM, 
the latter being sensitive to deficits of temporal lobe function.  Aβ42 and Aβ40 are 
major fibrillar components of amyloid plaques, one of the pathological hallmarks of AD 
(Selkoe, 1996; Caughey and Lansbury, 2003).  Although the pathophysiology of PD-MCI 
is poorly understood and likely to be heterogeneous, it is most likely the result of a 
complex and varying interaction between neurotransmitter dysfunction, synaptic 
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pathology, protein aggregation and neuronal damage. To date, only one 
neuropathological study in well-characterised PD-MCI in which participants were 
followed prospectively has been reported (Adler et al., 2010).  The neuropathology 
was heterogeneous, with some cases exhibiting limbic or neocortical Lewy body (LB) 
pathology and the remainder predominantly consisting of brainstem LB pathology.  
Diffuse amyloid plaques were seen in the majority of cases, with two of the amnestic 
MCI subgroup meeting the neuropathological criteria for AD.  Reduced Aβ42 in our 
participants with PD-MCI therefore suggests that these patients may have a higher 
burden of distinct pathology based within medial temporal lobe of an Alzheimer’s-type, 
a finding strengthened by the correlation with PRM on neuropsychological testing.  
PRM is insensitive to levodopa therapy (Lange et al., 1992) and has been associated 
with scores on a dementia screen in a large group of PD patients (Owen et al., 1993).  It 
is therefore possible that even with disease duration of less than six months, 
alterations in Aβ metabolism are present in a subset of patients, leading to Aβ 
fibrillization, aggregation and deposition of amyloid plaques, with subsequent 
increased risk of future dementia.  Indeed there is evidence that Aβ alterations occur 
early and may affect motor circuits in addition to cognition, with reduced Aβ in de 
novo PD patients (Alves et al., 2013; Halliday, 2013).  By contrast, a trend towards 
decreased T-tau and P181-tau in subjects with PD-MCI was found, consistent with 
some (Alves et al., 2010; Montine et al., 2010) but not all (Compta et al., 2009) 
previous work.  Indeed, there is evidence that tau levels are higher in AD and DLB than 
PDD (Parnetti et al., 2008; Andersson et al., 2011).  These findings are consistent with 
the temporal ordering of biomarker abnormalities seen in AD, which may have some 
translational application in the development of cognitive decline in PD: Here markers 
of Aβ deposition occur early and are only followed by markers of neuronal death (such 
as increased tau) much later in the disease trajectory.  The findings are also consistent 
with the autopsy study from Adler and colleagues in PD-MCI which demonstrated little 
neurofibrillary tangle deposition (Adler et al., 2010).  This is the first work on CSF 
findings in PD-MCI classified by the MDS criteria, and the small differences in tau levels 
seen between the groups are of uncertain significance, with further work required 
including longitudinal data to clarify the findings. 
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Some of the most interesting results from this work are derived from the regression 
models using CSF parameters to explain cognition.  Aβ42 was an independent 
contributor to global cognition, as measured by MoCA score, and explained 5% of 
variability.  As discussed above, Aβ42 was also an independent predictor of PRM, 
sensitive to deficits of temporal lobe function (Owen et al., 1995b) and hence a more 
‘posteriorly’ mediated cognitive test.   Semantic fluency has also been postulated to 
have a more posterior cortical than fronto-striatal basis and has been shown to predict 
cognitive decline in one incident cohort of PD (Williams-Gray et al., 2007a; Williams-
Gray et al., 2009a), but amyloid pathology did not seem to contribute in this study.  
Lesion studies have demonstrated that frontal lobe injuries produce similar deficits on 
phonemic and semantic fluency, whilst temporal lobe damage produces a greater 
impairment in semantic compared to phonemic fluency (Henry and Crawford, 2004a).  
In addition, PD patients are significantly more impaired on semantic relative to 
phonemic fluency, which is likely to reflect the dependence on semantic memory in 
the former test (Henry and Crawford, 2004b).  The neural networks of semantic 
memory, which require activation of long-term memory, are thought to originate in 
the temporal lobe, specifically in the medial temporal lobe (Pihlajamaki et al., 2000).  It 
is therefore surprising that Aβ did not contribute to variability in semantic fluency and 
may indicate a differing underlying pathophysiological process, such as cholinergic loss, 
dopaminergic denervation or cortical Lewy body deposition.  There was, however, a 
trend towards significance, and alternatively the study could have been underpowered 
to detect such differences.  Most previous studies of CSF in PD have not demonstrated 
an overall association between semantic fluency and Aβ (Alves et al., 2010; Leverenz et 
al., 2011), and although one study did report that CSF Aβ was significantly lower in 
those with impaired semantic and phonemic fluencies with a significant positive 
correlation with semantic fluency (Compta et al., 2009), the disease duration of the 
participants was much greater than in the present study (mean 10 years). 
Executive function as measured by OTS, a test of planning requiring working memory 
(Owen et al., 1995a) that has been shown to activate fronto-parietal-caudate circuitry 
(Baker et al., 1996; Cheesman et al., 2005), was more difficult to interpret in the 
context of CSF biomarkers.  In the initial regression model, Aβ40 contributed to OTS 
score, but after removing motor phenotype, it was P-tau that was a significant 
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contributor.  In addition, the latter relationship was positive, indicating that greater P-
tau levels predict a better score on OTS.  OTS is thought to be primarily mediated by 
cortical dopamine levels (Williams-Gray et al., 2009a).  It has been hypothesised that in 
PD, the reason for reduced tau and Aβ levels seen in the CSF is due to deposition of 
soluble tau and Aβ oligomers, which instead of forming insoluble tangles and plaques 
precipitate the aggregation of α-synuclein into soluble oligomers then the insoluble 
fibrils found in Lewy bodies (Shi and Zhang, 2011).  If this is true, it may explain in part 
why there is a positive relationship between P-tau and better scores on both OTS and 
PAL, with greater tau levels indicating reduced Lewy body burden.  Indeed, the finding 
that tau contributed to PAL ‘mean trials to success’ score but not ‘total errors’ score 
strengthens this assumption, as ‘total error’ score has been shown to predict AD 
(Swainson et al., 2001; Blackwell et al., 2004).  These findings also correspond with 
those indicating reduced tau levels in those with amnestic versus nonamnestic MCI.  
Although both T-tau and P-tau demonstrated a strong positive correlation with α-
synuclein, this does not disprove the above hypothesis, and may be because total and 
not soluble α-synuclein levels were measured; the latter is thought to be the more 
toxic species (Paleologou et al., 2009).  Hence this would support the thinking that 
cognitive impairment in PD has a somewhat different pathology to AD. 
Neither attention nor visuospatial function had CSF parameters in their final model.  
Attention is likely to be cholinergically mediated, at least in part (Yarnall et al., 2011), 
and therefore it is predictable that amyloid and tau pathology did not contribute to the 
model.  Although one study in PD did demonstrate an association between attention 
subscores and low CSF Aβ42, the effect was only seen after longitudinal assessment 
(Siderowf et al., 2010).  It is likely that the associations and independent contributions 
of CSF parameters will change over time in our ICICLE-PD study.  The lack of 
contribution of biomarkers to visuospatial function is perhaps more unexpected, given 
the previous work from Cambridge indicating that impaired pentagon copying early in 
disease is predictive of subsequent cognitive decline (Williams-Gray et al., 2007a; 
Williams-Gray et al., 2009a).  Again it is possible that this could be due to pathology 
that is not detected by CSF assays, such as the presence of cortical Lewy bodies. Also, it 
should be noted that in this study pentagon copying, with possible scores of 0, 1 or 2, 
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was the sole measure of visuospatial function and therefore may not have the 
sensitivity required to delineate independent contributors.  
Lastly, the finding that Aβ40 contributed to variability in language function is intriguing.  
As discussed above, Aβ40 is less prone to aggregate as compared to Aβ42, and it has 
been suggested that Aβ40 is more likely to reflect Aβ peptide production from amyloid 
precursor protein rather than amyloid deposition per se (Andreasson et al., 2007; 
Alves et al., 2010).  The language tests that were used as part of the study were 
relatively crude and form part of the MoCA, but it is well established that localisation 
of language function occurs in the temporal lobe and hence is a more posteriorly 
mediated cognitive domain (Spitsyna et al., 2006).  Although language function may be 
less affected than other cognitive domains in PD (Troster, 2008; Barone et al., 2011), 
the finding that Aβ pathology significantly contributes to language variability verifies 
the results for PRM above, and suggests that lower Aβ40 and Aβ42  increases the risk 
of subsequent cognitive decline due to temporal lobe AD-type pathology. 
The strengths of this project are its accurate characterisation of a homogeneous cohort 
of early PD participants and relatively large numbers of patients for a CSF study.  The 
analysis of CSF biomarkers was performed by an internationally-renowned team with 
multiple previous publications on the subject.  However, it should be noted that our 
mean values for CSF parameters were somewhat higher than those seen in other 
studies using an electroluminescence platform (Mollenhauer et al., 2011b).  The lack of 
comparators in the form of either control or AD participants who underwent CSF 
sampling could also be viewed as a weakness.  It can be seen from Figure 3-4 that 
there is considerable overlap in individual Aβ42 and Aβ40 levels between PD-MCI and 
PD-CN, and hence it is unlikely that CSF alone can be used as a biomarker for cognitive 
decline.  However, in the future, hopefully lower levels of these analytes could be used 
with other risk markers to predict subsequent risk of cognitive impairment.  As 
discussed in chapter 2, some of the neuropsychological domains may be simplistic in 
terms of localisation of separate functions.  Lastly, without neuropathological data, it is 
difficult to exclude concomitant AD pathology as a cause for our findings. 
In conclusion, significantly lower Aβ42 and Aβ40 levels were found in PD-MCI, and 
reduced Aβ42 correlated with temporal lobe impairments.  Lower CSF Aβ42 and Aβ40 
levels could therefore be used in a set of risk markers to determine those at a greater 
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risk of cognitive decline, with these subjects targeted for future early therapeutic 
intervention and disease modification.   
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Chapter 4 Short latency afferent inhibition as a biomarker for cognitive 
decline in Parkinson’s disease 
4.1 Rationale for short latency afferent inhibition as a biomarker in Parkinson’s 
disease 
The deposition of cortical and subcortical Lewy bodies is implicated in the underlying 
pathophysiology of dementia in PD (Aarsland et al., 2005a), with recent 
clinicopathological studies demonstrating a synergistic role for Alzheimer-type 
pathology in PDD (Lashley et al., 2008; Kempster et al., 2010; Compta et al., 2011b).  
Additionally, imaging (Bohnen et al., 2003) and post-mortem (Tiraboschi et al., 2000) 
studies support a cholinergic basis for cognitive impairment, although other 
neurotransmitters are likely to be involved.  Cholinergic dysfunction and its role in PDD 
are discussed more extensively in Chapter 1 (section 1.6.5).  The pathophysiology of 
mild cognitive impairment in PD patients (PD-MCI) is less well characterised, with some 
evidence suggesting that acetylcholine deficiency may contribute (Meyer et al., 2009). 
A biomarker that could predict those at risk of cognitive decline would be invaluable in 
allowing appropriate targeting of therapeutic interventions.  Short latency afferent 
inhibition (SAI) is one possibility and provides an in vivo non-invasive measurement of 
cholinergic function, substantiated by studies demonstrating decreased SAI in 
Alzheimer’s disease (AD) (Di Lazzaro et al., 2002; Nardone et al., 2008a), DLB (Di 
Lazzaro et al., 2007b) and after administration of the muscarinic antagonist 
scopolamine in normal subjects (Di Lazzaro et al., 2000).  Most recently, SAI was found 
to be significantly impaired in patients with PDD (Celebi et al., 2012).  To date, there 
have been no studies exploring the cholinergic basis of PD-MCI using SAI, or indeed 
examining SAI in early PD.  The aim of this part of the study was therefore to 
determine whether subjects with early PD had evidence of cholinergic dysfunction, 
and to establish whether SAI contributed to cognitive dysfunction.  We hypothesised 
that PD participants would have reduced SAI compared to controls, and that those 
with PD-MCI would have decreased SAI compared to cognitively normal PD patients 
(PD-CN).  An additional hypothesis was that more posteriorly-mediated cognitive tests 
would show greater association with SAI, being putatively more cholinergically 
mediated.   
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4.2 What is short latency afferent inhibition? 
SAI can be described as the inhibition of the motor cortex that occurs approximately 
20 milliseconds (ms) after median nerve stimulation at the wrist (Tokimura et al., 2000; 
Chen et al., 2008; Chen, 2013).  It is seen as suppression of a motor evoked potential 
(MEP) in hand muscles, produced by transcranial magnetic stimulation (TMS) of the 
contralateral motor cortex, after a conditioning afferent stimulation of the median 
nerve, and is measured by averaging conditioned/unconditioned MEPs (%) with a 
greater value indicating less inhibition.  For example, a value of 45% would indicate 
that the mean MEP responses were reduced to 45% of the test unconditioned 
response.  SAI is thought to be cortical in origin, as an early study demonstrated 
through recordings of reduced descending corticospinal volleys induced by TMS 
following median nerve stimulation in conscious patients with implanted electrodes in 
the cervical epidural space (Tokimura et al., 2000).  The same study also established 
that SAI arises around 1ms after latency of the N20 component (a negativity that 
usually peaks around 20ms after the stimulus) of the somatosensory evoked potential 
achieved after median nerve stimulation, and lasts for around 8ms (Tokimura et al., 
2000; Chen et al., 2008).  Although the exact underlying pathway of SAI is unknown, it 
is likely to involve a fast pathway from the periphery to the motor cortex, via 
thalamocortical projection to either the motor cortex directly or the sensory then 
motor cortex (Chen, 2013).  As discussed above, SAI is reduced in cholinergically-
mediated dementias ((Di Lazzaro et al., 2002; Di Lazzaro et al., 2007b; Nardone et al., 
2008a) and after administration of the muscarinic antagonist scopolamine (Di Lazzaro 
et al., 2000); it is also increased after a single dose of a cholinesterase inhibitor (Di 
Lazzaro et al., 2002) and SAI response predicts long term response to this drug (Di 
Lazzaro et al., 2005a).  Therefore acetylcholine (ACh) is likely to be involved in 
mediating SAI.   
Other neurotransmitters that may influence SAI in normal or diseased states include γ-
aminobutyric acid (GABA) and dopamine.  Previous studies have shown that diazepam 
increases (or has no effect) (Di Lazzaro et al., 2007a) whilst lorazepam and zolpidem 
decrease SAI (Di Lazzaro et al., 2005c; Di Lazzaro et al., 2007a).  Benzodiazepines act on 
GABAA receptors, with differing drugs having different affinity for receptor subtypes.  It 
is possible that the reason for these distinct actions on SAI could be due to actions on 
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separate receptor subtypes, as diazepam is relatively non-selective, the affinity of 
lorazepam for various GABA receptor subtypes is unknown, and zolpidem has a high 
affinity for α1-subunits bearing GABAA receptors (Di Lazzaro et al., 2005c).  The 
interaction between cortical ACh and GABA is complex, with human pathological 
studies demonstrating ACh-induced activation of GABA neurones with subsequent 
triggering of GABAergic postsynaptic currents (Alkondon et al., 2000), and animal 
models indicating decreased ACh release following administration of GABA receptor 
agonists (Imperato et al., 1993) and enhanced release with GABAA antagonists 
(Giorgetti et al., 2000; Diez-Ariza et al., 2002).  Whilst these studies using different 
benzodiazepines indicate that GABA receptors are involved in the circuitry underlying 
SAI, it is difficult to be certain entirely what the effects of changes in the 
synaptic/extrasynaptic concentration of endogenous and non-specific GABA would be.  
GABA receptors are likely to contribute to other cortical circuits including short-
interval intracortical inhibition (SICI) and long interval cortical inhibition (LICI), both of 
which interact with SAI (Alle et al., 2009; Udupa et al., 2009).  Other neurotransmitters 
are unlikely to be involved in SAI in healthy subjects as quetiapine, a serotoninergic, 
dopaminergic, histaminergic and α1&2 adrenergic antagonist, has no significant effect 
on SAI or SICI (Di Lazzaro et al., 2005b).   
There is also evidence that dopamine may modulate cortical cholinergic function and 
hence modify SAI in some diseases.  Administration of levodopa (Martorana et al., 
2009) and dopamine agonists (Martorana et al., 2013) restores SAI in AD but has no 
effect in healthy controls.  In PD, SAI was reported to be normal in patients off 
dopaminergic medications but reduced on the affected side after administration of 
dopaminergic medication (Sailer et al., 2003).  However, other researchers argue that 
SAI is actually pathologically increased in PD, and that treatment with levodopa 
restores this (Di Lazzaro et al., 2004a).  
In summary, SAI is an inhibitory cortical circuit that is likely to reflect ACh function, 
although other neurotransmitters may also be involved.  Quantification of SAI provides 
a mechanism to investigate neuronal circuits and alterations in different disease states, 
allowing increased understanding of the disease pathogenesis.          
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4.2.1 Other inhibitory and facilitatory cortical circuits 
TMS allows the non-invasive investigation of excitatory and inhibitory cortical circuits 
and their underlying neurobiology.  It involves stimulation of corticospinal neurones 
via a magnetic field produced by an electrical current passed through shielded wire 
coils (Cantello et al., 2002; Rogasch and Fitzgerald, 2013).  TMS applied to the primary 
motor cortex (M1) with sufficient intensity produces a motor evoked potential (MEP) 
in the target muscle.  In addition to SAI, a number of other inhibitory and facilitatory 
circuits can be investigated using TMS, and these plus their interactions are shown in 
Table 4-1 (Chen, 2004; Muller-Dahlhaus et al., 2008; Paulus et al., 2008; Alle et al., 
2009; Freitas et al., 2011; Ni et al., 2011; Tsutsumi et al., 2012a; Tsutsumi et al., 2012b). 
    
Table 4-1 Summary of cortical circuits investigated with TMS 
Circuit Method of measurement of 
individual circuits 
Neuro-transmission  Interaction with 
other circuits 
SAI TMS of M1 preceded by median 
nerve stimulus at ISI of ~20ms 
ACh (+/- GABAA) Reduces SIHI and LICI 
SICI Subthreshold conditioning 
stimulus applied ipsilateral to a 
suprathreshold test stimulus 
(‘paired pulse TMS’) over M1 at 
an ISI of 1-5ms 
Largely via 
inhibitory GABAA-R 
Reduces SAI 
LICI Paired pulse TMS with 2 
suprathreshold stimuli applied 
over M1 at an ISI of 50-200ms  
Inhibitory GABAB-R Reduces SIHI 
SIHI Inhibition seen after 
conditioning stimulus delivered 
to contralateral M1, followed by 
test stimulus at 6-15ms 
Transcallosal 
pathways ?via 
GABAB-R 
Reduces SICI and SAI 
LAI As for SAI but with ISI of 
~200ms 
Unknown Inhibits LICI 
ICF As for SICI but with longer ISIs 
of 7-20ms 
?Excitatory 
glutamate via 
NMDA-R (+/-
inhibitory GABAA) 
Increased by LAI 
SICI=short-interval intracortical inhibition; LICI=long-interval intracortical inhibition; SIHI=short-
latency interhemispheric inhibition; LAI=long latency afferent inhibition; ICF=intracortical 
facilitation; M1=primary motor cortex; ISI=interstimulus interval; NMDA-R=N-Methyl-D-
aspartic acid receptor. 
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4.2.2 Short latency afferent inhibition in neurodegenerative diseases 
As discussed above, it has been established that SAI is reduced in AD (Di Lazzaro et al., 
2002; Di Lazzaro et al., 2004b; Di Lazzaro et al., 2005a; Nardone et al., 2008a).  
Acetylcholinesterase inhibitors (AChE-I) can restore this loss (Di Lazzaro et al., 2002; Di 
Lazzaro et al., 2004b), with rivastigmine producing an increase in SAI from a mean 
baseline of 83.2% to 59.4% inhibition after a single dose in one study (Di Lazzaro et al., 
2002), and from 86.2% to 70.1% in a larger cohort (Di Lazzaro et al., 2004b).  There was 
no significant change in SAI in the controls given the drug (Di Lazzaro et al., 2002).  
Both baseline SAI and increase in SAI after treatment with rivastigmine predict long-
term response to the drug, as measured by the Global Deterioration Scale (Di Lazzaro 
et al., 2005a).  In this latter study, change in SAI following administration of an AChE-I 
correlated with changes in assessments of long-term verbal memory and verbal 
fluency (Di Lazzaro et al., 2005a).  Moreover, specific behavioural disorders are 
associated with cholinergic dysfunction, with hallucinations correlating with SAI in DLB 
and with affective symptoms in AD (Marra et al., 2011).  
In mild cognitive impairment (MCI), the data on SAI is less clear.  Three studies have 
examined SAI in MCI in non-parkinsonian patients; an earlier study in amnestic MCI did 
not demonstrate an impairment in SAI compared to controls (Sakuma et al., 2007), but 
more recent findings in those with more advanced cognitive impairments who 
displayed abnormalities on functional neuroimaging support the hypothesis that 
degeneration of cholinergic interneurons is an early process in MCI, with reduced SAI 
in those with cognitive deficits (Tsutsumi et al., 2012a).  Participants with MCI 
displayed a mean SAI of 85% compared to 50% in the control group; interestingly there 
was no difference in those who were and were not taking donepezil (Tsutsumi et al., 
2012a).  In a further study examining MCI subtypes, only those with amnestic MCI-
multiple domain had reduced SAI compared with other subtypes and controls 
(Nardone et al., 2012b).  Administration of donepezil in a sample of these participants 
significantly increased SAI, and in all participants, SAI significantly correlated with tests 
of verbal memory, attention and executive function (with the exception of verbal 
fluency).       
In contrast to AD and DLB, where there is a profound loss of cholinergic transmission, 
SAI is normal in frontotemporal dementia (Di Lazzaro et al., 2006) and in some subjects 
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with vascular dementia (Di Lazzaro et al., 2008), thus supporting the role of SAI as a 
non-invasive putative measure of cholinergic loss.  However, other studies have 
demonstrated that cholinergic loss may be a feature of vascular dementia, with 
reduced SAI in patients compared to controls (Nardone et al., 2008b), although it 
should be noted that individual responses varied widely.  In addition, emerging work in 
the hereditary small vessel disease Cerebral Autosomal Dominant Arteriopathy with 
Subcortical Infarcts and Leukoencephalopathy (CADASIL), where white matter lesions 
can affect cholinergic projections, has shown a loss of SAI (Manganelli et al., 2008; 
Palomar et al., 2013).  One small study included eight patients with progressive 
supranuclear palsy (PSP), where degeneration of cholinergic neurones in the 
pedunculopontine nucleus (PPN) and nucleus basalis of Meynert (nbM) is part of the 
pathology (Nardone et al., 2005).  Perhaps surprisingly, there was no difference in SAI 
between PSP patients and controls; the authors postulated that the cholinergic system 
is affected differently in PD and PSP, with loss of presynaptic cholinergic neurones and 
upregulation of muscarinic ACh receptors in PD but not PSP (Nardone et al., 2005). 
Recent work has examined SAI in subjects with and without idiopathic REM sleep 
behaviour disorder (iRBD) (Nardone et al., 2012c).  Over half the participants with iRBD 
also had MCI, with mean SAI significantly smaller in those with iRBD than controls (72.2% 
SAI in iRBD vs. 43.1% in controls).  SAI correlated with iRBD disease duration, global 
cognition and measures of episodic memory and executive functions (Nardone et al., 
2012c). 
4.2.3 Short latency afferent inhibition and ageing  
Because of evidence indicating that sensorimotor integration is altered during ageing 
with a decline in cholinergic function, a number of studies have examined the effect of 
age on SAI and other cortical circuits.  Earlier studies did not demonstrate differences 
in SAI between young and ‘elderly’ subjects (Oliviero et al., 2006; Degardin et al., 2011), 
although mean ages of older participants were only 71 and 62, respectively.  In more 
recent work with larger numbers and increased age (31 participants, mean age 70.3 
years, range 65-82), SAI was significantly reduced in the older compared to younger 
age group, with approximately half of the senior group exhibiting low levels of 
inhibition, and a number exhibiting facilitation (average conditioned MEP ≥ 100%) 
(Young-Bernier et al., 2012a).  Within the older age group, SAI did not correlate with 
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increasing age per se, but did predict motor performance.  The same authors published 
a further study in the same groups of patients and found that SAI explained 
approximately 10% of the variance in memory scores (which was significant), but did 
not predict executive function (Young-Bernier et al., 2012b).        
4.2.4 Short latency afferent inhibition in Lewy body diseases 
Studies that have explored SAI in Lewy body diseases are shown in Table 4-2.  The first 
study in PD assessed 10 young prevalent PD participants on and off dopaminergic 
medications (mean age 58.2 years) and 10 age-matched controls.  In PD subjects on 
the more affected side, SAI was normal in the ‘off’ state (~50% of conditioned MEP 
response) but was decreased after dopaminergic medication (~100%) (Sailer et al., 
2003).  SAI did not correlate with scores of motor severity or disease duration.  The 
authors of a consequent study of just three PD subjects and 12 age-matched controls 
argued that SAI was enhanced in PD in the ‘off’ state, and that this is restored by L-
dopa administration (Di Lazzaro et al., 2004a).  In the affected side of these 
hemiparkinsonian participants, SAI was 22.1% versus 54.1% on the unaffected side.  
The findings of increased SAI in PD was confirmed by a further study, whose authors 
reasoned that this could be due to upregulation of postsynaptic muscarinic ACh 
receptors due to loss of presynaptic cholinergic projective neurones (Nardone et al., 
2005).  Here SAI was 24.2% in PD versus 44% in PSP and 46.2% in controls, with no 
association found between SAI and neuropsychological data.  
Three studies have evaluated SAI in DLB.  Although an initial study did not demonstrate 
differences in SAI between DLB and control participants (Nardone et al., 2006), two 
further studies challenged these findings, with significant reductions in SAI (Di Lazzaro 
et al., 2007b; Marra et al., 2011).  The initial study by Nardone et al was criticised for 
the use of outdated diagnostic criteria for DLB and for the lack of randomisation when 
performing SAI under different conditions.  In keeping with outcomes in AD, 
administration of an AChE-I restored SAI in three out of four DLB patients (Di Lazzaro et 
al., 2007b) and correlated with hallucination scores (Marra et al., 2011).  Recently SAI 
was also found to be impaired in Parkinson’s disease dementia (PDD), with the degree 
of SAI correlating with tests of global plus specific cognitive functions (Celebi et al., 
2012).   
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Table 4-2 Studies to date on SAI in Lewy body diseases 
Reference Group, n Age (mean), 
years 
Disease 
duration 
 
Diagnosis Medications Muscle 
used; ISIs 
tested 
Main SAI 
findings 
Other comments 
(Sailer et al., 
2003) 
PD = 10; C = 
10 
PD= 58.2; C= 
59.5 
 
PD = 7.4 years Not discussed Performed ‘on’ 
and ‘off’ DA 
meds 
R + L FDI; 
ISI 20ms 
SAI normal off 
med (~50% vs. 
controls ~65%), 
↓ in ‘on’ state 
(~100%) 
DA med ↓SAI on 
more affected side 
but not on less 
affected side 
(~60%). All 
patients right-
handed  
 (Di Lazzaro et 
al., 2004a) 
PD = 3; C = 
12 
PD= 67.3; C= 
73.1 
‘Newly 
diagnosed’ 
Not discussed No DA meds R + L FDI; 
ISIs N20 + 
2-8ms 
Enhanced SAI on 
affected side in 
PD (22.1%) 
No difference 
between 
unaffected side of 
PD (54.1%) & 
controls (45.3%) 
(Nardone et al., 
2005) 
PD = 10 (6 
with 
dementia); 
PSP = 8 (4 
with 
dementia); 
C = 15 
 
PD= 66.5; PSP= 
68.2; C= 73.1 
PD= 22.4; PSP= 
19.1 months 
 
PD-Ward and 
Gibb criteria 
PSP- not 
discussed 
Dementia-
DSM-III-R 
criteria 
No 
anticholinergic 
drugs or drugs 
affecting motor 
cortex 
excitability; ‘off’ 
DA meds 
R or L FDI, 
depending 
on side 
affected by 
PD; ISIs 
N20 + 2-
8ms 
Enhanced SAI in 
PD (24.2%); no 
difference 
between PSP 
(44%) and 
controls (46.2%) 
No separate data 
given on those 
with cognitive 
impairment. No 
correlation of SAI 
with cognitive 
scores 
 (Nardone et al., 
2006) 
DLB = 10; 
AD = 13; C = 
15 
DLB= 71.2; AD= 
69.6; C= 67.5 
DLB= 30.6; AD= 
32.2 months 
DLB- McKeith 
1996 
consensus 
No 
anticholinergics, 
DA, or meds 
FDI 
(dominant 
hand); ISIs 
SAI reduced in 
AD (84.2%) but 
not DLB (56.4%) 
SAI performed 
without 
randomisation of 
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 criteria 
AD- NINCDS-
ADRDA 
criteria 
affecting motor 
cortex excitability 
N20 + 2-
8ms 
compared with 
controls (46.8%) 
different 
conditions, and 
1996 criteria (not 
revised) used for 
DLB diagnosis. No 
correlation of SAI 
with MMSE or DRS 
 (Di Lazzaro et 
al., 2007b) 
DLB = 10; 
AD = 10; C = 
10 
DLB= 73.1; AD= 
72.1; C= 72 
DLB= 25.5; AD= 
32.0 months 
 
DLB- Revised 
consortium 
criteria 2005 
AD- NINCDS-
ADRDA 
criteria 
No AChE-I or 
drugs affecting 
CNS 
L FDI; ISIs 
N20 + 2-
8ms 
SAI reduced in 
DLB (93.2%) and 
AD (90.8%) cf 
with controls 
(42.8%) 
4 DLB patients also 
given AChE-I & SAI 
repeated- 3 
showed large ↑ in 
SAI following drug 
(Sailer et al., 
2007) 
PD + 
bilateral 
STN DBS = 
7; C = 7 
PD = 56.1; C = 
56.0 
 
PD = 14 years Not discussed ‘On’ & ‘off’ DA 
meds 
R or L FDI; 
ISI N20 + 
3ms 
SAI ↓ in MED-
ON/STIM-OFF 
(~84%) state but 
normal in MED-
ON/ STIM-ON 
(~54%) 
Normal SAI in 
MED-OFF/STIM-
OFF (~60%) state 
vs. MED-OFF/ 
STIM ON (~62%) 
controls (~56%) 
 (Manganelli et 
al., 2009) 
PD+VH= 10; 
PD–VH= 12; 
C = 11 
PD+VH = 70.4; 
PD-VH = 65.5; 
C = 62.4 
 
PD+VH = 8.7; 
PD-VH = 9.0 
years 
Not 
discussed; 
Not 
demented 
No 
anticholinergic or 
anti-depressant 
meds; ‘on’ 
medication 
R or L FDI 
(according 
to most 
affected 
side); ISIs 
N20 + 2, 4 
& 8ms 
SAI reduced in 
PD+VH (89.4%) 
cf PD-VH 
(46.5%) & 
controls 
(46.4%).  All PD - 
66% SAI 
MCI present in 
16/22 PDs.  PD+VH 
more impaired on 
tests of attention/ 
frontal & 
visuospatial 
functions 
(Marra et al., 
2011) 
DLB = 18; 
AD = 18; C = 
DLB  = 73.0; AD 
= 71.8; C = 71.8 
DLB  = 28.8; AD 
= 34.0 months 
DLB- Revised 
consortium 
No AChE-I, 
antidepressant or 
L FDI; ISIs 
N20 + 2-
SAI reduced in 
DLB (73.8%) and 
SAI correlated with 
hallucinations in 
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10   criteria 2005 
AD- NINCDS-
ADRDA 
criteria 
antipsychotics 8ms AD (85.3%) cf 
controls (42.8%)   
DLB and euphoria 
in AD 
(Celebi et al., 
2012) 
PD = 10; 
PDD = 10; 
AD = 10; C = 
10 
PD  = 72.0; 
PDD  = 75.0; 
AD = 76.1; C = 
72.1 
PD = 2.3; PDD  = 
8.4; AD = 2.8 
years 
 
PD- UK Brain 
Bank criteria 
PDD- MDS 
consensus 
criteria 
AD- NINCDS-
ADRDA 
criteria 
No 
anticholinergic or 
AChE-I; ‘off’ 
medication 
R or L FDI; 
ISIs N20 + 
1-8ms 
SAI reduced in 
PDD (91.4%) & 
AD (94.7%) 
patients, but 
normal in PD 
(61.4%) & 
controls (55.5%) 
Negative 
correlation 
between SAI & 
MMSE, attention, 
executive, 
memory & 
visuospatial 
function 
(Nardone et al., 
2012a) 
PD+RBD = 
10; PD-RBD 
= 13; C = 15 
PD+RBD = 
65.9; PD-RBD = 
63.7; C = 66.4 
PD+RBD = 5.0; 
PD-RBD = 6.0 
years 
PD- not 
discussed; 
RBD- 
American 
Academy of 
Sleep 
Medicine 
criteria 
‘On’ DA 
medication; no 
anticholinergics 
or drugs affecting 
motor cortex 
excitability 
R or L FDI, 
depending 
on 
handed-
ness; ISIs 
N20 + 2-
8ms 
SAI ↓ in 
PD+RBD (77.4%) 
vs. PD-RBD 
(49%) & controls 
(45.4%) 
SAI values 
correlated with 
episodic verbal 
memory, 
executive and 
visuospatial 
function in PD 
(Rochester et al., 
2012) 
PD = 22; C = 
22 
PD = 70.2; C = 
67.4 
PD = 19.8 
months 
QSBB criteria ‘On’ DA meds; off 
meds affecting 
cortical 
excitability 
R or L FDI, 
depending 
on side 
affected; 
ISIs N20 – 
N20 + 4ms 
SAI ↓ in PD 
(77%) vs. 54% in 
controls 
↓ SAI 
independent 
determinant of 
gait speed, 
explaining 37% 
variability 
(Yarnall et al., PD-MCI = 
11; PD-CN = 
PD-MCI = 73.3; 
PD-CN = 66.9; 
PD-MCI = 20; 
PD-CN = 20.5 
PD- QSBB ‘On’ DA meds; off 
meds affecting 
R or L FDI, 
depending 
SAI ↓ in PD-MCI 
(88.4%) vs. PD-
SAI negatively 
correlated with 
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2013) 11; C = 22 C = 67.9 months criteria 
PD-MCI- 
MoCA <26 
cortical 
excitability 
on side 
affected; 
ISIs N20 – 
N20 + 4ms 
CN (62.8%) & 
controls (55.7%) 
MoCA in PD but 
not controls 
PD= Parkinson’s disease; AD= Alzheimer’s disease; DLB= dementia with Lewy bodies; C= healthy controls; PSP= progressive supranuclear palsy; DA= dopaminergic; 
AChE-I= acetylcholinesterase inhibitor; FDI= first dorsal interosseous; STN DBS= subthalamic nucleus deep brain stimulation; VH= visual hallucinations; RBD= REM 
sleep behaviour disorder; MMSE= mini mental state examination; DRS= Mattis Dementia Rating Scale; QSBB= Queen Square Brain Bank criteria; MCI= mild 
cognitive impairment; CN= cognitively normal; MoCA= Montreal Cognitive Assessment; cf=compared with. 
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A small study showed that in PD participants with subthalamic nucleus (STN) deep 
brain stimulation (DBS), SAI is normal in the ‘off’ state regardless of whether the 
stimulator is on (MED-OFF, STIM-ON or STIM-OFF, respectively), reduced in the MED-
ON/STIM-OFF state and restored to normal in the MED-ON/STIM-ON condition (Sailer 
et al., 2007).  Possible mechanisms for the STN DBS normalisation hypothesised by the 
authors included alterations in neuronal firing patterns, increased motor cortex 
excitability or a direct effect on cortical structures (Sailer et al., 2007). 
A study in patients with PD and visual hallucinations, believed to reflect functional 
involvement of cortical cholinergic circuits, showed reduced SAI compared to those 
without hallucinations (Manganelli et al., 2009).  In this study, 16 of the 22 PD 
participants were also found to have MCI, with more severe impairments in tests 
probing attention/frontal lobe and visuospatial functions in those with hallucinations.  
Similarly, in PD plus RBD, where cholinergic degeneration is recognised (Kotagal et al., 
2012a) and which is a risk factor for dementia (Postuma et al., 2012), SAI was reduced 
compared to PD participants without RBD and to controls (Nardone et al., 2012a).  
We examined SAI in our cohort of early PD patients (Rochester et al., 2012; Yarnall et 
al., 2013).  SAI was reduced in PD compared to control subjects and was an 
independent predictor of gait speed in those with PD (Rochester et al., 2012).  
Furthermore, SAI is decreased in PD-MCI, as defined by the Movement Disorder 
Society level 1 criteria (MoCA score < 26/30) (Yarnall et al., 2013). 
4.2.5 Limitations of SAI studies in PD 
To date, studies in PD have been small and contradictory, with some studies 
demonstrating enhanced (Di Lazzaro et al., 2004a; Nardone et al., 2005), reduced 
(Sailer et al., 2003; Sailer et al., 2007; Rochester et al., 2012) or normal SAI (Celebi et 
al., 2012).  The amount of inhibition seems to correlate with global cognitive function 
and tests of attention/executive, memory and possibly visuospatial function.  Work 
thus far has been limited by small sample sizes, disease heterogeneity and additional 
pathologies.  No studies have examined SAI in PD-MCI, where cholinergic dysfunction 
may contribute to the cognitive deficits (Meyer et al., 2009). We therefore sought to 
determine the relationship between PD-MCI, cognition and SAI in a large cohort of 
well-characterised early PD participants.   
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4.3 Specific project methodology 
4.3.1 Participants 
PD and control participants were recruited as part of the ICICLE-PD study in Newcastle 
(see Chapter 2).  Due to timings of this specific project, the majority of PD subjects 
were tested as part of their 18 month assessments as a convenience sample (see 
Results for details), whilst most of the controls underwent SAI at baseline.  
Neuropsychological and clinical assessments were performed as discussed in Chapter 2.  
Exclusion criteria were those participants with contraindications to magnetic 
stimulation (including metallic heart valve, cranial aneurysm clips, previous seizures), 
co-morbid diseases that could potentially affect somatosensory evoked potentials 
(such as a peripheral neuropathy or myelopathy) and a tremor score of >2 on the MDS-
UPDRS (Goetz et al., 2008b), as this adversely affects electromyogram (EMG) readings. 
The SAI protocol used in these experiments was based on the method described by 
Tokimura and colleagues (Tokimura et al., 2000) and followed international consensus 
criteria (Chipchase et al., 2012).  SAI was performed off medications affecting the 
central nervous system where possible (including benzodiazepines and 
antidepressants), and ‘on’ dopaminergic medications to reduce patient discomfort and 
improve acceptability of the protocol.  Anticholinergic drugs were stopped for at least 
five days prior to testing, and no participants were taking cholinesterase inhibitors.  
The technician performing TMS was blinded to the cognitive status of participants.     
4.3.2 Recordings 
Surface EMGs were recorded from abductor pollicis brevis (APB) and first dorsal 
interosseous (FDI) of the most symptomatic (patients) or the dominant upper limb 
(controls) with adhesive Ag-AgCI gel electrodes (Biosense Medical Ltd).  The active 
electrode was placed over the muscle belly and the reference electrode over the 
proximal metacarpophalangeal joint.  Somatosensory evoked potentials (SEPs) were 
recorded via adhesive electrodes (Neuroline 720, Ambu, Denmark) applied to the scalp 
(contralateral to median nerve stimulation; see below) after appropriate skin 
preparation, using a bipolar montage with the non-inverting electrode 2cm anterior to 
C3/C4 (according to the 10-20 system), the inverting electrode 2cm posterior to C3/C4 
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(depending on the side of stimulation) and the reference electrode placed on the 
forehead.  
Signals were amplified (EMG gain 1000-2000; EEG gain 50k) and bandpass filtered 
(EMG 30 Hz-2kHz; EEG 3Hz-2kHz), using a Digitimer D360 system (Letchworth Garden 
City, Herts, UK), before being digitised at 5kHz by a Power1401 interface (Cambridge 
Electronic Design Ltd, Cambridge, UK) connected to a computer running Spike2 
software (Cambridge Electronic Design Ltd).  
4.3.3 Nerve stimulation 
SEPs were obtained by stimulating the median nerve in the more symptomatic arm in 
patients and on the dominant side in controls. Stimuli (single pulses; pulse width 200µs; 
range 4 to 25 mA) were delivered to the median nerve at the wrist using a constant 
current stimulator (Digitimer DS7A) via adhesive electrodes (cathode proximal; 
Biosense Medical Ltd).  The intensity of the stimulus was adjusted to just above motor 
threshold, as determined by a visible twitch in the APB muscle.   
4.3.4 Magnetic stimulation 
Transcranial magnetic stimulation (TMS) of the motor cortex was performed using a 
high power Magstim 200 (Magstim Co. Whitland, Dyfed, Wales) and circular TMS coil 
(130mm diameter).  The vertex (Cz) was measured using standard procedures and 
marked with indelible ink.  The circular coil was then placed with the vertex marker 
positioned in the centre of the coil and the handle of the coil (held by the 
experimenter) posterior.  An anticlockwise coil current was used to stimulate the left 
hemisphere (right hand) and a clockwise coil-current for the right hemisphere (left 
hand).  The direction of the coil current used (and therefore the hemisphere 
stimulated) varied between patients (and controls).  In PD patients TMS was delivered 
to the hemisphere opposite the most affected side, whereas in controls the dominant 
hemisphere was targeted.  Motor evoked potentials (MEPs) were recorded from the 
contralateral FDI muscle.  Resting motor threshold (RMT) was determined as the 
percentage of maximum stimulator output which elicited a liminal MEP (approximately 
50µV in 5 out of 10 trials) at rest.  MEPs were digitized (see above) and stored for later 
analysis, when they were analysed blind to the diagnostic category. 
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4.3.5 Short latency afferent inhibition 
MEPs were conditioned by median nerve stimulation.  Conditioning stimuli delivered 
to the median nerve preceded cortical TMS by varying interstimulus intervals (ISIs).  
These were determined relative to the latency of the N20 component of the average 
SEP to median nerve stimulation (averages of 2000 raw sweeps).  SAI was randomly 
tested at five different ISIs with 10 trials at each ISI (from N20 in 1ms increments until 
N20+4ms), with 20 unconditioned (test) stimuli also delivered randomly (Figure 4-1).  
The peak to peak amplitude of the conditioned MEPs at each ISI were averaged and 
expressed as a percentage of the averaged unconditioned MEP (basal MEP).  To reduce 
variability, the conditioned responses were combined across all ISIs and expressed as 
the percentage of the unconditioned MEP to provide a grand mean of SAI, as described 
by others (Di Lazzaro et al., 2000; Nardone et al., 2008a).  Participants were given 
visual feedback to maximise complete relaxation, and any EMGs contaminated by 
interference were excluded.  
4.3.6 Statistics 
Statistics were carried out as for Chapter 2 and 3.  In addition, analysis of variance 
(ANOVA) and analysis of covariance (ANCOVA) were also performed.  The assumption 
of homogeneity of variance was not violated (Levene Statistic p>0.05).  Our a priori 
hypotheses were that PD participants would have decreased SAI compared to controls, 
and that those with PD-MCI would have a further decrement compared to the PD-CN 
group.  Therefore, in the ANOVA analysis, contrast 1 compared PD vs. controls, and 
contrast 2 PD-MCI vs. PD-CN participants.  Polynomial linear trends were established, 
with the groups coded as control=1, PD-CN=2 and PD-MCI=3 and weighted as -2, +1 
and +1, respectively for contrast 1 and 0, +1 and -1, respectively for contrast 2.  
Significance values are reported as one-tailed with a p value of <0.05 taken as 
significant.  Hochberg’s GT2 post hoc pairwise comparisons (as the samples sizes were 
different) reported for the comparisons between PD-MCI vs. controls and PD-CN vs. 
control subjects.  Further analyses were performed using ANCOVA to control for 
influences on SAI.  Simple planned contrasts were performed and adjusted means 
calculated. 
 
   
 
132 
 
Figure 4-1 Short latency afferent inhibition. Conditioned and unconditioned motor 
evoked potentials (MEPs) recorded from: A. A control subject (aged 66); B. A patient 
with Parkinson’s disease (aged 83). Baseline (unconditioned) MEPs are plotted in black 
and conditioned MEPs are plotted in colour (time intervals between the conditioning 
median nerve stimulation and the TMS test pulse are shown in parentheses): green 
(N20); blue (N20+2ms); and red (N20+4ms). Average MEPs (n=20) have been plotted. 
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4.4 Results 
4.4.1 General and clinical characteristics 
Recruitment of participants for this study is outlined in Figure 4-2.  Five PD subjects 
were recruited at baseline, and the remainder at their 18 month assessments, due to 
the timing of an ethical amendment.  The majority of controls were approached at 
baseline, but to increase numbers, additional participants who had not previously 
undergone TMS were consented when reviewed at 18 months.  Five PD participants 
declined to take part.  A number were unable to undergo SAI (PD n=13, controls n=15); 
reasons included previous seizures (n=3), metallic prostheses (n=15), use of 
anticholinergic and other medications that affect SAI that could not be stopped prior 
to testing (n=3) and significant co-morbid disease including sensory axonal neuropathy 
and cervical myelopathy (n=7).  Six subjects could not tolerate either the median nerve 
stimulation or TMS required to produce meaningful MEPs.  Other reasons for not 
obtaining SAI data included technical issues (for example, no clear N20 obtained), 
tremor score and participants not approached due to the timings of their assessments.  
Lastly, following SAI evaluation, nine were subsequently excluded due to poor quality 
EMG recordings, drug effects and one due to re-diagnosis from PD to progressive 
supranuclear palsy (PSP).   
Comparisons of participants who were available for SAI (PD n=87 (1 participant 
excluded due to PSP), control n=86) who did and did not undergo SAI are shown in 
Table 4-3.  PD participants who underwent SAI had less severe motor disease (MDS 
UPDRS 3 score 30.9 vs. 36.7, p=0.033) and had better MMSE scores (28.8 vs. 28.0, 
p=0.017) than those who did not, but were otherwise well-matched.  Controls 
undergoing SAI scored higher (i.e. better function) on MoCA, MMSE and spatial 
recognition memory (SRM) scores than those who did not, but otherwise the group 
was representative.  General and clinical comparisons of those PD and control 
participants who had SAI performed are shown in Table 4-4.  There were no significant 
differences in age, gender, handedness or years of education between the groups.  PD 
subjects scored higher on depression scores and lower on the majority of cognitive 
tests than controls, with the exception of digit vigilance, verbal fluency, pentagon 
score and language.  Memory sub-scores were unavailable for one PD participant 
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(refused computerised testing); with attention scores unavailable for a different PD 
subject (missing data).        
Figure 4-2 Flow diagram of recruitment of SAI 
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baseline 
assessment) 
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Table 4-3 Comparisons of participants who did and did not undergo SAI 
Characteristic  Control   PD  
 SAI- 
(n=43) 
SAI+ 
(n=43) 
p  SAI-
(n=42) 
SAI+ 
(n=45) 
p 
Age (yrs)a 67.0 69.2 0.240 67.5 69.3 0.396 
Male gender (%)b 24 (56) 26 (61) 0.662 27 (64) 28 (62) 0.842 
Education (yrs) 13.0 13.4 0.481 13.8 12.7 0.241 
Disease duration 
(mo) 
- - - 22.7 21.4 0.882 
UPDRS 3a - - - 36.7 30.9 0.033* 
LEDD (mg/d)a - - - 374.7 331.5 0.285 
PIGD score - - - 0.87 0.71 0.233 
Non-TD 
phenotype (n,%)b 
- - - 25 (60) 30 (67) 0.490 
GDS 1.0 0.8 0.341 2.9 2.6 0.190 
MoCA 26.8 28.0 0.034* 25.3 25.9 0.517 
MMSE 28.8 29.4 0.013* 28.0 28.8 0.017* 
PoA (msec) 1279 1271 0.705 1410 1358 0.311 
Digit Vigilance (%) 95.9 97.0 0.273 92.1 92.2 0.561 
PRM 20.7 21.2 0.189 20.4 19.7 0.274 
SRM 15.8 16.8 0.021* 15.0 15.1 0.710 
PAL 2.0 1.8 0.072 2.3 2.1 0.665 
OTS 16.0 17.1 0.194 13.3 15.1 0.079 
Phonemic fluencya 39.0 41.5 0.338 37.7 37.0 0.824 
Semantic fluencya 23.9 24.9 0.438 21.3 22.4 0.466 
Pentagon 1.9 2.0 0.309 1.8 1.8 0.514 
Language 4.5 4.7 0.219 4.4 4.6 0.153 
aUnpaired t-test; bChi-squared test; remainder used Mann-Whitney; Values are mean (%); 
PoA=power of attention; PRM=pattern recognition memory; SRM=spatial recognition memory; 
PAL=paired associates learning; OTS=one touch stockings of Cambridge. 
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Table 4-4 Demographic and descriptive data for PD and control participants who 
underwent SAI 
Characteristic Control (n=43) PD (n=45) p value 
Agea 69.2 (8.4, 50.6-89.7) 69.3 (10.3, 45.0-88.8) 0.939 
Male genderb 26 (60.5%) 28 (62.2%) 0.866 
Handedness (R/L)c 40/3 40/5 0.714 
Education 13.4 (3.5) 12.7 (3.5) 0.347 
GDS 0.8 (1.4) 2.6 (3.3) 0.001* 
MoCA 28.0 (1.9) 25.9 (4.1) 0.018* 
MMSE 29.4 (0.8) 28.8 (1.4) 0.018* 
PoA 1271 (145) 1358 (186) 0.025* 
Digit vigilance 97.0 (4.9) 92.2 (14.4) 0.095 
PRM 21.2 (2.4) 19.7 (3.0) 0.012* 
SRM 16.8 (1.7) 15.1 (3.0) 0.009* 
PAL 1.8 (0.7) 2.1 (0.7) 0.028* 
OTS 17.1 (1.8) 15.1 (4.1) 0.008* 
Phonemic fluencya 41.5 (12.2) 37.0 (13.5) 0.108 
Semantic fluencya 24.9 (5.7) 22.4 (8.0) 0.098 
Pentagon 2.0 (0.2) 1.8 (0.5) 0.056 
Language 4.7 (0.6) 4.6 (0.8) 0.295 
aUnpaired t-test; bChi-squared test; cFisher’s exact test; remainder used Mann-Whitney; Values 
are mean (SD, range for age). 
 
4.4.2 General neurophysiology results 
Recordings were made from the dominant hand in control subjects (40 right-handed 
and 3 left-handed) and in the side of onset or most symptomatic arm in participants 
with PD (27 right-dominant disease, of whom 25 were right-handed, and 18 left-
dominant disease, of whom 3 were left-handed).  Neurophysiological parameters for 
both groups are shown in Table 4-5.  There were no significant differences in N20, 
median nerve motor threshold or resting motor threshold between PD and controls.  
Mean SAI was significantly reduced in PD compared to control participants (77.4% of 
MEP test response vs. 59.0%, p=0.001, unpaired t-test), although individual responses 
varied widely (Figure 4-4). The amount of inhibition showed a trend towards a 
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reduction in PD participants at the N20 interval (p=0.102), but was significantly less at 
N20+1 to N20+4ms (p=0.031, p=0.012, p=0.001 and p<0.001, respectively). Figure 4-4 
demonstrates that there was an obvious outlier in both the control and PD groups 
(control SAI=128.6%, PD SAI=181.6%).  These figures were checked, with no obvious 
reason for the lack of inhibition (for example, no medications implicated); therefore 
they were included in the final analyses.  Removing these and re-analysing the 
difference in SAI did not alter the overall significance (PD mean SAI 57.3 ± 19.7%, 
control mean SAI 75.1 ± 24.7%, p<0.001).  Figure 4-3 shows the difference in SAI at 
each interstimulus interval in both groups, with a clear separation at each 
interstimulus interval. 
   
Table 4-5 Neurophysiological parameters of PD and control participants 
 Control PD P value 
N20 (ms) 22.0 (2.7) 22.2 (1.7) 0.698 
MNMT (mA) 11.6 (4.4) 11.4 (4.8) 0.806 
RMT (% max stim) 40.0 (5.8) 39.3 (6.6) 0.655 
SAI 59.0 (22.3) 77.4 (29.2) 0.001* 
Data are mean (SD); MNMT=median nerve motor threshold; RMT=resting motor threshold of 
maximum stimulator output; p values obtained using unpaired t-test. 
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Figure 4-3 Short latency afferent inhibition for PD and control participants at each 
interstimulus interval ; *p<0.05 
  
Figure 4-4 Scatterplot of percentage inhibition of SAI in PD and control subjects ; mean 
and SD are also displayed 
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4.4.3 Short latency afferent inhibition analysis 
The relationship between SAI and clinical characteristics for all participants are shown 
in Figure 4-5.  There was a significant association between age and SAI, with the 
amount of inhibition reduced as age increased (r=0.325, p=0.002, Pearson’s r).  A 
negative correlation was found between SAI and years of education and global 
cognitive score as measured by MoCA (r=-0.317, p=0.003 and r=-0.238, p=0.023, 
respectively, Spearman’s rho).  There was no correlation between SAI and depression 
score (r=0.124, p=0.249, Spearman’s rho).  These findings were largely influenced by 
the PD group, as when analysed separately, SAI correlated with age only in the control 
group (r=0.303, p=0.048), with no correlation seen between SAI and years of education 
or MoCA (r=-0.129, p=0.410 and r=.148, p=0.345, respectively).  In all participants 
there was no significant difference in SAI between males and females (70.5% vs. 65.1%, 
respectively, p=0.373, unpaired t-test).  PD subjects demonstrated a positive 
correlation with SAI and age (r=0.366, p=0.013), and a negative correlation between 
SAI and years of education completed (r=-0.445, p=0.002), MoCA score (r=-0.410, 
p=0.005) and MMSE (r=-0.336, p=0.024, Spearman’s rho).  There was no association 
between the amount of inhibition and GDS, disease duration, disease severity (as 
measured by MDS UPDRS 3), PIGD score or LEDD (r=0.097, r=-0.106, r=0.236, r=0.016 
and r=-0.031, respectively, Spearman’s rho). 
4.4.4 Short latency afferent inhibition and cognition 
SAI was examined in relation to cognition in PD and control participants.  Initially 
participants were classified by control group, cognitively normal PD (PD-CN) and PD 
with mild cognitive impairment (PD-MCI) according to the MDS level 1 criteria (a MoCA 
score of less than 26).  General characteristics of each group are shown in Table 4-6.  
There were significant group differences for age, years in education, GDS, disease 
severity, MoCA score and SAI (for SAI, F(2, 85) = 11.96, p<0.001).  The planned 
contrasts revealed a significant difference between PD and controls (t(85) = 4.06, 
p<0.001 (one-tailed)), and that the PD-MCI group had significantly less inhibition than 
the PD-CN (93.4 ± 30.6% vs. 67.7 ± 24.0%) group (t(85) = -3.40, p<0.001 (one-tailed)).  
Post hoc tests (Hochberg’s GT2) revealed a significant difference between PD-MCI vs. 
controls (p<0.001), but no difference between PD-CN and control participants (67.7 ± 
24.0% vs. 59.0 ± 22.3%, p=0.376).  There was, however, a large degree of overlap 
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between the groups (Figure 4-6). Excluding the two SAI outliers as discussed above did 
not affect the overall results.   
 
Table 4-6 Characteristics of controls, PD cognitively normal (PD-CN) and PD mild 
cognitive impairment (PD-MCI), according to MDS level 1 MCI criteria 
 Control (n=43) PD-CN (n=28) PD-MCI (n=17) p 
Age (yrs)a 69.2  65.3 76.0 0.001* 
Male gender (n, %)b 26 (61) 16 (57) 12 (71) 0.659 
Education (yrs) 13.4 13.9 10.9 0.001* 
Disease duration (mo) - 21.7 20.8 0.682 
MDS UPDRSa - 27.3 36.8 0.003* 
LEDD (mg/d)a - 341.3 315.5 0.597 
GDS 0.8 2.3 3.3 0.003* 
MoCA 28.0 28.4 21.8 <0.001* 
SAI (%, SD)a 59.0 (22.3) 67.7 (24.0) 93.4 (30.6) <0.001* 
      Data are mean (SD for SAI); aANOVA; bPearson Chi-Squared; remainder used Kruskal-Wallis    
 test. 
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Figure 4-5 Scatter plots demonstrating the relationship between SAI and clinical 
characteristics in PD and control subjects; A) SAI and age; B) SAI and MoCA score; C) 
SAI and years of education 
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Figure 4-6 Scatter plot showing mean values of SAI for controls, PD cognitively normal 
(PD-CN) and PD mild cognitive impairment (PD-MCI) according to level 1 criteria ; error 
bars are SDs 
  
The group differences in SAI remained after controlling for age, education and GDS in 
an ANCOVA (F(2, 82) = 6.97, p<0.01), although simple planned contrasts revealed that 
only the PD-MCI showed significantly less inhibition compared to the control group 
(adjusted mean SAI 86.8 vs. 59.4%; t(82) = -3.64, p<0.001) but not compared to PD-CN 
(adjusted mean SAI 86.8 vs. 71.2%; t(82) = -1.93, p>0.05).  The difference between PD-
CN and control subjects was also not significant (adjusted mean 71.2 vs. 59.4%, 
p=0.057).  Disease severity using MDS UPDRS was not controlled for, due to a lack of 
association between SAI (see above) or cognition (see Chapter 2).  
When PD participants were classified as PD-CN (n=27) or PD-MCI (n=18) using level 2 
criteria at 1.5 SDs below normative values (see Chapter 2 for details of methods), there 
was again a significant difference in the amount of inhibition across the PD-MCI, PD-CN 
and control groups (87.0 ± 32.7% vs. 71.1 ± 25.2% vs. 59.0 ± 22.3%, respectively, F(2, 
85) = 7.80, p<0.001) (Table 4-7), but with considerable overlap between participants 
0
20
40
60
80
100
120
140
160
180
 %
 o
f 
co
n
tr
o
l M
EP
 
Controls PD-CN 
 
PD-MCI 
p<0.001  
p<0.001 
p=0.376 
   
 
143 
 
(Figure 4-7).  Planned contrasts revealed that there was a significant difference 
between PD vs. controls (t(85) = 3.64, p<0.001 (one-tailed)), and that the PD-MCI 
group had significantly less inhibition than PD-CN subjects (t(85) = -2.04, p<0.05 (one-
tailed)).  In post hoc tests (Hochberg’s GT2), there was a significant difference in 
inhibition between the PD-MCI and control group (p=0.001) but not PD-CN and control 
subjects (p=0.162).  
Table 4-7 Characteristics of control, PD-CN and PD-MCI groups according to MDS level 
2 criteria 
 Control 
(n=43) 
PD-CN (n=27) PD-MCI 
(n=18) 
p 
Age (yrs)a 69.2  67.1 72.6 0.157 
Male gender (n, %)b 26 (61) 16 (59) 12 (67) 0.870 
Education (yrs) 13.4 13.7 11.4 0.039* 
Disease duration (mo) - 22.2 20.2 0.531 
MDS UPDRSa - 28.0 35.1 0.030* 
LEDD (mg/d)a - 326.9 338.5 0.809 
GDS 0.8 2.5 2.9 0.003* 
MoCA 28.0 28.2 22.6 <0.001* 
SAI (%, SD)a 59.0 (22.3) 71.1 (25.2) 87.0 (32.7) <0.001* 
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Figure 4-7 Scatter plot of mean SAI values for controls, PD-CN and PD-MCI according to 
MDS level 2 criteria 
 
After controlling for age, education and GDS in an ANCOVA, these group differences 
remained significant (F(2, 82) = 5.56, p<0.01).  In planned simple contrasts, PD-MCI 
participants had significantly reduced inhibition compared to the control group 
(adjusted mean SAI 81.9 vs. 59.5%; t(82) = -3.11, p<0.01) but not PD-CN subjects 
(adjusted mean 73.7%; t(82) = -1.09, p>0.1).  The control group demonstrated a 
greater degree of SAI compared to PD-CN (p=0.026).  The analysis was repeated 
excluding the two outliers (one from the control and one from PD-MCI group), which 
did not alter the results. 
Finally, those PD subjects with level 2 MCI at 1.5 SDs below normative values (n=18) 
were then examined.  Mean SAI values were compared in those with single- (n=10) and 
multiple- (n=8) domain MCI.  No significant difference was seen between the groups 
(single 79.1 ± 26.0% vs. multiple 96.8 ± 39.0%, p=0.268).  In addition, when 
dichotomised into amnestic (n=9) vs. nonamnestic (n=9) MCI, there was no difference 
in inhibition (SAI 80.9 ± 22.4% vs. 93.0 ± 41.1%, respectively, p=0.450).   When 
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amnestic/nonamnestic was entered into a binary logistic regression model as the 
dependent variable, with age, education and SAI as co-variates, the model chi-square 
was non-significant, plus SAI was not a significant determinant (chi-square(3) = 3.50, 
p>0.05; SAI B=.007, p=0.678).  Results were similar for single/multiple-domain (model 
chi-square(3) = 1.78, p>0.05; SAI B=.018, p=0.326).  The small numbers impaired may 
mean that these analyses are underpowered to detect differences between the groups. 
4.4.5 Cognitive domains and short latency afferent inhibition 
Associations between SAI and cognitive variables in the PD and control subjects were 
examined using simple bivariate correlations, shown in Table 4-8.  There were negative 
correlations between SAI and both phonemic and semantic fluency in PD but not 
control participants (r=-0.362, p=0.015; r=-0.380, p=0.010, respectively, Pearson’s r), 
with higher scores on verbal fluency correlating with greater inhibition of MEP 
response.  In addition, a significant positive correlation was found between paired 
associates learning (PAL) and SAI in PD subjects (r=0.439, p=0.003, Spearman’s rho).  
PAL (mean trials to success) is a visuospatial test of learning and memory, with a higher 
score indicating a greater degree of impairment; therefore here a higher score 
correlated with reduced inhibition.  Scatter plots of these correlations are shown in 
Figure 4-8.  Although a significant correlation was found between language score and 
SAI in controls, it can be seen from Figure 4-8 that the relationship was non-linear and 
therefore violated one of the assumptions for correlation. 
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Table 4-8 Bivariate analysis of explanatory cognitive variables for SAI in PD and control 
subjects  
 Control (n=43) PD (n=45) 
Power of Attention (PoA) 
r 
p value 
 
0.226 
0.145 
 
0.095 
0.541 
Digit vigilance 
r 
p value 
 
0.108 
0.490 
 
-0.210 
0.170 
Pattern recognition memory (PRM) 
r 
P value 
 
-0.196 
0.208 
 
-0.238 
0.120 
Spatial recognition memory (SRM) 
r 
p value 
 
-0.062 
0.692 
 
0.026 
0.866 
Paired associates learning (PAL) 
r 
p value 
 
-0.064 
0.684 
 
0.439 
0.003* 
One touch stockings (OTS) 
r 
p value 
 
-0.180 
0.249 
 
-0.185 
0.228 
Phonemic fluencya 
r 
p value 
 
0.058 
0.712 
 
-0.362 
0.015* 
Semantic fluencya 
r 
p value 
 
0.029 
0.855 
 
-0.380 
0.010* 
Pentagon copying 
r 
p value 
 
0.112 
0.475 
 
-0.239 
0.114 
Language 
r 
p value 
 
0.368 
0.015* 
 
-0.167 
0.273 
  aPearson’s r; remainder used Spearman’s rho 
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Figure 4-8 Scatter plots demonstrating relationships between SAI and phonemic 
fluency, PAL and semantic fluency in PD and SAI and language in control subjects 
 
 
To further evaluate the relationship between cognition in PD and SAI, tests from each 
cognitive domain were entered into a linear regression model as the dependent 
variable and are shown below: 
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1. Global cognition (Montreal Cognitive Assessment) 
Table 4-9 Regression model statistics and coefficients of variables for MoCA score in 
PD (n=44)
 Independent β p value 
Model 1   
Age -.220 0.177 
Education .112 0.500 
UPDRS III -.358 0.053 
Motor phenotype score .155 0.284 
GDS .064 0.692 
R2 = .315; P-value of change= 0.011   
Model 2   
Age -.130 0.404 
Education .005 0.975 
UPDRS III -.353 0.042* 
Motor phenotype score .259 0.070 
GDS .097 0.523 
SAI -.388 0.014* 
R2 = .419; P-value of change= 0.014   
 
In a bivariate analysis, MoCA score demonstrated a significant negative correlation 
with motor severity score (r=-0.497, p=0.001, Spearman’s rho) and near significant 
correlation with GDS (r=-0.269, p=0.074) and motor phenotype score (a greater score 
indicating more tremor-dominant features; r=0.291, p=0.056).  Therefore, these 
factors plus age and education were entered into the regression model.  A greater 
degree of inhibition (that is, a lower SAI percentage) was an independent determinant 
of MoCA score and independently explained 10% of variability (Table 4-9).  In the final 
model, motor severity score and SAI were independent determinants, explaining 42% 
of variability.  The regression model was repeated for control participants, with age, 
education then SAI entered into the model (Model 1 R2=.267, P-value of change=0.002; 
Model 2 R2=.365, P-value of change=0.018).  The final model explained 37% of 
variability on MoCA score, with age (β=-.605; p<0.001) and SAI (β=.335, p=0.018) 
independent predictors of MoCA score.  However, the relationship between SAI and 
MoCA score was positive, indicating that reduced inhibition (a greater SAI percentage) 
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predicted better function, which is not consistent with other results or indeed our 
knowledge of SAI.    
 
2. Executive function (One Touch Stockings of Cambridge) 
Table 4-10 Regression model statistics and coefficients of variables for OTS score (n=44)
 Independent β p value 
Model 1   
Age .079 0.607 
Education .112 0.465 
UPDRS III -.524 0.002* 
R2 = .303; P-value of change= 0.002   
Model 2   
Age .118 0.458 
Education .058 0.720 
UPDRS III -.534 0.002* 
SAI -.143 0.357 
R2 = .318; P-value of change= 0.357   
 
In addition to age and education, OTS displayed a significant negative association with 
UPDRS 3 score (r=-0.432, p=0.003), and only this motor severity score was significant in 
the final model, which explained 32% variability in OTS.  
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3. Executive function (phonemic  and semantic fluency) 
Table 4-11 Regression model statistics and coefficients of variables for phonemic 
fluency (n=45)
 Independent β p value 
Model 1   
Age .093 0.521 
Education .333 0.026* 
UPDRS III -.418 0.007* 
R2 = .359; P-value of change < 0.001   
Model 2   
Age .142 0.338 
Education .264 0.087 
UPDRS III -.423 0.006* 
SAI -.201 0.160 
R2 = .390; P-value of change= 0.160   
 
As both tests of verbal fluency correlated with SAI, these were also included as part of 
executive function to further explore cognition.  In a bivariate analysis of explanatory 
variables for both phonemic and semantic fluency, UPDRS 3 negatively correlated with 
test score (r=-0.525, p<0.001 for both, Pearson’s r).  Age, years of education, motor 
severity and SAI explained 39% of the variance in phonemic fluency (Table 4-11), 
although only UPDRS 3 score was an independent predictor in the final model.  
Similarly, for semantic fluency, the aforementioned variables explained a high degree 
of variance (48%), but SAI was not an independent predictor of semantic fluency in the 
final model (Table 4-12).  
Interestingly, when PD participants were dichotomised into whether they were or 
were not impaired on semantic fluency at 1 SD below normative values (normal, n=35, 
mean SAI=70.7 ± 23.1% vs. impaired, n=10, mean SAI 100.9 ± 36.9%, p=0.003); 1.5 SD 
below normal (n=38, SAI=72.6 ± 24.4% vs. impaired n=7, SAI=103.9 ± 39.9%, p=0.007); 
and 2 SD (normal, n=41, mean SAI=73.8 ± 24.1% vs. impaired n=4, SAI=115.2 ± 51.6%, 
p=0.005), significant differences were seen between normal and impaired groups.  
These differences remained robust after controlling for age, education and UPDRS 3 in 
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an ANCOVA.  Differences were not seen in controls, or in PD participants who were 
subsequently dichotomised by phonemic fluency or PAL scores.   
Table 4-12 Regression model statistics and coefficients of variables for semantic 
fluency (n=45)
 Independent β p value 
Model 1   
Age -.170 0.202 
Education .425 0.002* 
UPDRS III -.261 0.058 
R2 = .472; P-value of change < 0.001   
Model 2    
Age -.146 0.285 
Education .392 0.007* 
UPDRS III -.263 0.058 
SAI -.096 0.466 
R2 = .479; P-value of change= 0.466   
 
4. Attention (Power of Attention) 
Table 4-13 Regression model statistics and coefficients of variables for PoA (n=44)
 Independent β p value 
Model 1   
Age .296 0.075 
Education -.026 0.873 
R2 = .094; P-value of change= 0.131   
Model 2    
Age .255 0.134 
Education .031 0.858 
SAI .172 0.316 
R2 = .117;  P-value of change= 0.316   
 
PoA, a sum of reaction time scores, showed no correlations with other clinical or 
demographic characteristics in a bivariate analysis.  Therefore only age and education 
were entered in to a model with SAI.  These three variables together were a poor fit of 
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a model for PoA, explaining only 12% of variance, with non-significant P-values of 
change and no independent predictors in the final model. 
 
5. Memory (paired associates learning) 
Table 4-14 Regression model statistics and coefficient variables for PAL (n=44)
 Independent β p value 
Model 1   
Age .314 0.058 
Education -.083 0.606 
UPDRS III .174 0.308 
R2 = .219; P-value of change= 0.018    
Model 2    
Age .223 0.171 
Education .038 0.818 
UPDRS III .196 0.235 
SAI .326 0.042* 
R2 = .298; P-value of change= 0.042   
 
As part of the memory domain, paired associates learning (PAL) was assessed, as a 
significant correlation had been demonstrated between this variable and SAI.  ‘Mean 
trials to success’ was used as the score within this test (with a greater score indicating 
worse performance), as this was used in Chapter 2 as part of the definition of mild 
cognitive impairment.  PAL correlated with UPDRS 3 score in a bivariate association 
(r=0.323, p=0.033, Spearman’s rho), therefore this plus age, education and SAI were 
entered into the regression model.  The final model explained 30% of variance in PAL 
score, with only SAI an independent determinant (β=.328, p=0.042) explaining 8% of 
variability.  Reduced inhibition (that is, a greater percentage SAI value) predicted a 
worse test score.  The same model in control participants was not significant (Model 1 
R2=.105, P-value of change=0.108; Model 2 R2=.124, P-value of change=0.367), and SAI 
was not an independent predictor (β=-.146, p=0.367). 
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6. Visuospatial function (pentagon score) 
Table 4-15 Regression model statistics and coefficient variables for pentagon score 
(n=45)
 Independent β p value 
Model 1   
Age -.164 0.308 
Education .228 0.158 
R2 = .108; P-value of change= 0.091   
Model 2    
Age -.144 0.386 
Education .200 0.245 
SAI -.082 0.626 
R2 = .113;  P-value of change= 0.626   
    
Pentagon score was not associated with other clinical variables on bivariate analysis. 
The final model explained only 11% of variance in pentagon score, and was not 
significantly better at predicting pentagon score than using the mean pentagon score, 
with no clinical characteristics independent determinants of visuospatial function.  In 
addition, the assumptions for generalisation of the model were not met, with the 
standardised residual scores ranging from -3.5 to 0.974, and these were non-normally 
distributed. 
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7. Language 
Table 4-16 Regression model statistics and coefficient variables for language (n=45)
 Independent β p value 
Model 1   
Age -.001 0.998 
Education -.013 0.935 
UPDRS III -.421 0.016* 
R2 = .175; P-value of change= 0.049    
Model 2    
Age .045 0.790 
Education -.078 0.652 
UPDRS III -.426 0.015* 
SAI -.187 0.252 
R2 = .200; P-value of change= 0.252   
 
Language scores demonstrated a trend towards a negative correlation with motor 
severity score (r=-0.275, p=0.067), therefore UPDRS 3 plus age and education were 
entered into the initial model, with these plus SAI explaining 20% of variability in 
language score.  In the final model, only UPDRS was a significant determinant of 
language function, with increasing motor severity associated with poorer language 
score (β=-.426, p=0.015).  Below is a summary table of the contributors to cognition 
discussed in this section, using clinical and SAI parameters in regression models. 
Table 4-17 Summary table of independent contributors to cognitive assessments 
 MoCA OTS Phonemic 
fluency 
Semantic 
fluency 
PoA PAL Pentagon Language 
Age         
Education    X     
UPDRS 3 X X X     X 
LEDD         
GDS         
SAI X     X   
X=significant determinant of cognition in the final regression model 
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4.4.6 Hemispheric effects of short latency afferent inhibition 
To be certain that hemispheric effects had no impact on the results (Helmich et al., 
2005), PD patients in whom the dominant arm was not the most affected arm were 
excluded and the analysis limited to those in whom the most affected limb was the 
dominant limb (PD all = 28).  These were compared to the control group in whom the 
dominant arm was tested (40 right-handed; 3 left-handed). Mean SAI was 84.3 ± 31.9% 
for PD participants and 59.0 ± 22.3% for controls (p<0.001, unpaired t-test).  ANOVA 
confirmed that SAI was significantly different across the groups when PD subjects were 
classified according to level 1 MCI criteria (F(1, 69) = 15.50, p<0.001), with PD-MCI 
(n=10) showing significantly less inhibition that both PD-CN (mean SAI 106.6% vs. 
71.9%, p=0.002, Hochberg’s GT2 post hoc test) and controls (p<0.001), but no 
difference between controls and PD-CN (p=0.179).  These differences were robust 
when controlling for age, education and depression score.  Equally, differences 
between the groups were maintained when the PD participants were classified 
according to level 2 MCI criteria (F(2, 68) = 13.40, p<0.001, ANOVA).  Moreover, after 
excluding left-hand dominant patients and controls, the results remained significant. 
4.5 Discussion 
These results demonstrate that cholinergic dysfunction occurs early in both PD and in 
PD-MCI, as evidenced by the fact that SAI is abnormal in these patients, but not in 
those with PD and normal cognition or in control participants.  SAI may therefore serve 
as a biomarker of cholinergic dysfunction in a sub-group of people with PD who are at 
increased risk of dementia.  This concept is strengthened by the finding that in PD but 
not control participants, greater SAI was an independent determinant of MoCA score, 
a sensitive screening tool for determining MCI in PD and PDD.   
This is the first study to explore SAI in PD-MCI patients, and the largest study to 
investigate SAI in PD.  Much of the previous work on SAI and cognitive impairment has 
involved those with Alzheimer’s disease (AD), where cholinergic dysfunction is well 
established as a pathophysiological basis for dementia.  Although an earlier study in 
non-parkinsonian patients with amnestic MCI did not demonstrate an impairment in 
SAI (Sakuma et al., 2007), more recent findings in those with more advanced disease 
support the concept of cholinergic loss in MCI, with reduced SAI in those with cognitive 
deficits (Tsutsumi et al., 2012a) or with amnestic multiple-domain MCI (Nardone et al., 
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2012b).  The cholinergic deficit in the mid-frontal cortex is more severe in Lewy body 
dementia (LBD) compared with AD (Tiraboschi et al., 2000; Bohnen et al., 2003), and it 
is therefore possible that SAI may be more sensitive in detecting MCI in PD than in 
early AD. 
The pathophysiology of cognitive impairment in Lewy body diseases is not limited to 
cholinergic dysfunction, and is likely to involve both other neurotransmitters 
(serotonin,  GABA, glutamate), plus α-synuclein aggregation, Lewy body deposition, 
neurofibrillary tangles and amyloid plaque burden (Francis, 2009).  These mechanisms 
are unlikely to operate discretely and may have synergistic effects on cognition.  SAI 
provides a relatively simple, non-invasive and inexpensive neurophysiological method 
to evaluate cholinergic dysfunction, and we propose that it could serve as a biomarker 
with other measures to determine those at increased risk of dementia, thereby 
providing an opportunity for early clinical and pharmacological interventions.  Other 
inhibitory neurotransmitters that may also influence cholinergic neurotransmission 
include GABA, as diazepam increases (or has no effect) (Di Lazzaro et al., 2007a) whilst 
lorazepam decreases SAI (Di Lazzaro et al., 2005c).  Whilst these studies using different 
benzodiazepines indicate that GABA receptors are involved in the circuitry underlying 
SAI, as discussed earlier in this chapter it is difficult to be certain entirely what the 
effects of changes of endogenous and non-specific GABA would be.  Therefore, GABA 
could potentially influence the results, and further work is required to establish the 
effects on SAI.  GABA receptors are likely to contribute to other cortical circuits 
including short-interval intracortical inhibition (SICI) and long interval cortical inhibition 
(LICI), both of which interact with SAI (Alle et al., 2009; Udupa et al., 2009).  It is 
possible that changes in SAI could be related to changes in these other circuits; 
however, whilst it is established that cholinergic loss occurs in the basal forebrain in PD 
(Tiraboschi et al., 2000), loss of GABAergic neurones is not a feature of PD (Kish et al., 
1986; Halliday et al., 2005; Emir et al., 2012).  We therefore suggest that the reduction 
in SAI seen here in PD-MCI may be related to loss of cholinergic neurones. Moreover, 
we could be certain that the effects of hemispheric dominance (Helmich et al., 2005) 
had no impact, because our results remained robust after limiting the analysis to right-
handed controls and patients in whom the right arm was both the dominant and most 
affected.  
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Age correlated with SAI in both control and PD participants, strengthening recent work 
suggesting that there is an age-related reduction in cholinergic modulation of 
inhibitory cortical circuits (Young-Bernier et al., 2012a).  This is the first study that has 
suggested a link between SAI and education, and raises the possibility that in addition 
to delaying or protecting against AD and vascular dementia in the general population 
(Hall et al., 2007; Hall et al., 2009; Meng and D'Arcy, 2012), greater cognitive reserve in 
PD may protect against future decline, as measured by SAI.   
In PD participants but not controls, SAI was found to correlate with global cognition, 
verbal fluency and memory subscores.  SAI was an independent determinant of MoCA 
and PAL in regression analyses.  PAL is a visuospatial test of learning and memory that 
is sensitive to both temporal and frontal damage and has been shown to predict 
Alzheimer's disease with a high degree of accuracy (Swainson et al., 2001; Blackwell et 
al., 2004); it is therefore possible that poor scores on PAL plus reduced SAI could 
predict cholinergic deficit and future cognitive decline in PD.  Additionally, PD 
participants who were impaired in semantic fluency tests showed significantly less 
inhibition than those who had normal scores.  This supports previous work suggesting 
that poor performance on this posteriorly mediated cognitive test also predicts 
cognitive decline (Williams-Gray et al., 2007a; Williams-Gray et al., 2009a).  It was 
surprising that SAI did not predict tests of attention, which are thought to be 
cholinergically mediated, at least in part (Bohnen et al., 2006b; Amici and Boxer, 2007; 
Yarnall et al., 2011).  Possible reasons for the lack of association between these 
variables include the short disease duration or the fact that SAI is more a measure of 
cholinergic loss from the nbM rather than the PPN, where degeneration in PD is well-
recognised (Jellinger, 1988; Zweig et al., 1989; Rinne et al., 2008).   Neuronal loss from 
the nbM would lead to loss of ascending cholinergic projections to the cortex and be 
reflected in abnormal SAI, whereas cholinergic neuronal loss in PPN would be 
postulated to lead to thalamic dysfunction primarily.       
Strengths of this study are that a homogenous group of well-characterised participants 
with early Parkinson’s disease were evaluated, with age- and sex-matched controls.  
The extent of SAI in the controls was largely similar to that of previously published 
studies, with a comparable reduction in inhibition in our subjects with PD-MCI and 
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previous AD or DLB participants (Di Lazzaro et al., 2002; Di Lazzaro et al., 2004b; Di 
Lazzaro et al., 2005a; Di Lazzaro et al., 2007b).  
One weakness of this study is that we do not have evidence of test-retest reliability.  
Older age has been associated with increased variability in SAI, with TMS procedures 
displaying a degree of variability with time (Young-Bernier et al., 2012a).  No ‘normal’ 
values for SAI exist in older adults; therefore we cannot be certain that the variations 
seen are within normal limits for this age group.  Future work should include test-
retest reliability in PD and control participants.  It should be noted, however, that clear 
differences were seen between the groups studied, which supports the validity of the 
findings.   
Other weaknesses include the fact that other inhibitory circuits (such as SICI and LICI) 
were not measured, and thus we cannot be absolutely sure of GABAergic contribution 
to cognitive impairment.  Further differences in methodologies in this work compared 
with established publishers (Di Lazzaro et al., 2000; Chen et al., 2008; Di Lazzaro et al., 
2008; Nardone et al., 2008a) include that only ISIs of 1 to 4ms were utilised and 
averaged (other studies used a grand mean of ISIs at 2 to 8 ms), and we used a circular 
TMS coil (other studies used a figure-of-eight coil).  Whilst paired-pulse TMS paradigms 
were all initially described using figure-of-eight coils (outside diameter 90mm for each 
circle) placed over the motor ‘hotspot’ of the muscle being studied, it has become 
increasingly clear that equally reliable results can be obtained using a circular coil 
(130mm outside diameter) placed over the vertex (Trompetto et al., 1999; Zoghi et al., 
2003; Badawy et al., 2011).  With a hand held circular coil there is very little 
movement-related MEP variability, and it can be accurately and reproducibly 
repositioned during a study, particularly during longitudinal studies, as the vertex is 
easily marked.  However, as this was a multi-modal longitudinal study, the risk of 
patient fatigue is significant; therefore practical steps to ensure comfort are important.  
In addition, it should be noted that a large number of both PD and control subjects 
were unable to participate for both clinical and non-clinical reasons.  Therefore, 
whether these study findings are applicable to a wider patient group could be 
questioned.  In particular, as PD participants with a tremor score of greater than 2 on 
the MDS UPDRS III were excluded, these findings may not be valid for those with 
tremor-dominant disease.   
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Although the largest SAI study reported in this patient group to date, this sample size is 
still relatively modest, and the findings require validation in larger cohorts.  
Participants were studied on dopaminergic medications in contrast to earlier studies 
(Sailer et al., 2003; Di Lazzaro et al., 2004a; Nardone et al., 2005), and therefore 
whether SAI is abnormal in the off state cannot be determined.  However, the 
levodopa equivalent doses used in this study were small (mean 331.5 mg/day).  
Previous studies have demonstrated reduced SAI in PD patients on dopaminergic 
medications (Sailer et al., 2003; Sailer et al., 2007; Shukla et al., 2013); possible reasons 
for the differences in this study include shorter disease duration, lower doses of 
dopaminergic medications and less heterogeneity amongst our patient group.  We 
acknowledge that examining PD participants on and off treatment would strengthen 
the assumption that the effect on SAI seen in our subjects was not an artefact of 
dopaminergic medications on SAI, or that PD patients with MCI are more sensitive to 
dopaminergic medications, and would provide further useful information.  
Furthermore, since this study was cross-sectional, the assertion that reduced SAI may 
act as a biomarker for cognitive decline in PD-MCI clearly requires confirmation in the 
context of a longitudinal trial.  Due to the heterogeneity of the disease, it is unlikely 
that a single biomarker will predict dementia in PD, but SAI in combination with other 
biomarkers may prove useful.  
In conclusion, short latency afferent inhibition is impaired in PD-MCI and correlated 
with global cognition, verbal fluency and memory assessments.  SAI may represent a 
biomarker for early cholinergic dysfunction in these subjects in conjunction with other 
clinical measures to predict future cognitive decline. 
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Chapter 5 Predicting cognitive impairment in Parkinson’s disease: a 
multimodal approach 
5.1 Combining cerebrospinal fluid and short latency afferent inhibition to predict 
cognition 
As discussed in previous chapters, PD is a heterogeneous disorder, and it is unlikely 
that a single biomarker will have the required sensitivity or specificity to accurately 
predict cognitive decline in individual patients.  Therefore, a multimodal approach 
using a combination of biomarkers may permit more precise prognostication.  Earlier 
chapters have established that Aβ protein levels (namely CSF Aβ40 and Aβ42) and 
cholinergic dysfunction (measured using SAI) may identify high-risk individuals, and 
hence it would seem reasonable to combine these biomarkers to determine whether 
these could work synergistically.  This theory has biological plausibility, with increasing 
evidence in animal models of an interaction between the cholinergic system and Aβ in 
both disease states and normal ageing (Kar et al., 2004; Schliebs and Arendt, 2006). 
There is growing work suggesting that Aβ has neuromodulatory effects in addition to 
its known neurotoxicity (Mura et al., 2010a; Mura et al., 2012).  High concentrations of 
this protein have been shown to inhibit the cholinergic control of dopamine release 
(via both muscarinic and nicotinic receptors) plus GABA and glutamate in the rat 
nucleus accumbens, caudate putamen and hippocampus (Preda et al., 2008; Grilli et al., 
2010; Mura et al., 2010b; Mura et al., 2012).  However, lower Aβ concentrations 
potentiated cholinergic release of glutamate (Mura et al., 2012).  Additionally, 
picomolar-nanomolar concentrations of Aβ peptides are found with normal brain cells, 
with evidence that they decrease ACh concentrations via mechanisms including 
reduction of choline uptake at presynaptic hippocampal neurones, reducing choline 
acetyltransferase activity and reduced ACh release from synaptic vesicles (Kar et al., 
2004).  Of note, these changes occur without apparent neurotoxicity.  Although the 
above studies demonstrating a relationship between Aβ and cholinergic function have 
been in animal models, the work is supported in post-mortem subjects with AD, where 
an association between cholinergic activity and Aβ concentration has been 
demonstrated (Beach et al., 2000). 
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Aβ is derived from the proteolytic cleavage of Aβ precursor protein (APP), with the 
subsequent peptide production dependent on the length of amino acid chain produced 
by sequential action of β- then γ-secretases.  If instead APP is cleaved by α-secretase, 
full length Aβ peptide production is prevented, with soluble APPα formed in its place 
(Selkoe, 2003; Schliebs and Arendt, 2006).  ACh influences the production of Aβ, with 
both muscarinic agonists and AChE inhibitors increasing the production of soluble 
APPα and reducing total Aβ concentration (Fisher et al., 2003; Schliebs and Arendt, 
2006).  Conversely, scopolamine, a potent muscarinic antagonist, increased fibrillar 
Aβ40 and Aβ42 levels in transgenic mice (Liskowsky and Schliebs, 2006), whilst PD 
subjects treated with antimuscarinic medications for greater than two years 
demonstrated greater amyloid plaque densities than those who had not been exposed 
to these medications (Perry et al., 2003). 
In summary, there is evidence that Aβ peptide production and deposition adversely 
affects ACh synthesis and release, and that ACh in turn may alter APP processing.  
Therefore, an analysis was performed on a subset of ICICLE participants who had 
undergone both CSF sampling and SAI, to determine whether any relationship existed 
between cholinergic dysfunction and amyloid pathology.  
5.2 Specific methods 
Participants who had consented to both lumbar puncture at baseline visit and 
subsequent neurophysiology measurement (SAI) as part of the ICICLE study have 
already been described in Chapters 2-4.  As only PD patients had CSF sampling, control 
data are not included here.  Data of these participants were inspected visually and 
with scatter plots, and any correlation assessed using Pearson’s r or Spearman’s rho, 
depending on the distribution of the data.  Scatter plots were constructed, with 
reference lines demarcating participants as above or below median values.  
5.3 Results – general characteristics 
Of the 45 PD participants who had undergone SAI, 24 also had lumbar puncture at 
their baseline visit.  22 of these had SAI at their 18 month visit, with two having SAI at 
baseline.  Characteristics of those who had SAI with or without CSF sampling are 
shown in Table 5-1.  Those who had both SAI and CSF showed a trend towards younger 
age, lower dopaminergic medications, better MoCA score and superior memory score 
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(measured using paired associates learning, PAL) and had a shorter disease duration.  
However, there were no differences in neurophysiological measurements between the 
two groups. 
Table 5-1 Characteristics of PD participants with SAI plus/minus CSF 
 SAI – CSF (n=21) SAI + CSF (n=24) P value 
Age (years)a 72.1 (10.2) 66.9 (10.0) 0.088 
Male gender (n, %)b 12 (57.1) 16 (66.7) 0.511 
PD duration (months) 22.8 (9.8) 20.2 (5.5) 0.007* 
UPDRS 3a 31.4 (9.6) 30.4 (12.0) 0.749 
LEDD (mg/d)a 373.7 (132.0) 294.6 (168.6) 0.090 
Education 12.1 (3.3) 13.3 (3.6) 0.105 
GDS 3.5 (4.1) 1.9 (2.3) 0.296 
MoCA 24.7 (4.3) 26.9 (3.7) 0.050 
PoA (ms) 1393 (172) 1329 (195) 0.150 
OTS 14.8 (3.1) 15.5 (4.9) 0.195 
PAL 2.3 (0.8) 1.9 (0.6) 0.054 
Pentagon 1.8 (0.5) 1.8 (0.5) 0.862 
Language 4.5 (0.8) 4.6 (0.8) 0.669 
SAI (%)a 77.5 (25.7) 77.4 (32.4) 0.984 
N20a 21.8 (2.9) 22.7 (25.8) 0.319 
MNMT (mA)a 10.9 (4.5) 11.8 (5.2) 0.526 
TMS MSO (%)a 38.0 (5.9) 40.4 (7.1) 0.216 
Data are mean (SD) or number (%) for gender; aUnpaired t-test; bPearson Chi-Square; the 
remainder used Mann-Whitney test; MNMT=median nerve motor threshold; TMS 
MSO=transcranial magnetic stimulation maximum stimulator output 
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5.4 Combining CSF and SAI 
Results from regression modelling (chapters 3 and 4) were visually examined initially to 
determine whether a relationship existed between CSF data, SAI and cognition (Table 
5-2).  Reduced inhibition (that is, a greater value for SAI) and lower CSF Aβ42 levels 
both predicted poorer scores on global cognition, as assessed using MoCA.  Neither 
CSF parameters nor SAI predicted attention or visuospatial function.  Greater Aβ42 
values predicted improved temporal function, as measured using pattern recognition 
memory (PRM), and both Aβ42 and Aβ40 were significant predictors of language 
function, although Aβ40 was the stronger predictor.  Aβ40 or P-tau values were 
significant contributors to executive function, depending on whether motor phenotype 
score was or was not included in the final model, respectively.  Lastly, both reduced 
inhibition and greater P-tau levels were significant contributors to temporal/frontal 
lobe function, as measured using paired associates learning (PAL).       
Table 5-2 Predictors of cognition using regression modelling 
Domain SAI  
Aβ42 
CSF 
Aβ40 
 
P-Tau 
Global cognition X X O O 
Attention O O O O 
Executive O O X* X* 
Memory 
Temporal 
Temporal/frontal 
 
O 
X 
 
X 
O 
 
O 
O 
 
O 
X 
Visuospatial O O O O 
Language O X X O 
Single vs. multiple O O O O 
Amnestic vs. nonamnestic O O O O 
*Significant predictors varied according to whether motor phenotype was included in the final 
model; x=significant determinant of cognition in final regression model; o=non-significant 
determinant of cognition 
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Bivariate associations were then explored between SAI and CSF parameters.  No 
significant correlation was seen between SAI and Aβ42 (r=-0.056, p=0.794, Pearson’s r), 
SAI and Aβ40 (r=0.185, p=0.387, Pearson’s r), SAI and P-tau (r=0.254, p=0.232, 
Spearman’s rho) or SAI and α-synuclein (r=0.135, p=0.529, Pearson’s r).  There was a 
trend towards increased SAI and T-tau (r=0.349, p=0.095, Pearson’s r).  The lack of 
association may be due to the fact that this part of the analysis could have been 
underpowered to detect differences.  Controlling for age in a partial correlation did not 
alter these significance levels.  Scatter plots were then constructed, with the x- and y-
reference lines dichotomised around the median values for the amount of inhibition 
and the CSF parameter for this sample to indicate the area of “high-risk” for both 
biomarkers. 
Figure 5-1 demonstrates the first scatter plot for SAI versus Aβ42 levels, with the 
hatched area representing those participants with both reduced inhibition and 
reduced Aβ42.  Of the four participants within this section, three scored less than 26 
on the MoCA (therefore meeting level 1 MCI criteria) and also met level 2 MCI criteria 
at 1.5 SDs below normative values (shown in red and labelled as ‘a’, respectively) at 
their baseline ICICLE assessment.  Interestingly, these same three participants also 
scored well below 2 SDs on semantic fluency, and named less than 12 animals in 90 
seconds (11, 6 and 6 animals for the three subjects).  One participant (‘b’) has 
subsequently been diagnosed with PDD prior to his 36 month assessment.  The fourth 
participant (‘c’ and blue dot on plot) was cognitively normal, but also had Aβ40, T-tau 
and P-tau levels below median values.  All four participants were aged over 60 (mean 
age 70), and the three who were cognitively impaired were also male.  Motor 
phenotype was mixed, with one subject tremor-dominant, one indeterminate and two 
PIGD at baseline assessment.  The three other participants in the whole group who 
scored less than 26 on the MoCA (shown as red dots) were near the median values for 
SAI and /or Aβ42; these same three subjects also met the criteria for level 2 MCI at 1.5 
SDs below normal.     
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Figure 5-1 Scatter plot of SAI versus Aβ42 levels ; reference lines are across the median 
values for both parameters; hatched area represents those at highest risk according to 
previous results; red dots represent those with a baseline MoCA score < 26; 
a=participant with baseline level 2 MCI at 1.5 SDs below normative values; 
b=participant subsequently diagnosed PDD; c= Aβ42, Aβ40, T-tau and P-tau values all 
below median values 
  
 
Figure 5-2 shows the scatter plot of SAI versus Aβ40 levels.  Six participants were 
within the hatched “high-risk” area; two of these (‘c’) have already been discussed 
above as they also had Aβ42, T-tau and P-tau levels below the median.  Four of the six 
participants met level 1 criteria for MCI at baseline visit (labelled as red); two of these 
also met level 2 MCI criteria (‘a’).  One subject (‘b’; additional to that seen in Figure 5-1) 
has subsequently been diagnosed as PDD.  Mean age was lower than the SAI/Aβ42 
group (62 years), with only two of the six subjects scoring poorly in tests of semantic 
fluency.  Two of the participants within the hatched area were female, and four were 
assessed as PIGD at baseline. 
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Figure 5-2 Scatter plot of SAI versus Aβ40 levels ; reference lines are across the median 
values for both parameters; hatched area represents those at highest risk according to 
previous results; red dots represent those with a baseline MoCA score < 26; 
a=participant with baseline level 2 MCI at 1.5 SDs below normative values; 
b=participant subsequently diagnosed PDD; c= Aβ42, Aβ40, T-tau and P-tau values all 
below median values; d= Aβ40, T-tau and P-tau values all below median values 
 
  
 
Participants identified as “high-risk” using T-tau and P-tau levels did not seem to be as 
discriminatory (Figure 5-3 and Figure 5-4).  Five of the six participants also had lower 
Aβ42 and/or Aβ40 levels and have already been discussed above (‘c’ or ‘d’).  The 
remaining participant (unlabelled, blue dot within hatched area) scored normally on 
cognitive testing, although perhaps notably he did have a history of RBD, which has 
been postulated as a predictor of dementia risk (Postuma et al., 2012).  Half of the six 
participants scored less than 26 on the MoCA, with one of these also meeting criteria 
for level 2 MCI (‘a, c’).  This latter participant was the only one to score below 
normative values on semantic fluency.  Again two of the six subjects were female, and 
mean age within these six was 62 years.  Generally, the scatter plots show that SAI 
tends to be more variable at lower levels of T- and P-tau.  
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Figure 5-3 Scatter plot of SAI versus T-tau levels ; reference lines are across the median 
values for both parameters; hatched area represents those at highest risk according to 
previous results; red dots represent those with a baseline MoCA score < 26; c= Aβ42, 
Aβ40, T-tau and P-tau values all below median values; d= Aβ40, T-tau and P-tau values 
all below median values 
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Figure 5-4 Scatter plot of SAI versus P-tau levels ; participants in hatched area as for T-
Tau  
  
 
5.5 Discussion – combining CSF and SAI biomarkers 
These data provide some weak evidence that combining CSF parameters and SAI may 
be useful in determining PD patients at risk of future cognitive decline.  In particular, 
both lower baseline CSF Aβ42 and reduced inhibition (greater SAI absolute value) 
predicted poorer global cognitive scores, and decreased baseline P-tau levels plus 
decreased SAI predicted poorer memory function (temporal/frontal impairment, as 
measured using PAL) (Table 5-2).  It was clear that these were independent but not 
held concurrently in a model, although combining the two biomarkers together did 
identify more MCI than each alone.  Therefore, it is conceivable that participants with 
a combination of these abnormalities may be at risk of dementia, allowing targeted 
treatment and earlier therapeutic manipulation in studies aiming to halt progression of 
cognitive decline.  The potential interaction of amyloid deposition and the cholinergic 
system has been discussed in the introduction.  There is also biological plausibility for a 
link between tau and acetylcholine, with an in vitro study demonstrating a decrease in 
tau phosphorylation following administration of muscarinic agonists (Sadot et al., 
1996).  In AD models, Aβ accumulation with associated cholinergic dysfunction and 
impaired G-protein coupling leads to neurodegeneration, tau phosphorylation and 
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neuronal loss (Thathiah and De Strooper, 2009).   However, an increase in tau protein 
levels following stimulation of nicotinic acetylcholine receptors (Hellstrom-Lindahl et 
al., 2000; Kar et al., 2004) may offer an explanation for the findings here, with 
cholinergic loss precipitating a relative reduction in tau levels in those with, or at risk of, 
cognitive impairment. 
No significant correlations were found between any CSF parameter and SAI.  This is in 
contrast to a study in AD (n=19), where SAI was inversely correlated with Aβ42 levels 
and positively correlated with P-tau (Martorana et al., 2012).  Possible reasons for the 
differences seen here include differing pathologies and disease processes, in addition 
to the early disease status of our participants.  However, when scatter plots were used 
to dichotomise participants into “high-risk” categories, more interesting patterns 
emerged.  The most robust link seemed to be in those with Aβ42 levels less than 
median values and reduced SAI, where 75% of the participants also showed evidence 
of MCI using both level 1 and level 2 criteria.  One of these has subsequently been 
diagnosed as PDD, and these same three participants all performed poorly on a test of 
semantic fluency.  These findings support those from a comparable cohort of early PD 
participants in Cambridgeshire, where inability to name more than 20 animals in 90 
seconds was a predictor of subsequent dementia diagnosis at three and five years 
(Williams-Gray et al., 2007a; Williams-Gray et al., 2009a).  Our participants within this 
quadrant may therefore be at increased risk of future cognitive decline due to their 
more posteriorly-mediated cortical impairments due to cholinergic dysfunction and Aβ 
deposition.  Just two of the participants within the quadrant that contained reduced 
Aβ40 levels combined with reduced SAI had evidence of level 2 MCI, with four scoring 
less than 26 on the MoCA.  One of these participants has since been diagnosed with 
PDD.  Decreased T-tau and P-tau plus impaired SAI was a less discriminative grouping, 
with half the participants also having a concomitant diagnosis of level 1 MCI but only 
one also meeting criteria for level 2.   
A potential weakness of this analysis is that these assessments were performed at 
different time points, with all CSF samples collected at the baseline visit, whilst the 
majority of neurophysiological assessments were performed at 18 months.  
Comparison between the two time points may therefore be potentially misleading.  
However, no difference was found in cholinergic dysfunction as measured by cortical 
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AChE activity between PD participants with early (less than three years) or advanced 
disease (Shimada et al., 2009); therefore it is possible that between baseline and 18 
months there is no discernible acetylcholine loss and hence the extent of SAI may not 
change.  To date, there have been no studies examining longitudinal measurement of 
SAI, and future studies should address this in PD.  In addition, the small numbers of 
participants who underwent both CSF and SAI assessment may have resulted in a type 
1 error.  Lastly, lack of control data for this exploratory analysis could be perceived as a 
weakness.  Obtaining CSF from neurologically normal controls is notoriously difficult 
from various perspectives, however, not least participant acceptability and ethical 
considerations. 
In conclusion, there is evidence that a multimodal approach of combinations of 
biomarkers using CSF and SAI may increase the accuracy of prediction of future 
cognitive decline.  In particular, reduced Aβ42 and impaired SAI, surrogate markers of 
Aβ deposition and cholinergic loss, respectively, may be the most accurate 
combination to determine early PD participants at highest risk of dementia.          
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Chapter 6 Conclusion and future directions 
The prevalence of Parkinson’s disease and thus the burden of associated non-motor 
symptoms will increase in future years due to secular trends in the age-structure of 
populations, both UK and worldwide.  Rising age in the general population often 
equates to an increase in co-morbidities and associated polypharmacy.  Therefore, the 
detection and if possible, prevention, of cognitive impairment associated with 
Parkinson’s disease is of upmost importance for future generations in terms of 
healthcare costs, social care and prevention of morbidity and mortality.  Cognition is 
also intricately linked with other non-motor aspects of the disorder, including mood 
disturbance, gait alterations and falls.  A treatment that improved cognition may also 
have an impact on these other important aspects of PD.  A biomarker that could 
identify those who will develop cognitive impairment early in the disease process 
would permit more effective use of putative disease-modifying therapies and 
potentially contribute towards the identification of novel, tractable drug targets.  
Possible biomarkers include laboratory measures of blood and cerebrospinal fluid 
(CSF), neurophysiological procedures, imaging techniques such as magnetic resonance 
imaging and parameters of motor function comprising measures of gait and balance.   
The ICICLE-PD study is therefore timely, with its overarching aims being to determine 
the mechanisms underlying the evolution of PDD from early disease, to establish 
clinical risk factors associated with high dementia risk and to determine possible 
biomarkers predictive of future cognitive decline.  The latter two objectives were the 
subject of this thesis, the principal aim of which was to define cognitive subtypes in 
early Parkinson’s disease and to determine the interplay between putative markers of 
protein deposition and neurochemical dysfunction. 
PD-MCI, which may represent a pre-dementia state, was common in a large cohort of 
early PD participants.  42.5% of PD participants met new MDS criteria for level 2 MCI at 
1.5 SDs below normative values, compared to 21.1% of controls; these values are 
greater than previously reported for early PD.  These PD participants were significantly 
older, with greater motor disease severity, lower educational levels and had higher 
depression scores compared to the PD-CN group.  The most common single cognitive 
domain to be affected was memory, although a majority of participants were classified 
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as nonamnestic single-domain MCI according to subtype.  This is in contrast to a non-
PD older population, where amnestic MCI is the most common subtype.  Of the tests 
used to assess cognition, the largest effect sizes were seen in those probing frontal-
executive and attention domains, which may reflect differing underlying 
pathophysiological processes. 
Analyses in the subgroup of PD participants who underwent CSF sampling allowed 
further investigation of the underlying mechanisms and pathophysiology of cognition 
in early PD.  Reduced amyloid-β levels were associated with inferior global cognitive 
score and pattern recognition memory, the latter of which is sensitive to temporal lobe 
dysfunction.  Mean Aβ40 and Aβ42 levels were also significantly lower in our 
participants with PD-MCI compared to those with normal cognition.  These results 
indicate that cognition in early PD may be mediated by amyloid deposition, possibly 
within the temporal lobe.  Correlation between Aβ42 levels and pattern recognition 
memory was in keeping with one of the a priori hypotheses of this thesis: that reduced 
CSF amyloid-β would be associated with more posteriorly-mediated cognitive 
dysfunction.  The finding that Aβ40 was a significant contributor to language function 
in a regression model would also be in keeping with this hypothesis.  Somewhat 
unexpectedly, and contradictory to outcomes from the AD literature, we found that 
lower CSF tau levels were seen in those with MCI compared to the PD-CN group.  In 
accordance with this, P-tau was a significant predictor of paired associates learning, 
with poorer scores associated with reduced tau.  It is possible that these reduced tau 
levels may be due to tau deposition, with subsequent aggregation of α-synuclein and 
formation of cortical Lewy bodies, although this remains speculative at present and 
requires corroboration in post-mortem study.  
Further understanding of the pathophysiology of mild cognitive impairment was 
illustrated by the SAI data, which indicated that cholinergic dysfunction is likely to be 
involved.  In all participants, increased age was associated with a decrease in SAI, 
confirming that an age-related cholinergic loss occurs, regardless of disease state.  
Cognitive reserve also seemed to protect against cholinergic loss to some degree, with 
improved inhibition seen with greater number of years spent in education.  PD 
participants demonstrated significantly reduced mean SAI compared to control 
participants, confirming imaging studies that have shown that cholinergic loss is 
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present even in early disease.  In addition, cholinergic dysfunction is likely to be more 
severe in those with mild cognitive impairment, as SAI was abnormal in these 
participants, but not in those with PD and normal cognition.  SAI correlated with scores 
on global cognition, verbal fluency and memory tests, indicating that there may also be 
a cholinergic basis to impairments within these domains.   
The heterogeneity of PD means that is it unlikely a single biomarker will predict 
dementia risk, and hence SAI and CSF were examined together to determine if a 
multimodal approach could improve accuracy.  One of our a priori hypotheses was that 
abnormal SAI at 18 months would be associated with reduced Aβ42 levels, and 
although there was no direct correlation between these two parameters, both were 
significant predictors of poorer scores of global cognition.  In addition, participants 
who had both reduced Aβ42 and SAI values greater than the median were more 
cognitively impaired, with a majority meeting criteria for MCI.  Therefore, combining 
these biomarkers may enhance accuracy of cognitive classification. 
Future studies should involve the longitudinal assessment of participants, to determine 
whether PD-MCI is a pre-dementia state, and whether those with abnormalities on CSF 
and SAI parameters are associated with more rapid cognitive decline and/or dementia.  
It would also be useful to correlate cognition with falls and gait disturbance, as there is 
evidence these are associated both in PD and in the general population.  A treatment 
that would encompass these important non-motor characteristics would be 
enormously beneficial in reducing the morbidity and mortality related to the disease, 
with a net gain of improvement in both patient and carer quality of life.  One of the 
strengths of the ICICLE-PD study is that both controls and PD participants are to be 
assessed every 18 months; hence progression to defined end-points will increase in the 
coming years.  This, coupled with planned future brain tissue donation, will allow us to 
establish a robust set of biomarkers for the evolution of PDD.  Future work should also 
concentrate on assessing the validity of SAI as a biomarker.  We have started to assess 
test-retest variability in controls, and we aim to increase the numbers and perform 
repeat SAI on PD participants. 
 In conclusion, mild cognitive impairment is common in patients with early PD. 
Abnormal SAI and significantly lower Aβ42 and Aβ40 levels were found in PD-MCI, and 
this correlated with memory function.  We hypothesise that these subjects are at a 
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greater risk of cognitive decline and suggest that these participants should be targeted 
for future early therapeutic intervention and disease modification.  Longitudinal 
assessment will help determine which clinical, laboratory and neurophysiological 
measures best predict those who will ultimately develop PDD.
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Appendix A – Publications, awards and presentations arising from this 
thesis 
Awards 
Movement Disorder Society Junior Award for outstanding and innovative research for 
‘Characterising Mild Cognitive Impairment in Incident Parkinson’s Disease: The ICICLE-
PD Study.’  Oral presentation at Plenary Session of the 17th International Congress of 
Parkinson’s Disease and Movement Disorders in Sydney, Australia, June 19 2013.   
Publications 
1. Mild cognitive impairment in Parkinson’s disease.  Yarnall AJ, Rochester L, Burn DJ.  
Accepted June 2013, Age and Ageing. 
2. The Incidence of Parkinson’s Disease in the North East of England.  Duncan GW, 
Khoo TK, Yarnall AJ, O’Brien JT, Brayne CE, Coleman SY, Brooks DJ, Barker RA, Burn DJ.  
Accepted June 2013, Age and Ageing. 
3.Characterising Mild Cognitive Impairment in Incident Parkinson’s Disease: The 
ICICLE-PD Study.  Yarnall AJ, Duncan GW, Breen D, Khoo TK, Brooks DJ, Coleman S, 
O’Brien JB, Barker RA, Burn DJ.  Under review, Neurology. 
4.Frequency of primary sleep disorder in patients with newly diagnosed Parkinson’s 
Disease.  Prudon B, Duncan GW, Khoo TK, Yarnall AJ, Burn DJ and Anderson KN. Under 
review, Movement Disorders. 
5.Health-related quality of life in early Parkinson’s disease: the impact of non-motor 
symptoms.  Duncan GW, Khoo TK, Yarnall AJ, O’Brien JT, Coleman SY, Brooks DJ, 
Barker RA, Burn DJ.  Under review, Movement Disorders. 
5.Falls in Patients with Dementia (book chapter).  Rochester L, Lord S, Yarnall AJ, Burn 
DJ in Movement disorders in dementia.  Submitted June 2013. 
6.Dementia in Parkinson’s Disease (book chapter).  Burn DJ and Yarnall AJ, in Non-
Motor Symptoms of Parkinson’s disease, Second Edition, Oxford University Press, 2013. 
7.Bone Health and Neurological Disease.  Dobson R, Yarnall AJ, Noyce A, Giovannoni G. 
Practical Neurology 2013; 13: 70–79. 
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8.Short latency afferent inhibition: a biomarker for mild cognitive impairment in 
Parkinson’s disease?  Yarnall AJ, Rochester L, Baker M, David R, Khoo TK, Duncan GW, 
Galna B, Burn DJ.  Movement Disorders 2013: DOI: 10.1002/mds.25360. 
9.Rapid Eye Movement Sleep Behaviour Disorder in Parkinson’s Disease: Magnetic 
Resonance Imaging Study.  Ford AH, Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, 
Burn DJ, and O’Brien JT.  Movement Disorders 2013: DOI: 10.1002/mds.25367. 
10.The Spectrum of Non-Motor Symptoms in Early Parkinson’s Disease.  Khoo TK, 
Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, Barker RA, Burn DJ.  
Neurology 2013: 80; 1–6. 
11.New Horizons in the pathogenesis, assessment and management of movement 
disorders.  Duncan GW, Yarnall AJ, Marrinan S, Burn DJ.  Age and Ageing 2013; 42: 2–
10. 
12.Hot Topic: Further Evidence That Amyloid-β Oligomer and Cellular Prion Protein 
Interaction Produces Deleterious Consequences in Alzheimer’s Disease.  Yarnall AJ.  
Movement Disorders 2012; 27: 1612 
13.Cholinergic dysfunction contributes selectively to gait disturbance in early PD: an 
in vivo evaluation with short latency afferent inhibition.  Rochester L, Yarnall AJ, 
David R, Baker MR, Lord S, Galna B, Burn DJ.  Brain 2012: 135; 2779–2788. 
14.Parkinson’s disease.  Yarnall AJ, Archibald N, Burn DJ.  Medicine 2012 40(10). 
15.Amantadine-induced myoclonus in a patient with progressive supranuclear palsy. 
Yarnall AJ, Burn DJ.  Age and Ageing 2012: 41(5); 695-696.  
16.Falling short: Underestimation of fracture risk in atypical parkinsonian syndromes.  
Yarnall AJ, Duncan GW, Khoo TK, Burn DJ. Parkinsonism and Related Disorders 
2012:18;692-693 
17.The interplay of cholinergic function, cognition and falls in Parkinson’s disease. 
Yarnall AJ, Rochester L, Burn DJ.  Movement Disorders 2011:26; 2496-2503. 
18. Hot Topic: Low CSF a-Synuclein Levels May Facilitate the Prediction of 
Synucleinopathies.  Yarnall AJ.  Movement Disorders 2011: 26 (7); 1194 
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International presentations 
1. Characterising Mild Cognitive Impairment in Incident Parkinson's Disease: The 
ICICLE-PD Study 
Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Evans JR, Rowe J, O’Brien JT, 
Wesnes K, Robbins TW, Brooks DJ, Barker RA, Burn DJ. 
Oral Plenary Session and poster presentation at the 17th International Congress of 
Parkinson’s Disease and Movement Disorders, Sydney June 2013. 
2. Apomorphine: a potential modifier of amyloid deposition in Parkinson’s disease?  
Yarnall AJ, Lashley T, Ling H, O’Sullivan SS, Lees A, Revesz T, Burn DJ. 
Poster presentation at the 17th International Congress of Parkinson’s Disease and 
Movement Disorders, Sydney June 2013. 
3. Short latency afferent inhibition: a biomarker for mild cognitive impairment in 
Parkinson’s disease? 
Yarnall AJ, Rochester L, David R, Khoo TK, Duncan GW, Galna B, Baker MR, Burn DJ. 
Poster presentation at the American Neurological Association meeting, Boston October 
2012 
4. Cholinergic dysfunction in Parkinson’s disease with mild cognitive impairment: a 
short latency afferent inhibition study. 
Yarnall AJ, Rochester L, David R, Duncan GW, Khoo TK, Baker MR, Burn DJ. 
Poster presentation at the 16th International Congress of Parkinson’s Disease and 
Movement Disorders, Dublin June 2012 
5. Anticholinergic load: is there a cognitive cost in early Parkinson’s disease? 
Yarnall AJ, Khoo TK, Duncan GW, Rochester L, Barker RA, Burn DJ. 
Poster presentation at the 16th International Congress of Parkinson’s Disease and 
Movement Disorders, Dublin June 2012 
6. Atypical parkinsonian syndromes and fracture risk- are patients adequately 
managed? 
Yarnall AJ, Duncan GW, Khoo TK, Burn DJ. 
Poster presentation at the 16th International Congress of Parkinson’s Disease and 
Movement Disorders, Dublin June 2012 
Selected also as an oral presentation for the Guided Poster Tours 
7. Mild cognitive impairment in PD: does cholinergic dysfunction contribute?  
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Yarnall AJ, Rochester L, David R, Baker M, Lord S, Burn DJ 
Poster presentation at the 8th International Congress on mental Dysfunction and Other 
Non-Motor Symptoms in Parkinson’s disease and Related Disorders, Berlin, May 2012
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Appendix B - Questionnaire and Scales used in this thesis 
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Geriatric Depression Scale GDS-15  
Subject ID: __________________   Date: ______________ 
Choose the best answer for the way you have felt over the last week: 
         Please circle: 
 
1. Are you basically satisfied with your life?      YES NO 
2. Have you dropped many of your interests and activities? YES NO 
3. Do you feel that your life is empty?       YES NO 
4. Do you often get bored?          YES NO 
5. Are you in good spirits most of the time?      YES NO 
6. Are you afraid that something bad is going to happen  
to you?               YES NO 
7. Do you feel happy most of the time?       YES NO  
8. Do you often feel helpless?          YES NO 
9. Do you prefer to stay at home, rather than going out  
and doing new things?           YES NO 
10. Do you feel that you have more problems with your  
memory than most?            YES NO 
11. Do you think that it is wonderful to be alive now?   YES NO 
12. Do you feel pretty worthless the way you are now?   YES NO 
13. Do you feel full of energy?          YES NO 
14. Do you feel that your situation is hopeless?     YES NO 
15. Do you feel that most people are better off than you are? YES NO 
 
Total score:  
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CARU Operating Procedure 
Short Latency Afferent Inhibition 
General Preparation 
1) For PD participants, check MDS UPDRS 3.4, 3.5 and 3.6 bilaterally pre- and post-
procedure 
2) Ensure no contraindications: 
- Pregnancy 
- Seizures 
- Cardiac pacemaker/metallic heart valve/aneurysm clips 
- Metalwork in body 
3) Ensure no mobile phones in pockets of patient and tester, remove credit cards 
from pockets and take badge off 
4) Ensure stimulators unarmed (median nerve stimulator on 0) 
5) Switch on equipment 
6) Ensure patient relaxed, with arms on pillow placed over arms of chair 
7) Clean dominant arm and contralateral scalp with alcohol wipes (for PD use 
most affected arm) 
EMG Preparation 
Channel 1 – not working 
Channel 2 – APB (abductor pollicis brevis) 
Channel 3 – FDI (first dorsal interossei) 
Channel 4 - EEG 
Channel 5 – EDC (extensor digitorum communis) 
1) Place small adhesive EMG electrodes and attach wires over following sites: 
- Thenar eminence with reference electrode over 1st MCP joint 
- FDI with reference over 2nd MCP joint 
- EDC (landmark= move 3rd and 4th fingers) with reference over 
tendon 
- Common reference over radial styloid process 
2) Place median nerve stimulator electrodes over median nerve at wrist crease 
(ulna side of Palmaris longus tendon – press thumb and 3rd finger together to 
elicit this) with reference 3cm distal/lateral to tendon 
(cathode=purple=proximal; anode=white=distal) 
3) Secure wires with micropore tape to arm and pillow 
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EEG Preparation 
1) Measure electrode positions on scalp in accordance with 10-20 international 
EEG system and record distances: 
- Nasion – inion 
- Tragus – tragus 
- Intersecting line = vertex (Cz) 
- Measure and mark 3cm lateral, then 2cm anterior and 2cm 
posterior (F3 and P3, respectively) 
 
 
2) Apply conducting gel over forehead, F3 and P3 and apply EEG electrodes: 
- Grey = reference = forehead 
- Anode = yellow = F3 
- Cathode = purple = P3 
3) Place gauze over F3 and P3 electrodes then Coban over head to secure 
4) Secure wires by taping to shoulder 
 
Determining N20 
1) Check Digitimer gains as below: 
 
 
Cz to C3 = 3cm 
C3 to F3 = 2cm 
C3 to P3 = 2cm 
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2) Open Spike 2 sampling configuration: 
Local disc C / spike 2 / work / SAI / .pls files / SEPFHO / run now / 
‘sample now’ (see picture of button) /’start’ button: 
  
 
 
Ensure on the SEPHFO screen that the screen is current by pressing button 
below blue arrow 
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3) Check EEG working- ask patient to close eyes and clench teeth 
4) Check EMG working- move thumb/1st finger/3rd and 4th finger against 
resistance 
5) May need to reduce gain if these EMG readings fill -5 to +5 to avoid clipping 
6) Set up average: 
Analysis / new result view / waveform average / APB / trigger nerve / unclick 
mean / new / all data / ok / last data / 2 seconds 
Do not ’Optimise display’  
7) Median nerve stimulation – warn patient it may feel like pins and needles: 
o Check pulse width 200 uV 
o Turn on clear button 
o Turn on output (button up) 
o Click on ‘m’ button 
o Increase voltage until you find luminal threshold (see M wave on 
screen = direct activation of muscle)  
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o Note threshold 
o Add 20% to find SEP and note this 
o NB –need to optimise Y axis- right click on Y axis, optimise Y axis, 
change gain from 2 to -2 
8) Click on abort 
9) Click on ‘sample now’ button on top left of screen 
10)  Ensure SEPFHO configuration open and current, then Analysis / new result 
view / waveform average / EEG /display mean / all data / optimise data 
11)  Click ‘write’ then ‘start’ then ‘s’ (=SEPs) 
12)  Check on average screen.  2000 sweeps takes around 8 minutes, may need to 
enlarge EEG screen 
13) When sweeps have finished, click on data screen (not average screen): 
File / save / local disc C / data storage / save as e.g.20110824INC061MRB00 
(New directory) 
14) On average 2 screen, check N20: 
Click on ‘cursor’ / label mode / position 
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15) Note peak at N20 (e.g.19.6 = 0.0196) and negative peak at p15 (e.g. 15.8 = 
0.0158) 
16) Do not save average screen 
17) Close data 2 
18)  Remove EEG electrodes 
19) Turn median nerve output off on digitimer box (isolate switch) 
 
TMS 
1) Open file / open / SAI (ensure ‘files of type’ are sequencer files.pls) / SAI.diffint 
2) In proc 2-6, insert N20 in proc 2 then add 1ms each time e.g 206, 216 etc and 
save – Ctrl ‘S’ 
Do not input to proc1 or ‘both’ – only change proc 2 and continue to proc 6 
3) Analysis / new result view / waveform average / FDI channel / trigger – TMS / 
unclick mean / new / last 5 seconds / take ‘off’ optimise display / apply / ok 
4) Place Magstim with centre of coil over vertex.  If using R arm, A side up; L arm = 
B side up 
5) Magstim power on and armed 
6) Green button arms 
7) Take ‘write’ off 
8) Start 
9) Click on ‘t’ (=TMS) 
10) Start at 30% maximum stimulator output (MSO) and increase until MEP (~5 µV 
in size) is elicited in APB in 50% of 10 trials, to nearest 1% MSO.  This is the 
resting motor threshold (RMT).  Note this value 
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11) Increase MSO to 20% above this for SAI testing and note this, where 20 TMS 
only trials will be randomly alternated with 50 conditioned trials at N20, N20 
+1ms, N20+2ms, N20 +3ms and N20 +4ms. 
12) Turn on median nerve output 
13)  Click on ‘write’ and then ‘g’ (=go) 
14) Click on data screen: 
File / save / local disc C / date storage e.g. 20110824INC061MRB01 
 
Analysis 
 
1) Open the data, then Analysis / new result view / waveform average / FDI / 
trigger = 32DigMark (Marker) / display mean / new / Gated by events / insert 
gate marker code separately for each value (i.e. 00 for TMS alone, 01 for TMS 
plus N20 etc) 
2) Measure peaks on average screen
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